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Abstract 
Galectin-3 is an animal lectin that recognises and binds to β-galactosides in glycoconjugates. It 
performs numerous functions within the body including mediating cell adhesion, apoptosis and the 
cell cycle. It is frequently over-expressed in cancerous states, potentially allowing inhibitors to serve 
as vector tags for targeted image contrast agents to give enhanced MRI and fluorescence images. 
Derivatives of lactosamine with 3’-arylamides have been shown to be excellent inhibitors of galectin-
3, exploiting a π-cation interaction between the aryl ring and ARG144 of galectin-3. 3’-Naphthamide 
derivatives of lactosamine have previously been shown to bind to galectin-3 with kd < 1 μM, and form 
the basis of the target imaging agent. 
This project is focussed on the synthesis of 3’-naphthamide derivatives of lactosamine, the 
incorporation of a spacer unit and attachment of a probe molecule. Initially FITC has been used as 
probe, though the design of the target allows for incorporation of other probe molecules, such as 
paramagnetic species, with minimal changes to the synthetic pathway. 
Problems with the reduction/acylation of an azide in a key disaccharide intermediate could not be 
resolved by alterations in the reaction conditions; incorporation of the required amide earlier in the 
synthesis failed to lead to disaccharide products. 
Employing a phthalimide as nitrogen protecting group has successfully produced a glycosyl donor 
precursor that will only require ring opening rather than the troublesome reduction/acylation. 
Using a propargyl group to protect the anomeric position in the glycosyl acceptor has allowed for the 
attachment of the linker via a click reaction and subsequent deprotection reactions and FITC 
installation has produced one of the compounds required for comparison studies. 
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CRD Carbohydrate Recognition Domain 
CuAAC Copper Catalysed Alkyne Azide Click Reaction 
DCC Dicyclohexyl Carbodiimide 
DCM Dichloromethane 
DMAP 4-(Dimethylamino)pyridine 
DMDS Dimethyl Disulfide 
DMF N,N-Dimethylformamide 
DOWEX DOWEX 50WX8-200 Ion Exchange Resin (Acid Form) 
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ECM Extra-cellular Matrix 
Et Ethyl 
FDG 2-Deoxy-2-(18F)-fluoro-D-glucose 
FeNP Iron Nanoparticle 
FITC Fluorescein Isothiocyanate 
Gal Galactose / Galactoside 
Gal-3 Galectin-3 
GFP Green Fluorescent Protein 
Glc Glucose / Glucoside 
HMBC Heteronuclear Multiple Bond Correlation 
Im Imidazole 
Lac Lactose / Lactose Derivative 
LacNAc N-Acetyllactosamine 
mCPBA Meta-Chloroperbenzoic Acid 
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Me Methyl 
Ms Mesyl / Methanesulfonyl 
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1 Introduction 
The primary aim of this project is to develop a new diagnostic tool to aid in the earlier detection of 
cancer. Cancer is a catch-all term for over 200 different types of malignant neoplastic disease, which 
becomes progressively more difficult to treat as the disease advances – thus there is considerable 
benefit from tools that allow early detection. The design of such a tool requires the understanding of 
healthy cell function (discussed in Section 1.2) and how processes become altered in malignant 
neoplasms (discussed in Section 1.3). The mode of action that the tool employs requires an 
understanding of current diagnostic tools and treatments (discussed in Section 1.4). 
Galectin-3 is involved with many of the processes of healthy cells that become perturbed in 
malignant states (discussed in Section 1.5) and compounds which exhibit good binding characteristics 
(discussed in Section 1.5.3) have formed that basis of the synthetic target, shown in Figure 1-1. 
 
Figure 1-1: Synthetic Target 
1.1 Cancer 
In 2011, over 330,000 cases of cancer were diagnosed in the UK*, with over half of these being 
diagnoses for breast, lung, colorectal or prostate cancers (see Figure 1-2).1 
                                                          
*
 Excluding Non-Melanoma Skin Cancer (NMSC) 
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Figure 1-2: UK incidence, 2011 - Commonly Diagnosed Cancers 
Cancer is predominantly an age-related disease with more than 75% of diagnosed cases in 2009-2011 
being in people aged 60 and over.2 
In 2011, cancer was attributable to the deaths of over 158 000 people, accounting for nearly a 
quarter of all deaths in the UK, with breast, lung, colorectal and prostate cancers causing nearly one-
half of all cancer deaths (see Figure 1-3).1 
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Figure 1-3: UK Mortality, 2011 - Common Deaths Caused by Cancer 
1.2 Normal Cell Life 
1.2.1 The Cell Cycle 
The adult human body is made up of 100 million million cells,4 only dividing when required – some 
dividing frequently e.g. stomach epithelia and bone marrow and some not at all e.g. neurons and 
skeletal muscle. 
The cell cycle (see Figure 1-4) lists the stages involved in cell division. Most cells in an adult human 
spend most of their time in the G0 phase – that is, not undergoing nor preparing to undergo division, 
performing their normal bodily functions instead. 
When a growth signal is received e.g. from cell damage, positive and negative regulation factors are 
produced and the cell moves into the G1 phase
5. During this phase the equipment needed for DNA 
replication (such as DNA polymerase III) is synthesised.  If the cell’s DNA is undamaged, it will move 
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place – should the repair fail, then apoptosis will be induced. In the G2 phase the remaining cell 
components are duplicated in preparation for mitosis, which occurs in the M phase. The two 
daughter cells may then enter a second G0 phase or pass directly on to a second G1 phase. 
 
Figure 1-4: The Cell Cycle 
There is a second restriction point between the G2 and M phases – though the mechanisms operating 
at the point are less well-known.5 
Extracellular actions also need to be performed during the cell cycle: the extracellular matrix (ECM) 
needs to be sculpted to allow room for the new cells, a process mediated by metalloproteinases, and 
angiogenesis need to occur in order that the new cells receive adequate blood supply. 
1.2.2 Apoptosis 
Death is essential to life. The human brain would not develop properly unless millions of neurons die 
during infancy.6 The mechanism for programmed and controlled cell death is called apoptosis, where 
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Cells need constant signals to not commit suicide. These signals are local to the cells, such that if the 
cell migrates to a region that it is not supposed to be in, the survival signals cease and the cell 
undergoes apoptosis. These signals stimulate the production of anti-apoptotic Bcl-2 proteins (B-cell 
lymphoma type 2), thus withdrawal of the signals leads to a shift in the balance of pro- and anti 
apoptotic proteins which begins a cascade of reactions culminating in death. DNA damage also 
results in death by this pathway, as protein P53, which prevents the cell from entering the S phase of 
the cell cycle, also affects the pro-anti-apoptotic balance. 
The second pathway, known as the death receptor pathway, involves receptors of the TNFR (tumour 
necrosis factor receptor) in the cell membrane. When the cell receives a death signal, the receptors 
trimerise and initiate another cascade resulting in cell death. 
1.2.3 Angiogenesis 
Diffusion limits the distance away from blood vessels that cells can survive to around 2 mm. Thus as 
tissues grow, vascularisation must occur such that the daughter cells receive adequate blood supply. 
The important stages of angiogenesis are: 
 
A. VEGF (vascular endothelial growth factor) released from the dividing cells diffuses to the 
endothelial cells of a nearby blood vessel, causing them to migrate toward the source. 
Metalloproteinases are also secreted to breakdown to break down the ECM, allowing room 
for the new vessel. 
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B. Cells in the vascular endothelium divide and a lumen begins to form. Fibroblasts are 
stimulated to create new matrix around the growing vessel. 
 
C. Nascent tubules form into loops and the new vessel is stabilised by cell-to-cell and cell-to-
matrix binding. 
1.3 Carcinogenesis 
The processes of cell division, apoptosis and angiogenesis discussed above become altered in 
cancerous states and these changes can reasonably be ascribed to the failure of regulatory 
processes. 
The cell cycle contains numerous checks and feedback mechanisms to ensure that the cell does not 
turn cancerous: genes that promote growth often trigger apoptosis should they become over-active. 
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Genes can be classified into two families: proto-oncogenes, which stimulate growth and tumour 
suppressing genes, which retard it. 
In order for a cell to develop into a carcinoma, several mutations or malfunctions must occur: proto-
oncogenes must become fully-fledged oncogenes, jamming the cell’s growth switches into the ‘on’ 
position; tumour suppressing genes must become broken, jamming the cell’s regulation and repair 
switches into the ‘off’ position; mutations must occur to render the cell independent of the survival 
signals needed to suppress apoptosis. All-in-all, the chances of this happening are minute – if it 
weren’t for the mind-bogglingly enormous number of cells in the body and the fact that only one of 
them needs to turn cancerous, then it would be all but impossible. 
These mutations confer 3 characteristics on cancer cells: 
1. Uncontrolled proliferation: this says nothing about the speed of proliferation, merely that 
the cell’s progress around the cell cycle is unrestricted. 
2. Invasiveness: as the cells no longer require the local survival signals to prevent apoptosis, 
they can spread into areas where they would not normally be found. 
3. Loss of function: as the cell contains many mutations and is constantly dividing, the 
biochemistry of the cell is fundamentally altered, leading to the cell ceasing to perform its 
normal function. 
The 4th characteristic of metastasis is unique to cancer cells and infectious disease. Here, the cancer 
cells may leave their original location and move anywhere in the body, forming secondary tumours; 
the location of the secondary tumour usually has some similarity to the location of the primary 
tumour e.g. breast cancer cells often metastasise to the bones, as calcium is readily available in both 
locations. 
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1.4 Imaging and Treatment 
The changes that occur in carcinogenesis such as altered metabolic demand and the formation of a 
solid mass tumour have been used to develop imaging techniques to aid in diagnosis and in 
treatment regimes. 
1.4.1 Imaging 
Accurate imaging is essential to effective treatment of cancer: the size and characteristics of a 
tumour may dictate which drugs should be used for treatment and the precise location of a tumour is 
needed for radiotherapy and surgery, such that damage to healthy tissue is minimised. 
The main imaging techniques used are: 
 CT Scanning – an anatomical technique using x-rays 
 MR Imaging – an anatomical technique using magnetic resonance 
 PET Scanning – a functional technique using radio-emissions 
 Fluorescence Spectroscopy – a functional technique using fluorescence. 
1.4.1.1 CT Scanning 
A CT scan is essentially an advanced x-ray. In a conventional x-ray, the rays pass through the body in 
a single direction toward a detector. Dense tissues such as bone absorb more x-rays than diffuse 
tissues such as blood vessels and therefore bone appears light on the developed image. In a CT scan, 
several x-ray beams are used, angled at different directions in a single plane. This allows an image of 
a slice through the body to be taken rather than a composite image of all tissues between the x-ray 
source and the detector. 
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A contrast agent (commonly iodinated compounds) may be used to attenuate the signal from certain 
tissues such as blood vessels, giving greater contrast between them and the surrounding tissue. 
 
Figure 1-5: CT Image
7
 
1.4.1.2 MR Imaging 
MR imaging is similar to CT scanning except that the permanent magnetic moment of the protons in 
hydrogen is exploited rather than the absorption of x-rays. Water is the commonest constituent of 
the body, and the intensity of the magnetic resonance of the protons can be used to calculate 
densities. Gradient magnetic fields are used to localise the source of the resonance. 
MR images are often weighted with respect to longitudinal (spin-lattice) and transverse (spin-spin) 
relaxation times (T1 and T2 respectively). 
When molecular motion occurs with a similar frequency to the proton resonance frequency, the 
protons may relax by interaction with the lattice. This reduces T1, leading to more protons being 
relaxed, and therefore excitable by the subsequent magnetic pulse: resulting in increased signal in 
the MR image. Very small molecules such as water and very large molecules such as proteins tumble 
with a frequency that is very different to the resonance frequency – consequently T1 is long, and the 
MRI signal weak (bulk water and proteins appear dark and fat, light.) 
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Motion of the protons within the molecules causes local magnetic fields and therefore field 
inhomogeneities. These inhomogeneities result in loss of phase coherence and thus a decay in the Mz 
magnetisation vector. Flexible molecules generate stronger local magnetic fields and therefore have 
a shorter T2 than rigid molecules (both bulk water and fat appear light.) 
MRI can be used to detect pathological conditions, for example, cerebro-spinal fluid (CSF) contains a 
high proportion of bulk water and therefore appears dark on T1-weighted images and light on T2-
weighted images. If CSF leaks into the brain, it will form hydration sheaths around myelin, reducing 
molecular tumbling: T1 is decreased and the MRI signal, increased. 
Contrast agents are often used in MR imaging. Gadolinium (III) is paramagnetic and shortens both T1 
and T2, the effect on image brightness depends on the composition of the tissue, the proton density 
and the concentration of the contrast agent; T1 images often show brightening and T2 images, 
darkening in the locality of the contrast agent. 
 
Figure 1-6: T1 (L) and T2 (R) Images
8
 
The different magnetic properties of iron in oxyhaemoglobin (oHb) and deoxyhaemoglobin (dHb) can 
also be exploited. On binding to oxygen, a water molecule is displaced by an oxygen molecule. 
Oxygen is higher up in the spectrochemical series than water and thus produces a larger splitting (∆O) 
and results in a change from high-spin Fe2+ in dHb to low-spin Fe2+ in oHb, see Figure 1-7. As high-spin 
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Fe2+ is paramagnetic, poorly oxygenated areas will have greater contrast and stronger T1 signals than 
well oxygenated areas; this forms the basis of functional MR imaging (fMRI), which is used to image 
brain function. 
 
Figure 1-7: Spin States of Fe
2+
 in Deoxyhaemoglobin (dHb) and Oxyhaemoglobin (oHb) 
Elemental iron is ferromagnetic and iron nanoparticles (FeNPs) have excellent potential for use as 
MRI contrast agents. 
1.4.1.3 PET Scanning 
PET scanning is a functional rather than an anatomical technique which can be used to distinguish 
between harmless scar tissue and cancerous tissue, because of their different metabolic demands. 
The technique uses positron-emitting nuclides: the positron annihilates an electron, producing 2 
gamma-rays at almost 180° apart, coincident arrival of these γ-rays at the detectors allow the 
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location of the emission to be calculated, and an image constructed in a similar way to CT scans. 11C, 
13N and 15O can be used as the radio-nuclide but logistical problems are apparent as they have half-
lives of under 20 min. 18F has a half-life of 110 min and is often used  in 2-deoxy-2-(18F)-fluoro-D-
glucose (FDG, see Figure 1-8) 
 
Figure 1-8: FDG 
The advantages of FDG are: 
1. Being a glucose derivative, it is actively absorbed by cells with high metabolic demands – 
such as cancer cells. 
2. The emissive half-life of 110 min is long enough for the images to be acquired, but short 
enough for the radiation to diminish to negligible levels within 24h. 
3. After entering a cell, hexokinase phosphorylates the 6-hydroxyl of FDG, preventing it from 
leaving the cell before emission occurs. 
4. The decay product is 2-(18O)-D-glucose, which is harmless. 
It is often advantageous to combine PET scanning with CT scanning or MR imaging, as this combines 
the functional aspect of PET with the anatomical aspects of CT/MRI, examples are shown in Figure 
1-9. 
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Figure 1-9: PET/CT Images
9, 10
 
1.4.1.4 Fluorescence spectroscopy 
Fluorescence spectroscopy is another important technique that uses the fluorescence of endogenous 
fluorophores such as porphyrins and NADH or exogenous fluorophores such as Green Fluorescent 
Protein (GFP), scorpion toxin and lanthanide complexes. Incident radiation is used from the UV, VIS 
or NIR regions and the technique can be used both in vitro and in vivo. The fluorescence of 
endogenous fluorophores often show a  change in their emission spectrum on going from a healthy 
to a diseased state11 and this can be used for diagnosis or during surgery. Exogenous fluorophores 
may be combined with a targeting vector, such as an antibody, so that the fluorescence only occurs 
at the site of interest. Forward scattering by cells limits fluorescence to being a surface technique; UV 
light only penetrates to a few hundred microns, whereas NIR may penetrate to several centimetres. 
1.4.2 Treatment 
Once diagnosed, one of the greatest difficulties in treating cancer is the difficulty in discriminating 
between cancerous and non-cancerous cells. Penicillins work by interfering with the mechanism that 
bacteria use to make cell walls; as eukaryotes do not have cell walls, it is not possible for penicillins to 
disrupt human cell wall production. In cancer, all of the proteins and pathways are human proteins 
and pathways, and it is very difficult to target the cancer cells without interfering with healthy cells. 
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Differences in protein expression and metabolism can be used for the discrimination and forms the 
basis of cancer chemotherapy. 
Cancer chemotherapeutic drugs offer little more than blanket cytotoxicity and kill any cell that they 
accumulate in. As cancer cells have increased metabolic demand, cytotoxic drugs accumulate in 
them, killing the tumour cells. These drugs have significant and serious side-effects as they exert a 
toxic effect on any cell-line that divides frequently: on stomach epithelia, producing nausea and 
vomiting; on bone marrow, producing anaemia; on hair follicles, producing alopecia. Targeting these 
drugs such that they only show a cytotoxic effect on cancer cells is highly desirable.  
High doses of ionising radiation are also cytotoxic and can be used for treatment. In order that only 
the tumour is targeted, several radiation beams are used, with them converging on the treatment 
site. The main mechanism of action of radiation damage is through the production of free radicals, 
notably reactive oxygen species (ROS), including the ferociously reactive hydroxyl radical. One of the 
main drawbacks of radiotherapy is that the tumour may outgrow its blood supply resulting in local 
hypoxia and limiting the amount of ROS that may be formed. This can lead to malignant cells being 2-
3 times more resistant to radiation than healthy cells. 
The most conceptually simple treatment for cancer is surgery to remove the tumour. Surgery is not 
always possible as the tumour may be in an inaccessible site, such as the brain stem or there may be 
no tumour, such as in leukaemia. Further complications arise from the fact that every single 
malignant cell must be removed, otherwise the tumour may re-grow. Thus the margin of the tumour 
must be known precisely and healthy cells are often removed to ensure that the entire tumour is 
excised. 
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1.4.2.1 Targeted Drug Delivery 
It is highly desirable that cytotoxic drugs are only active in the target cells/tissues. In passive drug 
targeting, the drug or inactive drug precursor (pro-drug) is administered and preferentially 
accumulates in the target zone. This could be effected by specific uptake in certain cell lines or by 
conversion of the pro-drug in the active form by enzymes present in the target zone that are not 
found elsewhere. In active drug targeting, the drug actively seeks out the target, often by use of a 
vector tag such as an antibody. The antibody binds to specific surface proteins expressed in the 
target and may then be transported into the cell or simply increase the local concentration of the 
drug. 
1.5 Galectins 
1.5.1 Role of Galectins 
Galectins are a family of 15† animal lectins which bind to β-D-galactoside residues in glyco-
conjugates. The region of the protein where the carbohydrate binds is known as the carbohydrate 
recognition domain (CRD), some galectins contain a single CRD and form dimers or aggregates and 
others contain two CRDs (see Table 1-1.)12 
                                                          
†
 So far discovered 
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Table 1-1: Galectin Types 
Type Structure Galectins 
One CRD (Dimer) 
 
1, 2, 5, 6, 8, 10, 11, 13, 14, 15 





4, 6, 8, 9, 12 
 
The role of galectins in the body is varied: they act both intra- and extracellularly. Extracellularly they 
may form cross-links between membrane-bound glyco-conjugates and the ECM, increasing cell 
adhesion or they may form lattices between different membrane-bound conjugates, thereby 
reducing cell adhesion. Galectin-3 (Gal-3) also has a role in angiogenesis: breast cancer tissues that 
over-express Gal-3 have a higher density of capillaries. Intracellularly, galectins can modify signal 
transduction by binding to membrane-bound, cytosolic or nuclear glyco-conjugates;12, 13 they have a 
role in regulating the cell cycle and can act in an anti-apoptotic manner. The exact mechanisms of 
these complicated and diverse actions have not been fully elucidated. 
1.5.2 Galectins and Carcinogenesis 
Acquisition of a cancerous phenotype is frequently coincident with a change in galectin expression. 
An increase in galectin production is frequently seen in cell lines that do not express a high level of 
galectin.12 The actions of galectins can clearly be seen to contribute to the characteristics of cancer: 
altered cell adhesion contributes to invasiveness and metastasis; uncontrolled proliferation is 
contributed to by galectins’ role in regulating the cell cycle and their anti-apoptotic effects. 
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1.5.3 Substrate Binding 
The CRD of galectins is a saddle-shaped groove as opposed to the classical pocket of the lock-and-key 
analogy. Whist galectins are selective for β-D-galactose, there is sufficient room for other saccharides 
present to interact with the CRD, increasing binding and specificity; many substrates contain 
polylactosamines chains. Figure 1-10 shows N-acetyllactosamine (LacNAc) bound to Gal-3. 
   
 
Figure 1-10: LacNAc bound to Gal-3 – created from PDB: 1KJL
14
 (L: Ribbon, R: Electrostatic) 
Whilst the binding to LacNAc is selective, it is also relatively weak (Kd = 67 µM.) It has been shown 
that 3’-arene derivatisation of LacNAc can decrease the dissociation constant by 2 orders of 
magnitude: methyl N-acetyl-3’-(2,3,5,6-tetrafluoro-4-methoxybenzamido)-3’-deoxy-lactosamine 
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Figure 1-11: TFMBL 
The increase in binding is thought to be caused by π-interactions between the 3’-arene group and 
ARG144 of Gal-3, there are also increased direct and indirect hydrogen bonding interactions. Figure 
1-12 shows TFMBL bound to Gal-3. 
   
 
Figure 1-12: TFMBL bound to Gal-3 – created from PDB: 1KJR
14
 (L: Ribbon, R: Electrostatic) 
 The amide group of LacNAc points away from the CRD of Gal-3, and can thus serve as a point of 
attachment for drug targeting. 
When the substrate binds to Gal-3, the binding groove becomes more tightly curved. This change 
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increase in the conformational entropy of these groups. This increase helps to offset the reduction in 
entropy that occurs on binding.15, 16 The entropy of binding lactose to Gal-3 has been calculated by 
ITC at ∆S = -15.6 J K-1 mol-1. 
1.6 Active Gal-3-Targeted Imaging and Contrast Agents 
The low Kd and accessible nitrogen of 3’-arene-lactosamines allow for the synthesis of Gal-3-targeted 
imaging and contrast agents. Methyl N-acetyl-3’-(2-naphthamido)-3’-deoxy-lactosamine (NDL) 
exhibits stronger binding to Gal-3 (Kd = 480 nM) than either LacNAc (Kd = 67 μM) or TFMBL (Kd = 880 
nM), and will form the basis of the indicator shown in Figure 1-13. Also shown are compounds 
required to perform comparison studies. 
 
Figure 1-13: NDL-Tagged Imaging/Contrast Agent 
The combination of NDL with MRI contrast agents or a suitable fluorophore would allow for 
enhanced images of cancerous growths; the combination with chemotherapeutic drugs would allow 
for treatment with fewer side-effects. 
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Iron nanoparticles offer an enticing combination of being ferromagnetic, and thus excellent for MRI 
contrast, and generating heat in an oscillating magnetic field;17 the local hyperthermia could 
potentially be used to kill cancer cells – possibly in the same machine as that used for the imaging. 
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2 First Generation 
2.1 Design & Retrosynthesis 
The proposed first-generation target 1, shown in Figure 2-1 contains the required aromatic amide, 
lactosamine, linker and probe molecule. Figure 2-1 also shows compounds required to allow for 
comparison studies (2 & 3). 
 
Figure 2-1: Proposed First-Generation Target and Comparison Compounds 
Retrosynthetic analysis of target 1, shown in Figure 2-2, leads to the use of 2-naphthoyl chloride, 
2,4,6-tri-O-acetyl-3-azido-3-deoxy-β-D-galactopyranoside 5 and methyl 3,4,6-tri-O-acetyl-2-deoxy-2-
tetrachlorophthalimido-β-D-glucopyranoside 4 as starting materials. 
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Figure 2-2: Retrosynthetic Analysis of Target 1 
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Similar retrosynthetic analyses on the comparison compounds leads to the use of 2,3,4,6-tetra-O-
acetyl-β-D-galactopyranose 6 and glucosamine derivative 4 as starting materials. The required 
monosaccharides are summarised in Figure 2-3. 
 
Figure 2-3: Required Monosaccharides 
2-Naphthoyl chloride is commercially available.  Azido-galactosides derivatives have been 
synthesised by Lowary18 and Sörme19 from diacetone glucose using zu Reckendorf’s synthesis of 
gulose20 in a total of 8 steps, and from galactose by Oberg21 in a total of 6 steps. The 1,2,6-tri-
protected glucosamine 4 has been synthesised from glucosamine hydrochloride in 7 steps by Main.22 
2.2 Glycosyl Donor 
One of the required monosaccharides is shown in Figure 2-4. Acetyl groups were chosen to protect 
the hydroxyl groups as this renders the latter non-nucleophilic, and the groups may be attached and 
removed with ease. The 1-O-acetyl group allows for flexibility as it is simple to convert 5 into glycosyl 
halides or thioglycosides for use in coupling reactions. 
 
Figure 2-4: Galactose Derivative 
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Two routes to the required galactose derivative have been investigated: one route starting from 
diacetone glucose and the other from galactose penta-acetate. 
2.2.1 Diacetone Glucose Route 
The transformation of glucose into azido-galactose 5 requires epimerisation at C4 (shown in red in 
Figure 2-5) and retention at C3 i.e. a double inversion at C3, with the azide group installed on the 
second inversion (shown in green).  
 
Figure 2-5: The required stereochemical changes at C3 (Green) and C4 (Red) 
Diacetone gulose 11, is a key intermediate on this route as C3 remains as an unprotected hydroxyl 
and available for activation and azide substitution; the epimerisation at C4 has been effected. The 
synthesis of diacetone gulose is outlined in Scheme 2-1. 
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Scheme 2-1: Synthesis of Gulose 
The remainder of the synthesis of azido-galactose 5 requires azide substitution with inversion at C3 
and transprotection of the acetonides to acetates, as outlined in Scheme 2-2. 
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Scheme 2-2: Synthesis of Azido-Galactose Derivative 
2.2.1.1 Synthesis of Diacetone Gulose 
The first step to the synthesis of diacetone gulose is the acetonide protection of glucose. Acetonide 
protection favours cis 1,2 diols and drives the formation of the less-favoured furanose form, which 
allows 2 acetonide groups to be installed. This leaves the C3 hydroxyl free for further 
transformations. Diacetone glucose 8 was only obtained in 22% yield (compared to 70% reported in 
the literature23), attributable to the poor solubility of glucose in acetone. Fortunately diacetone 
glucose is cheap and readily available, thus no further work on this acetonide protection was 
required. 
Oxidation of diacetone glucose to hexos-3-ulose 9 was achieved in 98% yield by employing PDC.24 
The carbonyl group is readily hydrated and the compound can be precipitated as the hydrate from a 
toluene solution by addition of water. The IR spectrum of the hydrate showed no carbonyl stretching 
band. The ketone can easily be regenerated by dissolving the hydrate in CHCl3 and drying over 
magnesium sulfate. 
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Formation of enol acetate 10 was accomplished in 95% yield by heating 9 in pyridine and acetic 
anhydride,25 proceeding via the enolate. Only one of the possible two enol acetates is formed, see 
Figure 2-6. Enol acetate A is thought to be the thermodynamic product as the geometry of enol 
acetate B imposes a twist on the double bond, thus destabilising the molecule compared to enol 
acetate A. 
 
Figure 2-6: Possible Enol Acetates 
The planarity of the enol acetate is key to the required stereochemical changes. The original method 
for the conversion of the enol acetate to diacetone gulose was reduction with NaBH4.
20  
 
Scheme 2-3: Reduction of Enol Acetate 10 
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This reaction is hypothesised to proceed by reduction of the acetate, exposing the enolate, which is 
re-protonated on the more-available top face followed by reduction of the carbonyl, again from the 
top face, as shown in Scheme 2-3. Yields were modest and frustratingly variable; ranging from 13% to 
84%, see Table 2-1. The reduction of the enol acetate also produced unidentified, partially 
deprotected side-products. 1H NMR suggested that these may be dimers, due to the number of 
proton signals; the mass spectra were complicated and did not help in the identification of these by-
products. 
Table 2-1: Results from a series of enol acetate reduction experiments
† 
Entry Reductant Solvent Time Yield Comment 
1 
NaBH4 
1 mL MeOH 5 min 57% Crude yield 
2 2 mL MeOH 2 h 76% Crude yield 
3 5 mL MeOH 3.5 h 37% Isolated yield 
4 5 mL MeOH 40 min 42% Crude yield 
5 5 mL MeOH 20 min 84% Crude yield 
6 2.5 mL MeOH 20 min 51% Crude yield 
7 7.5 mL MeOH 20 min 47% Crude yield 
8 20 mL MeOH 40 min 56% Crude yield 
9 20 mL MeOH 5 min 68% Isolated yield 
10* 50 mL MeOH 2 h 13% Isolated Yield 
11 THF  0%  
12 LiBH4 5 mL MeOH 25 min <50% Determined by 
crude NMR 
† Reactions performed with 100 mg (0.33 mmol) of starting material and 1.2 eq. of reductant. 
* Reaction performed with 5.8 g (19.3 mmol) of starting material and 1.2 eq. of reductant. 
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The issues with this reduction could stem from the reactivity of the deprotected enolate or the 
reduction of the subsequently produced xylo-hexos-3-ulose 13, and both possibilities were 
investigated. Reduction of ribo-hexos-3-ulose 9 with NaBH4 produced diacetone allose 14 cleanly and 
in high yield, see Scheme 2-4. This suggests that the reduction of the ketone intermediate of the enol 
acetate reduction should proceed smoothly. 
 
Scheme 2-4: Reduction of Hexos-3-ulose 9 
Attempts to remove the acetate group of 10 with NaOMe/MeOH, Et3N or LiOH all failed to produce 
xylo-hexos-3-ulose 13 (Scheme 2-5), again producing unidentified products with partial deprotection. 
Therefore it was posited that the exposure of the enolate was causing the reduced and variable 
yields, and an alternative method was sought. 
 
Scheme 2-5: Deacetylation of Enol Acetate 10 
Catalytic hydrogenation of 10 followed by methanolysis of the acetate has been used for the 
reduction of the enol acetate,25-27 and was investigated. Hydrogenation at atmospheric pressure with 
catalytic Pd/C produced modest yields of acetate 15 after 3 days in both Et2O and EtOAc, with an 
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unknown, partially-deprotected side-product formed. It was later discovered that increasing the 
quantity of catalyst from 5 mol% to 10 mol% increased the yield to 88% and reduced the reaction 
time to 2.5 days. Using DMF as reaction solvent further decreased the reaction time to 2 days, 
although with a small reduction in isolated yield to 74%. Finally, increasing the pressure of H2 to 1.75 
Bar dramatically reduced the reaction time to 4 hours whilst preserving a high yield of 76%, see 
Scheme 2-6. 
  
Scheme 2-6: Hydrogenation and Hydrolysis of 10 
Methanolysis of acetate 15 by Na/MeOH resulted in high-yielding, clean production of diacetone 
gulose 11 when the reaction mixture was neutralised with dry ice, which presumably introduces a 
small amount of carbonic acid to the reaction liquor. It was found that neutralisation with DOWEX 
50WX8-200 resulted in decomposition of the product with, curiously, some apparent re-formation of 
the starting material. This is possibly due to the low local pH in the pores of the DOWEX. TLC of the 
reaction liquor prior to neutralisation showed complete consumption of the starting material. It was 
discovered that methanolysis by K2CO3/MeOH allowed for a faster reaction and a simpler work-up – 
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only filtering and partitioning between water and CHCl3 was required, rather than a tedious 
neutralisation with dry ice. 
Overall, diacetone gulose was produced from diacetone glucose in 48% yield over 4 steps. 
2.2.1.2 Diacetone Gulose to Azido-Galactose 
Conversion of diacetone gulose to azide 12 was easily accomplished by formation of the triflate with 
Tf2O in DCM followed by substitution with NaN3 in DMF,
18 in 80% yield, see Scheme 2-7.  
 
Scheme 2-7: Azide Substitution with Inversion 
The crude product was sufficiently pure to be transprotected to azido-galactopyranose 5 using 90% 
aq. TFA followed by Ac2O/DMAP/Py, with Ac2O in 5-fold excess. It was found that addition of 
imidazole reduced the reaction time from 3 days to 16 hours and increased the yield from 43% to 
60%, see Scheme 2-8. 
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Scheme 2-8: Transprotection of Azide 12 
The anomeric mixture (α:β 1:1) was not considered problematic as further reactions at the anomeric 
centre are controlled by either anchimeric assistance in the formation of thioglycosides, or by the 
anomeric effect in the formation of glycosyl halides. The main difference between the further 
reactions of the anomers involves rate: the α anomer is expected to be slower to activate than the β 
anomer due to steric effects, but once activated the α leaving group is quicker to leave, due to the 
anomeric effect. 
Overall, galactose derivative 5 was produced in 29% yield over 6 steps. 
2.2.2 Galactose Route 
Due to the difficulties in reducing the enol acetate in the diacetone glucose route, a second route 
was investigated in parallel. Azido-galactose derivative 17 has been prepared by Oberg21, giving a 
thiogalactoside derivative that may be used as a glycosyl donor, see Figure 2-7. 
  First Generation 
  33 
 
Figure 2-7: Oberg's Galactose Derivative 
The synthesis of 17 is outlined in Scheme 2-9, below. A key step in this synthesis is the conversion of 
galactose-derivative 20 into gulose-derivative 21. Inductive effects deactivate the C2 hydroxyl, due to 
its proximity to the hemithioacetal, resulting in preferential reaction with triflic anhydride at C3. 
 
Scheme 2-9: Synthesis of 17 
The preparation of galactose penta-acetate was first attempted using Ac2O/I2
28 but no product was 
formed. Galactose was fully acetylated with Ac2O/DMAP/Py but only the α anomer of 6 was 
produced, this anomer is slower to react in subsequent reactions than the desired β anomer of 6. 
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Heating galactose, Ac2O and NaOAc in pyridine
29 at reflux resulted in a 1:1 mixture of anomers, as 
shown in Scheme 2-10.  Thus, attempts to produce the β anomer in a cheap synthesis were 
unsuccessful; fortunately this anomer is commercially available. 
 
Scheme 2-10: Peracetylation of Galactose 
The conversion of pentaacetate 6 into thiogalactoside 18 was easily accomplished using 
BF3·Et2O/PhSH,
30, 31 proceeding via a glycosyl cation as per Scheme 2-11. 
 
Scheme 2-11: Formation of Thiogalactoside 18 
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Participation of the C2 acetyl group blocks the bottom face of the molecule, resulting in exclusive 
production of the β anomer. It was discovered that modifying the literature procedure to washing 
with sat. Na2CO3, instead of sat. NaHCO3, removed the need to purify the product by 
chromatography: the main impurity is unreacted thiophenol (pKa = 6.6), which is deprotonated by 
Na2CO3 (pKa = 10.4) but not by NaHCO3 (pKa = 6.3). 
To allow for the deacetylation to produce 19, thiogalactoside 18 was dissolved in MeOH and reacted 
with a sub-stoichiometric amount of Na, giving the product in 85% yield. The remaining 
thiogalactoside was left as a methanolic solution for 1 week, after which it was serendipitously 
discovered that complete transesterification had occurred in 93% yield. As a single run of each 
deacetylation reaction produced a combined total of 5 g of product, neither reaction needed to be 
repeated. 
Benzylidene protection of thiogalactoside 19 preferentially protects the C4 and C6 hydroxyls as this 
results in a cis-decalin structure, allowing the bulky phenyl group to occupy an equatorial position. 
1,2-Benzylidene protection is not favoured as the available pseudo-equatorial position on the formed 
5-membered ring does not confer the same steric advantage. 
4,6-Benzylidenes have previously been synthesised using α,α-dimethoxytoluene in acetonitrile with 
catalytic tosic acid,32 which can present purification difficulties. The literature protocol was modified 
to use DOWEX 50WX8-200 as an acid catalyst and 4 Å molecular sieves. Benzylidene 19 is poorly 
soluble in MeCN, and precipitated on to the DOWEX/sieves; the use of DCM as co-solvent prevented 
this from occurring and gave the product in 76% yield. 
The next step was the conversion of galactose derivative 20 into gulose derivative 21. Unfortunately 
all attempts at this conversion failed to produce the desired product. The reaction was difficult to 
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monitor due severe streaking in the TLC which did not improve by adding NEt3 to the eluent. Crude 
NMR spectra did not appear to show product peaks, though these may have been swamped by the 
tetrabutylammonium peaks. Column chromatography failed to produce identifiable saccharides 
though the majority of the crude material failed to pass through the column despite increasing the 
polarity of the eluent to 1:4 hexane/EtOAc and flushing with 100% EtOAc. These difficulties may have 
been introduced by insufficient differentiation between the hydroxyl groups at C2 and C3 in the 
reaction with Tf2O. At this point, the diacetone glucose route – which was run in parallel to this route 
– had successfully produced the desired galactose derivative 5. 
2.3 Glycosyl Acceptor 
The second monosaccharide required is shown in Figure 2-8. Tetrachlorophthalimide was chosen for 
N-protection as the nucleophilicity of the nitrogen is completely suppressed and the group may be 
removed under milder conditions than the popular phthalimide group.33 The TCP group also 
participates in glycosyl coupling reactions, giving the required β anomer and significantly reduces the 
nucleopilicity of the C3 hydroxyl, through inductive and possibly steric effects. This deactivation of 
the C3 hydroxyl significantly simplifies the synthesis as it is only necessary to protect the C6 hydroxyl, 
which may be achieved easily as it is the only primary centre in 4. 
 
Figure 2-8: Glucosamine Derivative 
Main’s22 synthesis of 4 is outlined in Scheme 2-12, the majority of which concerns protecting group 
transformations. The hydroxyl groups cannot be protected with acetyl groups in the presence of the 
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more nucleophilic amine; the amine cannot be protected with a TCP group in the presence of free 
hydroxyls. Thus the amine was temporarily protected as imine 24, allowing the acetyl groups to be 
installed. Acid hydrolysis of the peracetylated imine was accomplished with 5M HCl in Me2CO; the 
amount of Me2CO was doubled to prevent the formation of a semi-solid swollen gel and produced 
hydrochloride 26 in 72% yield. 
  
Scheme 2-12: Synthesis of 4 
Hydrochloride 26 was poorly soluble in pyridine and produced a thick gel which prevented TCPA from 
dissolving, seriously affecting the TCP protection step. It was found that partially dissolving the TCPA 
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in a small amount of DCM allowed the reaction to begin, accompanied by a swift reduction in 
viscosity. The first step in the protection is the formation of a phthalamic acid; subsequent addition 
of Ac2O produces a phthalamic anhydride which immediately ring-closes to the phthalimide, as 
shown in Scheme 2-13. 
 
Scheme 2-13: Mechanism of TCP Protection 
The next step to produce methyl glycoside 28 was attempted using phenyl thioglycoside 30 (Scheme 
2-14) and glycosyl bromide 31 (Scheme 2-15). Formation of the thioglycoside proceeded smoothly 
and in 77% yield. Unfortunately conversion of the thioglycoside to the methyl glycoside using 
NBS/TMSOTf gave the product in only 28% yield while NIS/TfOH did not give any appreciable 
conversion. This was probably due to the strongly disarming nature of the TCP group inductively 
suppressing the nucleophilicity of the sulfur. 
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Scheme 2-14: Methyl Glycoside Formation via Thioglycoside 
The glycosyl bromide was formed in quantitative yield with HBr/AcOH/Ac2O. At lower concentrations 
only the α-anomer is produced, but as the concentration increases so too does the proportion of the 
β-anomer. 
 
Scheme 2-15: Methyl Glycoside Formation via Glycosyl Bromide 
Conversion of the glycosyl bromide to the methyl glycoside was first attempted using AgBF4, but this 
was found to cause a variable amount of deacetylation, possibly due to traces of HBF4. The use of 
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AgOTs caused complete deacetylation. Changing the silver salt to Ag2CO3 (i.e. to mildly basic 
conditions) produced the methyl glycoside in 86% yield, and in sufficient purity to carry the crude 
forward. 
Removal of the acetate groups to give triol 29 using catalytic NaOMe in MeOH failed, producing a 
residue that was insoluble in CHCl3 or MeOH, probably due to the opening of the phthalimide ring. As 
reported by Ellervik,32 the reaction is concentration dependent, due to the base-sensitive nature of 
the TCP group. Performing the reaction in 18 mM NaOMe in MeOH produced a crude product which 
was soluble in CHCl3, but was difficult to fully characterise because of severe line-broadening in the 
1H NMR spectra. At this point, acid-catalysed deacetylation was attempted using AcCl/MeOH 
(generating a methanolic solution of HCl). A 1H NMR spectrum was obtained confirming the 
deacetylation had completed. In order to avoid possible complications arising from trace residues of 
HCl, the triol was immediately taken through to the next step. The literature procedure for the 
mono-acetylation19 involves using 1.1 equivalents of AcCl at -42 °C followed by a further addition of 
0.25 equivalents of AcCl at -20 °C. It was found that no reaction occurred at -42 °C and that the 
reaction can be conducted at -20 °C with an excess of AcCl. Interestingly, the starting material is not 
soluble in DCM whereas the product is – thus the reaction can be monitored visually, indeed the 
reaction was quenched when the suspension had cleared. 
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Scheme 2-16: Formation of Glycosyl Acceptor 
2.4 Disaccharides 
The next stage was to couple the galactose and glucosamine monosaccharides together and 
attention was turned to selecting a suitable glycosyl donor. Glycosyl bromides and thioglycosides 
were investigated in parallel. 
2.4.1 Glycosyl Bromide 
A glycosyl bromide had successfully been employed to perform the aglycosyl coupling producing 
methyl glycoside 28. This protocol was employed to form lactosamine 33 as shown in Scheme 2-17. 
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Scheme 2-17: Glycosyl Coupling via Glycosyl Bromide 
The glycosyl bromide was successfully formed, as determined by NMR spectroscopy, but no 
disaccharide was formed. This may have been due to difficulties in maintaining the rigorously 
anhydrous conditions required for glycosyl couplings for 3 days. Fortunately, couplings via 
thioglycosides were successful, and are discussed below. 
2.4.2 Thioglycosides 
Methyl and phenyl thioglycosides have precedent for their use in glycosyl coupling reactions. Whilst 
methyl thioglycosides are the more reactive of the two, they are also the more difficult to synthesise, 
requiring either trimethyl(methylthio)silane or the formation of S-glycosyl isothioureas from glycosyl 
halides followed by treatment with MeI and hydrolysis. This complication arises from the simple fact 
that MeSH is a gas at room temperature. Phenyl glycosides have reduced reactivity due to overlap 
between the sulfur lone pair and the phenyl π-system reducing the nucleophilicity of the sulfur. As 
well as phenyl thioglycosides, ethyl thioglycosides were investigated as they should have similar 
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reactivity to methyl thioglycosides, but are simpler to synthesise as EtSH is a liquid at room 
temperature. 
 
Scheme 2-18: Thioglycoside Couplings 
The yields for the formation of the various thioglycosides and their glycosyl coupling reactions are 
shown in Table 2-2. Ethyl thioglycoside was chosen for galactose 6 due to the higher overall yield and 
phenyl thioglycoside was chosen for azido-galactose 5 – although the overall yield is lower the 
handling and purification of the phenyl thiogalactoside is much simpler.  
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Table 2-2: Thioglycoside Formation and Glycosyl Coupling Results 






1 OAc Et 86 63 54 
2 OAc Ph 81 61 49 
3 N3 Et 77 59 45 
4 N3 Ph 47
* 77 36 
* Reaction not fully optimised 
Figure 2-9 shows the spectra from HMBC NMR experiments that confirm the formation of β(1-4) 
glycoside linkages, the peaks showing the 3JH-C correlations are ringed in blue. 
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2.4.3 Alcohol Protection 
In order to prevent complications in subsequent reactions, acetyl protection of the free alcohol was 
investigated, see Scheme 2-19. 
 
Scheme 2-19: Acetylation of Free Alcohol 
Neither acetic anhydride nor acetyl chloride successfully acetylated the free alcohol, suggesting that 
the alcohol is sufficiently unreactive to be left unprotected. 
2.4.4 TCP Removal 
Removal of the TCP group was attempted using Debenham’s33 method and was found to proceed in 
high yield, see Scheme 2-20. This method employs ethylene diamine in MeCN/THF/EtOH to remove 
the phthalimide. It was discovered that filtering and a water wash was sufficient to remove the 
impurities. 
 
Scheme 2-20: TCP Removal 
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2.4.5 Azide Reduction & Naphthamide Installation 
The azide group of lactosamine 37 is acting as a nitrogen protecting group and thus reduction of the 
azide prior to installation of the naphthamide was required. It was envisioned that care would be 
needed to avoid a possible acetyl migration, show in Scheme 2-21. 
 
 
Scheme 2-21: Acetyl Migration 
Aplander34 used catalytic hydrogenation to produce the amine that was then converted to the amide. 
Initial reactions were run in EtOH but this was modified to 30% EtOH in Et2O as this facilitated easier 
removal of the solvent without heating – to reduce the possibility of an acetyl migration. The 
intermediate amine was immediately taken through to the acylation with 2-naphthoyl chloride. Only 
a small amount of naphthamide was produced, as determined by crude NMR spectra, even when the 
reaction time was increased to 1 week. 
The reduction was attempted with both Pd/C and Pd(OH)2/C; TLC analysis showed complete 
consumption of the starting material, though IR analysis on the intermediate did not show the 
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characteristic symmetric and asymmetric stretches of a primary amine. Despite over 20 repeats of 
the reduction/acylation involving variations in stoichiometry, Pd catalyst and reaction time, no 
optimal conditions were found, and other methods were sought. 
Burés35 showed that it was possibly to modify the Staudinger reduction to directly produce amides 
without releasing the intermediate amine. As this procedure requires 20 mol% 2,2’-dipyridyl 
diselenide (which is not commercially available) and Me3P, it was not attempted. As expected, 
conducting the reaction with Ph3P instead of Me3P and without PySeSePy failed to produce any 
amide. 
An unmodified Staudinger reaction successfully produced the phosphazene intermediate, as shown 
by MS, but hydrolysis did not occur at room temperature. Heating the hydrolysis reaction was not 
attempted due to the possibility of acetyl migration. 
A sulfur equivalent of the Staudinger reaction36 (Scheme 2-22) which utilises propane-1,3-
dithiol/NEt3 in place of Ph3P/H2O was attempted as heating is not required. Once again, TLC showed 
the complete consumption of starting material but NMR and IR spectra showed no evidence of the 
amine. 
Due to these difficulties, further reactions were not pursued and the glycosyl donor was redesigned, 
as discussed in section 2.7. 
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Scheme 2-22: Mechanism of Dithiol Reduction of an Azide 
2.5 Linkers 
Investigations into the synthesis of the 3’-amide-derivatised lactosamine derivative were run in 
parallel with the synthesis of the non-derivatised lactosamine. Although none of the amide-
derivatised lactosamine was available, the non-derivatised lactosamine was, and methods for the 
attachment of linkers were investigated, such that these protocols could be applied to the amide 
derivative when it became available. 
Previous work within the group used linkers derived from caproic acid. This, however, has the 
possibility of introducing solubility problems. Linkers based on poly(ethylene glycol) are topologically 
similar to caproic acid, and have the advantage of being water soluble and biocompatible. It is also 
desirable to be able to produce both an amine-terminated linker for conjugation to FITC and a 
carboxyl-terminated linker for conjugation with FeNPs, as used by Hadjipanayis.17 Finally, inclusion of 
amide bonds within the chain is thought to stabilise the coating shell of FeNPs. 
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It was found that diamine 41 was commercially available and cheap. This diamine could easily be 
converted to being carboxyl-terminated by reaction with succinic anhydride producing ω-amino 
acids; this would also introduce amide bonds within the chain. 
 
Figure 2-10: Diamine Building Block Used for Linkers 
2.5.1 ω-Amino Acid Synthesis 
The first probe molecule to be used was FITC, which thus requires a carboxyl terminus for 
conjugation to the disaccharide, and an amine terminus for conjugation to FITC. The synthesis of this 
linker is shown in Scheme 2-23. 
 
Scheme 2-23: Linker Synthesis 
The mono-Boc protection of 41 was straightforward, employing 0.1 equivalents of Boc2O to prevent 
bis-protection. The yield was only 67%, probably due to the fact that the starting material and 
product are soluble in both EtOAc and water, reducing the efficiency of the partitioning. The 
acylation reaction was also straightforward and proceeded in 97% yield. 
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An alternative linker based on aminoethoxy ethanol, without the amide in the chain was also 
synthesised, as shown in Scheme 2-24. N-protection proceeded smoothly and in 96% yield and the 
alkylation was attempted using  KOtBu/ethyl bromoacetate.37 Unfortunately, this procedure only 
produced the desired product once, and in a low yield of 27%. This may possibly be due the similarity 
in the predicted pKas of the alcohol and BocNH leading to over-alkylation or exclusive N-alkylation. 
Attempts to avoid this complication by varying the amount of butoxide, the reaction temperature 
and reaction time failed and thus only 350 mg of 46 was available to take forward. 
 
 
Scheme 2-24: Synthesis of Alternative Linker 
The literature method for hydrolysing the ester involved the use of LiOH in TFH/H2O followed by 
acidification to pH 1 with HCl. It was felt that the use of HCl would promote removal of the Boc 
group, and 1 M citric acid was used instead. This modification improved the yield from 75% to 84%. 
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2.6 Coupling to Disaccharide 
Only lactosamine 40 was available for coupling, due to problems with the azide reduction, and a 
suitable coupling method was sought. Initially, coupling via an N-hydroxysuccinimide ester was 
attempted, as shown in Scheme 2-25. 
 
 
Scheme 2-25: Coupling of Disaccharide to Diamine-Derived Linker 
Once production of the NHS-ester had been confirmed by isolation and characterisation, the coupling 
was run as domino reactions. After stirring with the lactosamine for 3 days, no product had been 
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produced – this suggests the NHS ester is not sufficiently reactive to promote amide formation at 
room temperature. 
The acid chloride 50 suffers the opposite problem and is too reactive. Even when the acid chloride is 
produced under mild conditions using TCAN/Ph3P,
38 a succinimide was produced (as determined by 
mass spectrometry), see Scheme 2-26. 
 
Scheme 2-26: Succinimide Formation 
Finally a PyBOP-mediated coupling was attempted and successfully produced the linker-derivatised 
lactosamine 49 in yields ranging from <5% - 54%. As this protocol requires heating at reflux for 20 h, 
it was anticipated that linker cyclization would occur – this may account for the variable yield as 
succinimide 51 would be unreactive under these conditions.  
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Characterisation by 1H NMR spectroscopy (see Figure 2-11) showed that the coupling was successful, 
due the presence of 2 amide proton signals at δ = 6.78 and 6.66 ppm. HRMS also confirmed the 




H NMR Spectrum of Compound 49 
Although the coupling was successful, the variability in yield meant that this protocol was not 
suitable for the naphthamide-derivatised lactosamine. 
In order to confirm that the problems in the coupling were due to the linker cyclising, amine 40 was 
reacted with acetic and succinic anhydrides successfully, as shown in Scheme 2-27.  
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Scheme 2-27: Acylations at Lactosamine Nitrogen 
The success of these acylations was confirmed by the presence of amide proton signals in the 1H 




H NMR Spectrum of Compound 52 
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H NMR Spectrum of Compound 53 
The results of these acylations suggest that the difficulties in attaching the linker stem from the 
ability of the linker to cyclise to form a succinimide. 
In order to avoid these difficulties lactosamine 40 was coupled to the diethylene glycol-derived linker 
47. Whilst this linker does not contain the desired amide bonds within the chain, there is no 
possibility of it cyclising. An NHS ester was again chosen, as in this case, heating the reaction is 
possible should the coupling fail at room temperature (see Scheme 2-28).  
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Scheme 2-28: Coupling of Disaccharide to Amino-Alcohol-Derived Linker  
Whilst the coupling was successful, producing 55 in a modest yield of 41%, difficulties in the 
production of ω-amino acid 47 mentioned in section 2.5.1, meant that this route was unsuitable. 
2.7 Redesigned Glycosyl Donor 
When the difficulties in the reduction and acylation of azide 37 became apparent, an alternative 
glycosyl donor was designed. It was envisioned that earlier incorporation of the amide may lead to 
the successful production of the required disaccharide. Incorporation of the amide at the 
galactofuranose stage eliminates the possibility of an acetyl migration, leading to the revised 
synthesis shown in Scheme 2-29. 
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Scheme 2-29: Synthesis of Revised Glycosyl Donor Precursor 
Catalytic hydrogenation of the azide using Pd/C smoothly produced the amine, which was acylated 
with 2-naphthoyl chloride producing 57 in 76% overall yield from diacetone gulose. 
Furanose 57 was transprotected to tetra-acetate 58 with TFA followed by Ac2O/DMAP/Py in 76% 
yield. Unlike the acetylation to produce the azide derivative 5 on page 32, this reaction only 
produced the α anomer. This is possibly caused by the amide being more electron withdrawing than 
the azide, withdrawing electron density from the ring and increasing the strength of the anomeric 
effect – favouring the production of the α-anomer. 
Attempts to convert tetra-acetate 58 to a thioglycoside using BF3
.Et2O/PhSH failed and it was not 
possible to identify the products of these reactions. In light of the results from the reactions of the 
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glycosyl bromide, below, it seems likely that the PhSH was reacting with the intermediate oxazoline, 
and further reactions were not pursued. 
The glycosyl bromide 59 could successfully be produced using HBr/AcOH/Ac2O, but it was found that 
on exposure to silver salts, the glycosyl bromide cyclised to oxazoline 60 rather than producing 
disaccharides, see Scheme 2-30. Similar oxazolines have previously been reported by Paulsen39 on 
exposure of 3-acetamido glucose derivatives on exposure to SbF5 or AgBF4. 
 
Scheme 2-30: Silver Promoted Cyclisation 
Whilst this reaction failed to produce the desired product it provides an interesting pathway to 3-
amino-3-deoxy-D-talose derivatives through acid hydrolysis of the isoamide. No literature reference 
has been found for 3-amino-3-deoxy-D-talose derivatives. 
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2.8 Conclusions 
A route to diacetone gulose has been established and although there were initial difficulties with the 
reduction of enol acetate 10, these difficulties were successfully bypassed. Diacetone gulose can now 
be produced on the multi-gramme scale within 1 week in greater than 40% overall yield. 
Transformation of diacetone gulose into azido-galactose 5 has also been optimised, giving the 
product in 60% yield over 4 steps. The only disadvantage is that the product forms a sticky semi-solid 
that is rather inconvenient to work with. Thioglycoside donors have also been successfully produced: 
whilst the ethyl thioglycosides are produced in higher overall yield, the phenyl thioglycosides are 
easier to handle and there is still room for optimisation to improve yields. 
The synthesis of the glycosyl acceptor, devised by previous members of the group, has been further 
optimised with improvements in yield and purity gained from the substitution of AgBF4 for Ag2CO3 in 
the production of the methyl glycoside 28, the use of an acid catalysed transesterification to produce 
triol 29, and a simplification of the monoacetylation procedure for the synthesis of 4. 
Disaccharides have been produced using standard NIS/TfOH-mediated glycosyl couplings in excellent 
yield. Unfortunately further transformations have all proved problematic; reduction of the azide 37 
and acylation failed to produce the desired amide and attachment of linkers to the lactosamine 
nitrogen failed to produce a satisfactory pathway. 
Attempts to solve the azide reduction problem by introducing the amide earlier in the synthesis 
resulted in the formation of oxazoline derivatives rather than disaccharides; although this has 
produced a previously unreported D-talose derivative. 
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In light of these problems, both the donor and acceptor were re-designed. The donor was modified 
to use a nitrogen protecting group that would be simpler to transform to the relevant amide. The 
acceptor was modified to provide alternative linker attachment sites. The modifications are 
discussed in the next chapter. 
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3 Second Generation 
3.1 Design & Retrosynthesis 
Sörme has show that disaccharide 61 binds to galectin-3 with Kd = 320 nM,
14 and is thus a suitable 
motif for our target. This naphthalamide could be generated from a naphthalimide, which should 
serve as a nitrogen protecting group through the synthesis, see Figure 3-1.  
 
Figure 3-1:Retrosynthesis of Naphthalamic Saccharide Derivative 
Due to the expense of 2,3-naphthalimide, a phthalimide group would serve as a model, allowing the 
reactions to be optimised whilst minimising expense. Phthalimide 64 can be synthesised from 
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diacetone gulose using a protocol similar to the production of the azide derivative discussed earlier, 
see Figure 3-2. 
 
Figure 3-2: Retrosynthesis of Phthalimide 
For the acceptor, a literature search revealed that 66 has been synthesised by Izumi40 in 2 steps from 
Troc-protected glucosamine. This allows for flexibility as the linker could be attached either through 
the nitrogen or through the alkyne. 
 
Figure 3-3: Izumi's Protected Glucosamine 
The literature method produces only the α-anomer. Examination of the crystal structure for LacNAc 
bound to Gal-3 suggests that there should be sufficient room to accommodate α-substituents, see 
Figure 3-4. Thus it is viewed that the exact anomer used is unimportant, although anomerically pure 
materials are desirable to simplify characterisation. 
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Figure 3-4: Gal-3 Bound LacNAc Showing Room for α-Substituents at C1 (Marked in Green) – created from PDB: 1KJL
14
 
In the first generation synthesis, the inductively withdrawing TCP group was used to differentiate 
between OH3 and OH4 and thus allow the exclusive formation of β(1-4) glycosyl bonds. As the 
second generation acceptor does not contain such a group, another strategy to differentiate 
between OH3 and OH4 would be needed – this can be achieved by acetyl protection prior to the 
reductive ring opening of the benzylidene acetal, as shown in Scheme 3-1. 
C1 
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Scheme 3-1: Synthesis of Second-Generation Acceptor 68 
3.2 Glycosyl Donor 
The first step in the preparation of the second generation glycosyl donor is the activation of 
diacetone gulose with triflic anhydride followed by substitution with phthalimide. This is similar to 
the process for preparing the azide derivative 12, although the temperature for the reaction was 
reduced to -20 °C to reduce the possibility of elimination reactions. The phthalimide was produced in 
66% yield. 
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Scheme 3-2: Synthesis of Phthalimide 65 
The acetonide protecting groups were easily removed with TFA/H2O, though the acetylation proved 
troublesome – probably due to the electron withdrawing nature of the phthalimide group, combined 
with the successive additional deactivation caused by the addition of each acetyl group. Several 
acetylation conditions were attempted and the best was found to be Ac2O/Im/MeCN, which 
produced the product in 51% yield in 2 days. 
  Second Generation 
  67 
  
Scheme 3-3: Transprotection of Phthalimide 70 
As 70 is novel, no spectra were available for comparison and it was unclear that the reaction had 
produced the desired product. This uncertainty was compounded by the appearance of a [2M + Na]+ 
peak in the mass spectrum, which suggests the possibility of dimerization,  and an alternative 
synthesis was sought. 
Garcia41 has demonstrated a method of converting azides directly to phthalimides by using Ph3P and 
phthalic anhydride, see Scheme 3-4. 
 
Scheme 3-4: Alternative Synthesis of Phthalimide 
The reaction was conducted in toluene under reflux for 1 week, yet only a yield of 23% was achieved 
with the phosphazene intermediate 71 still present in the crude. This can be accounted for by the 
high steric demand of arranging Ph3P, phthalic anhydride and galactose around the nitrogen, see 
intermediate 72 in Scheme 3-5. 
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Scheme 3-5: Formation of Phthalimide from Azide 
Although the yield was low, a sample of phthalimide 70 was synthesised providing reference spectra 
and thus confirming that the method in Scheme 3-3 was successful. Unfortunately, due to time 
constraints, it was not possible to investigate further reactions in this sequence. 
3.3 Glycosyl Acceptor 
The first stage of the synthesis of the glycosyl acceptor is the Troc protection of glucosamine. This 
was easily achieved in 99% yield, the only quirk was that the reaction generates a foam that floats on 
top of the reaction solvent, thus a large reaction flask is needed. 
 
Scheme 3-6: Troc Protection of Glucosamine 
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The next step is a Fischer glycosidation with propargyl alcohol and TMSCl as an acid catalyst,40 
immediately followed by a benzylidene acetal formation, see Scheme 3-7. 
 
Scheme 3-7: Fischer Glycosidation & Benzylidene Formation 
The Fischer glycosidation was straightforward, although the removal of the propargyl alcohol solvent 
was laborious, involving extensive co-distillation with toluene. The procedure for the formation of 
the benzylidene acetal was modified (as discussed in section 2.2.2) allowing for a simple work-up and 
giving the product in 68% yield. 
The acetylation of the unprotected hydroxyl group presented no difficulties and was easily 
accomplished with Ac2O/DMAP/Py in 96% yield. 
 
Scheme 3-8: Acetylation of Open Hydroxyl Group 
The final step to produce the acceptor is reductive ring opening of the benzylidene acetal to produce 
a 6-O-benzyl derivative 68. DeNinno42 has shown that this may be achieved selectively by the use of 
TES/TFA. 
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It is hypothesised that the origin of the selectivity is a fast equilibration between ring-opened 
oxocarbenium cations followed by rate limiting reduction by the silane, as shown in Scheme 3-9. Of 
the two oxocarbenium cations, B is anticipated to be the more stable, on steric grounds, and thus be 
the dominant oxocarbenium cation. B would also be expected to be reduced faster than A, again on 
steric grounds, thus allowing time for A to be converted to B. 
 
 
Scheme 3-9: Selectivity in Reductive Ring Opening 
Figure 3-5 shows a reaction coordinate diagram that shows the anticipated relative energies of the 
species involved in this reaction. We suppose that protonation at O4 is less favourable than 
protonation at O6, but the O4-protonated species opens to form the oxocarbenium ion that is more 
  Second Generation 
  71 
easily attacked by TES – the transition state is predicted to be lower in energy that that of the 
alternative oxocarbenium ion, and therefore lead to the dominant product. 
 
Figure 3-5: Reaction Coordinate Diagram for Reductive Ring Opening 
The glycosyl acceptor 68 has been synthesised in 46% yield over 4 steps, as compared to 26% yield 
over 5 steps for the first generation acceptor 4. 
3.4 Disaccharides 
Thiogalactosides 18 and 34 were coupled to acceptor 68 in a NIS/TfOH-mediated glycosyl coupling, as 
shown in Scheme 3-10. The yields for ethyl and phenyl thiogalactosides couplings are very similar and 
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Scheme 3-10: Glycosyl Couplings 
Table 3-1: Thioglycoside Formation and Glycosyl Coupling Results 






1 Et 86 65 56 
2 Ph 81 66 53 
The final transformation before the linker attachment was the transprotection of the Troc group to 
an acetate. A typical method for the removal of Troc groups is with Zn/Ac2O, it was found that this 
method also performed a dissolving metal reduction on the alkyne, see Scheme 3-11. 
 
Scheme 3-11: Transprotection with Concomitant Alkyne Reduction 
Huang43 has shown that it also possible to remove a Troc group with TBAF – a method that is 
compatible with an alkyne group, see Scheme 3-12. 
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Scheme 3-12: Troc Removal 
This method produced N-acetyl lactosamine derivative 77 in 83% yield. 
3.5 Linkers 
The presence of an alkyne group in disaccharide 77 allows for the use of alkyne-azide click reactions 
for the attachment of the linker. As before, an FITC probe was investigated first and thus the 
synthesis of PEG-based amino-azides was required. The linkers show in Figure 3-6 could be based on 
those used in the first generation synthesis discussed in Section 2.5. 
 
Figure 3-6: Amino-Azide Linkers 
3.5.1 Long Linker 
The long linker 78 was synthesised in a single step from the Boc-protected diamine by employing a 
diazo-transfer reaction in 97% yield, see Scheme 3-13. Imidazole-1-sulfonyl azide hydrochloride was 
chosen as the diazo-transfer reagent as it is simple to prepare and handle, and is shelf-stable.44 
  Second Generation 
  74 
 
Scheme 3-13: Diazo-Transfer Reaction 
A possible mechanism for this reaction involves the co-ordination of the alkyl amine and sulfonyl 
azide at copper followed by cyclization to form a tetra-azo-cupracycle which collapses to form the 
alkyl azide and sulfonamide, as shown in Scheme 3-14. 
 
Scheme 3-14: Possible Mechanism of Diazo Transfer 
3.5.2 Short Linker 
The short linker 79 was synthesised from the Boc-protected alcohol by activation with MsCl followed 
by substitution with NaN3 in 71% yield over 2 steps, see Scheme 3-15. 
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Scheme 3-15: Alcohol Activation and Azide Substitution 
3.6 Click Reactions & Conjugation to FITC 
In order to avoid potentially wasting disaccharide, conditions for the attachment of the linker by 
CuAAC were optimised using a glucosamine-derived propargyl glycoside 81. This substrate was 
prepared from 27 via a glycosyl bromide in 61% yield, see Scheme 3-16. 
 
Scheme 3-16: Synthesis of Model Substrate 81 
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3.6.1 Optimisation on Model System 
CuAAC reactions require Cu(I), which was generated in situ by reduction of Cu(II) with sodium 
ascorbate. tBuOH/H2O is commonly employed as solvent,
45, 46 but solubility problems were 
encountered; it was found that switching to acetone solved these problems.  
  
Scheme 3-17: CuAAC Reactions on Model Substrate 
The cycloaddition reactions shown in Scheme 3-17 were complete within 26 hours at 50 °C, 
producing the short- and long-linker triazoles in 75% & 67% yield respectively. 1H NMR studies (see 
Figure 3-7) showed the appearance of a triazole signal at ca. δ = 7.6 ppm and the disappearance of 
the alkyne signal at δ = 2.43 ppm, confirming the successful attachment of the linker. 
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H NMR Showing the Appearance of a Triazole Signal (Orange) and the Disappearance of the Alkyne Signal 
(Grey) for Short (Blue) and Long (Green) Linker Click Reactions on Model Alkyne (Red) 
3.6.2 Linker Attachment to Disaccharides 
The modified conditions for the CuAAC reactions above were then applied to disaccharide 77, 
producing the short- and long-linker triazoles in 67% & 48% yield respectively (Scheme 3-18). These 
yields are similar to those obtained for the first generation linker attachment reactions, but without 
the issues surrounding linker cyclisation and synthesis (as discussed in sections 2.5.1 and 2.6) 
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Scheme 3-18: CuAAC Reactions on Disaccharides 
Once again, the success of the reactions was confirmed by 1H NMR spectroscopy (see Figure 3-8), 
which showed the appearance of the triazole signal at ca. δ = 7.6 ppm and the disappearance of the 
alkyne signal at δ = 2.43 ppm. 
Click reactions on 1-O-propargyl lactosamine derivatives have not been reported, and thus this 
method provides an excellent alternative to attaching linkers through the amine. 
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H NMR Showing the Appearance of a Triazole Signal (Orange) and the Disappearance of the Alkyne Signal 
(Grey) for Short (Blue) and Long (Green) Linker Click Reactions on Disaccharide 77 (Red) 
3.6.3 Deprotection and FITC Installation 
For the final set of transformations there was a choice between installing the FITC before or after the 
deprotection. It was uncertain whether the deprotection conditions would interfere with the FTIC 
group, therefore the deprotection was done first. The deprotection steps are shown in Scheme 3-19. 
In order to maximise solubility in organic solvents, the benzyl group was removed first. Benzyl ethers 
can be removed by hydrogenation,47, 48 strong acids,49 oxidation to benzoyl esters followed by 
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hydrolysis50, 51 or dissolving metal reduction.52 Wilkinson53 has shown that H2, Pd/C is compatible with 
glycosyl triazoles; this method successfully produced the de-benzylated product in 98% (86) and 93% 
(87) yield. 
Deacetylation was achieved using Na/MeOH in 84% (88) and 77% (89) yield. Whilst the reaction 
appeared clean by 1H NMR, some impurities were evident in the analytical HPLC trace. These 
impurities were also evident in the HPLC traces of subsequent reactions with the same retention 
time, suggesting that they do not participate in the reactions. These impurities were carried though 
in order to avoid loss of material during purification and would be removed by purification after the 
final step. 
 
Scheme 3-19: Deprotection Steps 
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Boc removal and FITC installation were run as domino reactions. Boc removal was achieved with 1:1 
TFA/DCM and the crude was taken up in 1:1:1 Py/DMF/DCM to ensure maximal solubility of 
materials, see Scheme 3-20. The reaction was stirred for 1 week to ensure maximal conversion.  
 
Scheme 3-20: Boc Removal and FITC Installation 
Analytical HPLC of 90 showed complete removal of the Boc group and HPLC analysis of 91 showed 
that no amine 90 was present in the reaction crude after FITC addition; the relevant HPLC traces are 
shown in Figure 3-9. A molecular ion of 91 was not evident in the mass spectrum, though amine 90 
and aminofluoroscein were. This, in combination with the HPLC analysis strongly suggests that 
product had formed but fragmented at the thiourea during acquisition of the mass spectrum. 
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Figure 3-9: HPLC Traces; A) Boc-Protected Amine 98, B) Deprotected Amine 90, C) FITC Derivative 91 
Semi-preparative HPLC did not yield enough material for NMR analysis and the mass spectra of the 
isolated fractions were complicated by the presence of [TFA]nNa
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associated with the product.  Work on the conjugation of FITC to the long linker was not attempted 
in order to avoid potential loss of material due to the issues mentioned above. Unfortunately, time 
constraints precluded further work in the synthesis and characterisation of 91. 
3.7 Conclusion 
Encouraging work has been done on the redesign and synthesis of the glycosyl acceptor 68, 
producing an acceptor in higher yield and fewer steps than the first generation synthesis. 
The redesigned glycosyl donor 65 has proved more challenging, partly due to the replacement of the 
electron-donating azide group with an electron-withdrawing phthalimide group and partly due to 
there being no literature sources available to provide reference data for the product. 
Synthesis of the donor from azide 5 by using a modified Staudinger reaction did not provide a useful 
alternative synthesis of 70 but has provided a sample allowing for confirmation of the product from 
the original route. Phthalimide 70 has been synthesised from diacetone glucose in 21% yield over 6 
steps. 
The second generation disaccharide 75 has been synthesised via thioglycoside 18 and transprotected 
to N-acetyl lactosamine derivative 77 ready for attachment of the linker. 
The attachment of 2 different linkers via CuAAC reactions was first investigated on a monosaccharide 
and the modified procedure successfully applied to the disaccharide, giving linker-attached products 
in greater than 48% yield. 
Deprotection reactions proceeded smoothly and without problem and initial experiments into 
conjugation to FITC are promising. 
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4 Future Work 
The next steps in the immediate future are to scale up the synthesis of the FITC conjugation to the 
short-linker disaccharide 89 to allow for further characterisation to be performed and to create a 
stock of material for comparisons during binding studies, and to create a similar stock of long-linker 
disaccharide 88. 
In concert with this, further work on phthalimide 70 will create the precursors to 2 more indicators, 
see Scheme 4-1. 
 
Scheme 4-1: Phthalimide Indicators 
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Experiments will need to be conducted to ascertain the optimal time to open the phthalimide ring. 
The most opportune time may be to perform this ring opening in tandem with the deacetylations by 
using 1M NaOH in MeOH, as employed by Hada,54 see Scheme 4-2. 
 
Scheme 4-2: Phthalimide Ring Opening 
Conjugation of these phthalamides to FITC will provide 2 indicators which, whilst not hypothesised to 
bind to Gal-3 with a sufficiently low Kd, may still prove useful. 
Once the synthesis of the phthalamide indicators has been achieved, work on producing the second 
generation target should be relatively straightforward, producing the naphthalamide indicators 
shown in Figure 4-1. 
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Figure 4-1: Naphthalamide Indicators 
Finally, MRI contrast agents could be produced by reacting amines 94 and 95 with succinic anhydride 
for the creation of functionalised FeNPs, see Scheme 4-3. 
 
Scheme 4-3: Disaccharides Required for Functionalised FeNPs 
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5.2 General Methods 
Solution phase reactions were carried out, when appropriate, in flame or oven-dried (175 ˚C) 
glassware. Anhydrous solvents were either purchased or dried according to standard methods55. 
Unless otherwise stated, reagents were purchased and used without further purification. 
DOWEX refers to DOWEX 50WX8-200 ion-exchange resin pre-washed with 5M HCl and MeOH. 
Thin layer chromatography (TLC) was performed on pre-coated glass- or aluminium-backed silica-gel 
plates: (silica gel 60, F254 s, 0.25mm thickness, supplied by Merck). Visualisation was achieved using a 
variety of methods including UV light (254 nm lamp), basic KMnO4 solution and ceric ammonium 
molybdate solution.  
Flash column chromatography was performed using laboratory-grade solvents on silica gel 40-63μ 
60A, supplied by Fluorochem, UK. 
1H, 13C and 2D- NMR spectra were recorded on Bruker AVIII300, AVIII400 or DRX500 spectrometers. 
Coupling constants (J) are given in Hertz (Hz) and the multiplicities of spectral signals as follows: ‘s’ 
singlet; ‘d’ doublet; ‘t’ triplet; ‘q’ quartet; ‘p’ quintet; ‘m’ multiplet; ‘br’ broad; ‘ps’ pseudo. Chemical 
shifts (δ) are expressed in parts per million (ppm) downfield from tetramethyl silane (TMS): individual 
spectra are referenced relative to the residual solvent signal. Off-line processing was accomplished 
using MNova software. 
Positive and negative ion electrospray (ES+ & ES-) mass spectra were measured on a Micromass LCT 
spectrometer using a methanol mobile phase. High resolution mass spectra (HRMS) were achieved 
using an appropriate lockmass. 
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Infra-red spectra were obtained on a Perkin Elmer Spectrum 100 FTIR spectrophotometer. 
Wavenumbers (ν) are reported in cm-1 and spectra obtained from neat samples. 
Melting points were determined in open ended glass capillaries using Stuart scientific SMP1 
apparatus and are uncorrected. 
High performance liquid chromatography (HPLC) was performed on Dionex summit HPLC systems 
with Chromeleon 6.11 software. Analytical and semi-preparative separation and purifications were 
acquired with the aid of a Summit p580 quaternary low pressure gradient pump with built in vacuum 
degasser. Helium-degassed HPLC-grade solvents were used throughout.   
The following columns were used: 
Analytical – Phenomenex Kinetex 5 μm C18 100Å, 250 x 4.6 mm. 
Semi-preperative – Phenomenex Luna 10 μm C18 100Å, 250 x 10mm. 
The HPLC solvent programme outlined below was employed to maximise separation and streamline 
purification.  
Solvent A Solvent B Run Details 
H2O + 0.05% TFA MeOH + 0.05% TFA 0% → 100% Solvent B over 40 min, 
then 100% Solvent B for 20 min. 
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5.3 Glycosyl Donors 
5.3.1 First Generation 
5.3.1.1 1,2:5,6-Di-O-isopropylidene-α-D-glucofuranose (8)23, 26, 56, 57  
 
D-Glucose (10 g, 56 mmol) and H2SO4 (98%, 8.0 mL) was stirred in dry acetone (200 mL) at room 
temperature for 4 h. The reaction mixture was bought to pH 8 by addition of sat. Na2CO3 solution and 
the solvents evaporated. Dry acetone (200 mL) was added with shaking, the mixture filtered and the 
solvents evaporated to afford a pale yellow solid. Precipitation from CHCl3 with hexane, followed by 
filtering and drying resulted in a fine white solid (3.2 g, 22%). 
δH(400 MHz, CDCl3) 5.92 (d, J=3.6, 1H, H1), 4.51 (d, J=3.6, 1H, H2), 4.35 – 4.28 (m, 2H, H3 & H5), 
4.15 (dd, J=8.7, 6.2, 1H, H6), 4.04 (dd, J=7.8, 2.8, 1H, H4), 3.98 (dd, J=8.7, 
5.3, 1H, H6’), 2.80 (d, J=3.9, 1H, exchangeable, OH), 1.48 (s, 3H, Me), 1.43 
(s, 3H, Me), 1.35 (s, 3H, Me), 1.30 (s, 3H, Me). Data match literature 
values.56, 57  
δC(101 MHz, CDCl3) 111.9 ((CH3)2C), 109.7 ((CH3)2C), 105.4 (C1), 85.2 (C2), 81.3 (C4), 75.2 (C3), 
73.4 (C5), 67.7 (C6), 26.9 (Me), 26.9 (Me), 26.3 (Me), 25.3 (Me). Data match 
literature values.57 
Rf 0.5 (2:3 hexane/EtOAc) 
m.p. 112-113 °C (Lit. 26 110 °C)  
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ν (cm-1) 3424 (OH), 2984, 2950, 2903, 2873 (CH) 
m/z (ES+ TOF) 283.1146 [M+Na]+ (C12H20O6Na), calc. 283.1158 – 100% 
5.3.1.2 1,2:5,6-Di-O-isopropylidene-ribo-α-D-hexofuran-3-ulose (9)24, 25, 58 
 
1,2:5,6-Di-O-isopropylidene-α-D-glucofuranose (8, 10 g, 38 mmol) in DCM (50 mL) was added, 
dropwise over 1 h to a stirred suspension of PDC (8.7 g, 23 mmol) and Ac2O (11 mL, 120 mmol) in 
DCM (150 mL) at 0 °C. The mixture was heated under reflux for 2 h and then cooled to room 
temperature. EtOAc (100 mL) was added and the DCM removed by evaporation. The residue was 
filtered through a plug of silica and eluted with EtOAc. Removal of the solvents by co-evaporation 
with toluene afforded the product as a golden syrup (9.7 g, 98%). 
δH(400 MHz, CDCl3) 6.09 (d, J=4.5, 1H, H1), 4.36 – 4.28 (m, 3H, H2, H4 & H5), 4.00 – 3.95 (m, 
2H, H6 & H6’), 1.40 (s, 3H, Me), 1.38 (s, 3H, Me), 1.28 (s, 6H, 2 x Me). Data 
match literature values, although assignments differ.25 
δC(101 MHz, CDCl3) 208.9 (C3), 114.3 ((CH3)2C), 110.4 ((CH3)2C), 103.1 (C1), 79.0 (C4), 77.3 (C2), 
76.4 (C5), 64.3 (C6), 27.6 (Me), 27.2 (Me), 26.0 (Me), 25.3 (Me). Data 
match literature values.25  
Rf 0.3 (2:3 hexane/EtOAc) 
ν (cm-1) Ketone: 2988 (CH), 1772 (C=O) 
Hydrate: 3403 (OH), 2982, 2865 (CH) 
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m/z (ES+ TOF) 299.1100 [M+H2O+Na]
+ (C12H20O7Na), calc.299.1107 – 70% 
313.2 [M+MeOH+Na]+ (C13H22O7Na) – 100% 
5.3.1.3 3-O-acetyl-1,2:5,6-di-O-isopropylidene-erythro-α-D-hexofuran-3-enose (10)20, 25  
 
1,2:5,6-Di-O-isopropylidene-ribo-α-D-hexofuran-3-ulose (9, 3.0 g, 12 mmol) and Ac2O (30 mL) were 
heated in pyridine at reflux overnight. The solvents were removed by co-evaporation with toluene, 
producing a dark brown syrup. Purification by dry flash chromatography (0% → 50% EtOAc in hexane, 
in 5% increments) and removal of the solvents afforded the product as a pale yellow solid. (3.3 g, 
95%). 
δH(400 MHz, CDCl3) 6.03 (d, J=5.5, 1H, H1), 5.39 (d, J=5.5, 1H, H2), 4.70 (ps t, J=6.4, 1H, H5), 
4.11 – 4.03 (m, 2H, H6 & H6’), 2.21 (s, 3H, COCH3), 1.54 (s, 3H, Me), 1.47 (s, 
3H, Me), 1.45 (s, 3H, Me), 1.38 (s, 3H, Me).  
Data match literature values.20, 25  
δC(101 MHz, CDCl3) 169.1 (COCH3), 145.4 (C4), 129.2 (C3), 113.6 ((CH3)2C), 110.6 ((CH3)2C), 
104.2 (C1), 81.0 (C2), 68.8 (C5), 66.1 (C6), 28.1 (Me), 28.0 (Me), 25.9 (Me), 
25.8 (Me), 20.7 (COCH3). Data match literature values.
25 
Rf 0.8 (2:3 hexane/EtOAc) 
m.p. 49-51 °C, recrystallised from hexane (Lit. 20 62-63 °C, recrystallisation 
details not specified)  
  Experimental 
  97 
ν (cm-1) 2992, 2940, 2905 (CH), 1762 (C=O) 
C=C not visible 
m/z (ES+ TOF) 323.1092 [M+Na]+ (C14H20O7Na), calc. 323.1107 – 100% 
5.3.1.4 3-O-acetyl-1,2:5,6-di-O-isopropylidene-α-D-gulofuranose (15)25, 26 
 
3-O-acetyl-1,2:5,6-di-O-isopropylidene-erythro-α-D-hexofuran-3-enose (10, 2.00 g, 6.62 mmol) was 
stirred in EtOAc (40 mL) with Pd/C (ca. 0.2 g) under hydrogen at 1.75 Bar for 4 h. Filtering through 
Celite and concentration afforded a pale yellow solid. Purification by column chromatography (4:1 
hexane/EtOAc) afforded the product as a colourless syrup which slowly solidified to a white solid on 
standing (1.52 g, 76%).  
δH(400 MHz, CDCl3) 5.71 (d, J=4.1, 1H, H1), 4.98 (dd, J=6.5, 5.7, 1H, H3), 4.72 (dd, J=5.7, 4.1, 1H, 
H2), 4.51 (d ps t, J=9.2, 7.2, 1H, H5), 4.03 – 3.95 (m, 2H, H4 & H6), 3.44 (dd, 
J=8.3, 7.2, 1H, H6’), 2.03 (s, 3H, COCH3), 1.48 (s, 3H, Me), 1.33 (s, 3H, Me), 
1.28 (s, 3H, Me), 1.25 (s, 3H, Me). Data match literature values.25 
δC(101 MHz, CDCl3) 169.4 (COCH3), 114.3 ((CH3)2C), 109.0 ((CH3)2C), 104.9 (C1), 81.1 (C4), 78.4 
(C2), 75.0 (C5), 71.6 (C3), 66.2 (C6), 26.7 (Me), 26.6 (Me), 26.5 (Me), 25.1 
(Me), 20.4 (COCH3). Data match literature values.
25 
Rf 0.6 (2:3 hexane/EtOAc) 
m.p. 96-98 °C, not recrystallised (Lit.26 73-74 °C, recrystallised from EtOH) 
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ν (cm-1) 2989, 2939, 2870 (CH), 1742 (C=O) 
m/z (ES+ TOF) 325.1253 [M+Na]+ (C14H22O7Na), calc. 325.1263 – 100% 
5.3.1.5 1,2:5,6-Di-O-isopropylidene-α-D-gulofuranose (11)20, 25, 26  
 
From 3-O-acetyl-1,2:5,6-di-O-isopropylidene-erythro-α-D-hexofuran-3-enose (10): 
3-O-acetyl-1,2:5,6-di-O-isopropylidene-erythro-α-D-hexofuran-3-enose (10, 1.00 g, 3.33  mmol) was 
dissolved in MeOH (20 mL) at room temperature. NaBH4 (151 mg, 4.00 mmol) was added and the 
mixture stirred for 1 h. Water (20 mL) was added and the product extracted into CHCl3. Purification 
by column chromatography (2:3 hexane/EtOAc) afforded the product as a white solid (687 mg, 68%). 
From 3-O-acetyl-1,2:5,6-di-O-isopropylidene-α-D-gulofuranose (15): 
3-O-acetyl-1,2:5,6-Di-O-isopropylidene-α-D-gulofuranose (15, 24.2 g, 80.0 mmol) was dissolved in 
MeOH (200 mL) at room temperature. K2CO3 (1.00 g) was added and the mixture stirred for 30 min. 
The solvent was swapped to CHCl3 (100 mL), washed with water, dried over MgSO4, filtered and ca. 
80 mL of CHCl3 removed by evaporation. Precipitation with hexane, filtering and drying afforded the 
product as a white solid (18.9 g, 90%). 
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δH(400 MHz, CDCl3) 5.76 (d, J=4.1, 1H, H1), 4.64 (dd, J=6.2, 4.1, 1H, H2), 4.46 (d ps t, J=8.7, 7.2, 
1H, H5), 4.25 – 4.17 (m, 2H, H3 & H6), 3.88 (dd, J=8.7, 5.8, 1H, H4), 3.69 (dd, 
J=8.6, 7.2, 1H, H6’), 2.69 (d, J=6.0, 1H, exchangeable, OH), 1.61 (s, 3H, Me), 
1.43 (s, 3H, Me), 1.40 (s, 3H, Me), 1.36 (s, 3H, Me). Data match literature 
values.25 
δC(101 MHz, CDCl3) 115.1 ((CH3)2C), 109.3 ((CH3)2C), 105.4 (C1), 84.4 (C4), 80.0 (C2), 75.6 (C5), 
69.8 (C3), 66.5 (C6), 27.2 (Me), 27.2 (Me), 26.8 (Me), 25.3 (Me). Data match 
literature values.25 
Rf 0.5 (2:3 hexane/EtOAc) 
m.p. 103-104 °C (Lit.26 105-106 °C) 
[α]D +1.6° (c = 1, CHCl3) (Lit.
20 +7.5°, c=1, CHCl3) 
ν (cm-1) 3486 (OH), 2989, 2938 (CH) 
m/z (ES+ TOF) 283.1162 [M+Na]+ (C12H20O6Na), calc. 283.1158 – 100% 
5.3.1.6 3-Azido-3-deoxy-1,2:5,6-di-O-ispropylidene-α-D-galactofuranose (12)18 
 
1,2:5,6-Di-O-isopropylidene-α-D-gulofuranose (11, 200 mg, 0.76 mmol) was dissolved in DCM (5 mL) 
and pyridine (0.5 mL) at 0 °C. Tf2O (0.26 mL, 1.5 mmol) was added dropwise and the mixture stirred 
for 15 min, when TLC revealed the complete consumption of starting material. The mixture was 
diluted with DCM, washed with ice-cold 1M HCl then water and the solvent removed by evaporation 
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to give an orange oil. The crude triflate was immediately taken up in DMF (10 mL), NaN3 (249 mg, 
3.83 mmol) added and the mixture stirred for 2 h. The mixture was diluted with DCM and washed 6 
times with water, twice with brine and dried over MgSO4. Removal of the solvent gave the azide as a 
pale yellow oil (165 mg, 76%) which analysis revealed to be sufficiently pure to take forward without 
further purification. 
δH(400 MHz, CDCl3) 5.76 (d, J=3.9, 1H, H1), 4.57 (dd, J=3.9, 1.8, 1H, H2), 4.32 (d ps t, J=6.7, 5.7, 
1H, H5), 4.04 (dd, J=8.4, 6.7, 1H, H6), 3.91 (dd, J=5.7, 1.8, 1H, H3), 3.84 
(dd, J=8.4, 6.7, 1H, H6’), 3.79 (ps t, J=5.7, 1H, H4), 1.54 (s, 3H, Me), 1.42 (s, 
3H, Me), 1.35 (s, 3H, Me), 1.34 (s, 3H, Me). Data match literature values.18 
δC(101 MHz, CDCl3) 114.4 ((CH3)2C), 110.1 ((CH3)2C), 104.9 (C1), 85.8 (C2), 83.1 (C4), 74.6 (C5), 
65.6 (C6), 65.5 (C3), 27.5 (Me), 26.9 (Me), 26.4 (Me), 25.2 (Me). Data 
match literature values.18 
Rf 0.6 (3:1 hexane/EtOAc) 
ν (cm-1) 2988, 2939 (CH), 2104 (N3) 
m/z (ES+ TOF) 308.1235 [M+Na]+ (C12H19N3O5Na), calc. 308.1222 – 100% 
5.3.1.7 1,2,4,6-Tetra-O-acetyl-3-azido-3-deoxy-D-galactopyranose (5)18, 59  
 
1,2:5,6-Di-O-isopropylidene-α-D-gulofuranose (11, 4.00 g, 15.4 mmol) was converted to 3-azido-3-
deoxy-1,2:5,6-di-O-ispropylidene-α-D-galactofuranose using the procedure in 5.3.1.6. The azido-
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galactofuranose was dissolved in 80% aq. TFA (20 mL) and stirred at room temperature for 2 h, when 
TLC (2:3 hexane/EtOAc) revealed only a baseline spot. The solvent was removed by co-evaporation 
with toluene. The residue was taken up in pyridine (100 mL) and cooled to 0 °C. DMAP (ca. 0.5 g), 
imidazole (5.00 g, 73.4 mmol) and Ac2O (20.0 mL, 212 mmol) were added and the mixture stirred for 
16 h whilst warming to room temperature. The mixture was poured into ice-cold sat. NaHCO3 
solution (500 mL) and the product extracted into DCM, washed with sat. NaHCO3 solution and dried 
over MgSO4. Removal of the solvents by evaporation gave crude product as a sticky brown solid. 
Purification by stepped gradient column chromatography (20% → 30% → 40% EtOAc in hexane) 
yielded the product as a colourless syrup, which turned to a semi-solid on standing (3.43 g, 60%, α:β 
1:1). 
δH(400 MHz, CDCl3) 6.34 (d, J=3.6, 0.5H, H1α), 5.66 (d, J=8.2, 0.5H, H1β), 5.48 (dd, J=3.2, 1.2, 
0.5H, H4α), 5.44 (d, J=3.2, 0.5H, H4β), 5.26 – 5.21 (m, 1H, H2), 4.27 (d ps t, 
J=6.5, 1.2, 0.5H, H5α), 4.16 – 3.97 (m, 3H, H3α, H5β,H6 & H6’), 3.67 (dd, 
J=10.6, 3.2, 0.5H, H3β), 2.19 – 2.01 (m, 12H, 4 x COCH3) 
Anomeric proton signals match those found by Lowary18 (other peaks are 
not reported.) 
NMR data reported by Hainrichson59 are inconsistent with either 
anomerically pure products nor an anomeric mixture and are disregarded. 
δC(101 MHz, CDCl3) 170.5 (COCH3), 169.9 (COCH3), 169.7 (COCH3), 169.3 (COCH3), 169.1 
(COCH3), 168.8 (COCH3), 92.3 (C1β), 89.3 (C1α), 72.7 (C5β), 69.1 (C5α), 68.8 
(C2), 68.1 (C2), 67.7 (C4α), 67.4 (C4β), 61.7 (C3β), 61.5 (C6), 61.3 (C6), 57.7 
(C3α), 21.1 (COCH3), 20.9 (COCH3), 20.8 (COCH3), 20.7 (COCH3), 20.6 
(COCH3), 20.6 (COCH3). No literature values found. 
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Rf 0.6 (2:3 hexane/EtOAc) 
ν (cm-1) 2977 (CH), 2110 (N3), 1746 (C=O) 
m/z (ES+ TOF) 396.1023 [M+Na]+ (C14H19N3O9Na), calc. 396.1019 – 100% 
5.3.1.8 1,2:5,6-Di-O-isopropylidene-α-D-allofuranose (14)26, 58, 60 
 
1,2:5,6-Di-O-isopropylidene-ribo-α-D-hexofuran-3-ulose (9, 100 mg, 0.33  mmol) was dissolved in 
MeOH (5 mL) at room temperature. NaBH4 (17 mg, 0.46 mmol) was added and the mixture stirred for 
1 h. Water (10 mL) was added and the product extracted into CHCl3. Removal of the solvent by 
evaporation afforded the product as a white solid (100 mg, 99%).  
δH(400 MHz, CDCl3) 5.79 (d, J=3.9, 1H, H1), 4.59 (dd, J=5.1, 3.9, 1H, H2), 4.29 (d ps t, J=6.6, 4.8, 
1H, H5), 4.08 – 3.97 (m, 3H, H3, H6 & H6’), 3.80 (dd, J=8.5, 4.8, 1H, H4), 
2.58 (d, J=8.3, 1H, OH), 1.56 (s, 3H, Me), 1.44 (s, 3H, Me), 1.36 (s, 3H, Me), 
1.35 (s, 3H, Me). Data match literature values.25 
δC(101 MHz, CDCl3) 112.9 ((CH3)2C), 109.9 ((CH3)2C), 104.0 (C1), 79.8 (C4), 79.0 (C2), 75.68 (C5), 
72.5 (C3), 65.9 (C6), 26.6 (Me), 26.6 (Me), 26.4 (Me), 25.3 (Me). Data match 
literature values.25 
Rf 0.5 (2:3 hexane/EtOAc) 
m.p. 73-75 °C, not recrystallised (Lit.26 73-74 °C, recrystallised from cyclohexane) 
[α]D +22.4° (c=1, CHCl3) (Lit.
26 +38°, c=1, CHCl3) 
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ν (cm-1) 3471 (OH), 2993, 2949, 2919, 2891, 2874 (CH) 
m/z (ES+ TOF) 283.1163 C12H20O6Na (calc. 283.1158) – 100% 
5.3.1.9 Ethyl 1,2,4,6-tetra-O-acetyl-3-azido-3-deoxy-D-thiogalactopyranoside (35)  
 
No literature reference found 
1,2,4,6-Tetra-O-acetyl-3-azido-3-deoxy-D-galactopyranose (5, 300 mg, 0.80 mmol), was dissolved in 
DCM (10 mL) at 0 °C. EtSH (0.09 mL, 1.1 mmol) and BF3·Et2O (0.30 mL, 2.4 mmol) were added and 
stirred overnight at reflux. The mixture was quenched with sat. NaHCO3, extracted into DCM, dried 
with MgSO4 and the solvent removed by evaporation producing a dark brown syrup. Purification by 
flash column chromatography (5:1 hexane/EtOAc) gave the product as an orange syrup (232 mg, 
77%, α:β 1:1 ). A small amount of pure α and pure β products were obtained which allowed for NMR 
characterisation of each anomer. 
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δH(400 MHz, CDCl3) α-anomer: 
5.71 (d, J=5.6, 1H, H1), 5.40 (dd, J=3.4, 1.1, 1H, H4), 5.18 (dd, J=10.9, 5.6, 
1H, H2), 4.51 (ddd, J=8.7, 5.7, 1.1, 1H, H5), 4.11 (dd, J=11.5, 5.7, 1H, H6), 
4.02 (dd, J=11.5, 7.1, 1H, H6’), 3.89 (dd, J=10.9, 3.4, 1H, H3), 2.61 – 2.48 
(m, 2H, CH3CH2), 2.13 (s, 3H, COCH3), 2.12 (s, 3H, COCH3), 2.03 (s, 3H, 
COCH3), 1.31 – 1.18 (m, 3H, CH3CH2) 
β-anomer: 
5.45 (dd, J=3.4, 1.1, 1H, H4), 5.19 (ps t, J=10.0, 1H, H2), 4.46 (d, J=10.0, 1H, 
H1), 4.10 (dd, J=6.6, 0.9, 2H, H6 & H6’), 3.88 (d ps t, J=6.6, 1.1, 1H, H5), 
3.64 (dd, J=10.0, 3.4, 1H, H3), 2.79 – 2.05 (m, 2H, CH3CH2), 2.16 (s, 3H, 
COCH3), 2.13 (s, 3H, COCH3), 2.05 (s, 3H, COCH3), 1.30 – 1.24 (m, 3H, 
CH3CH2) 
δC(101 MHz, CDCl3) α-anomer: 
170.4 (COCH3), 170.0 (COCH3), 169.9 (COCH3), 81.7 (C1), 69.8 (C2), 68.3 
(C4), 66.9 (C5), 62.0 (C6), 58.7 (C3), 24.1 (CH3CH2), 20.9 (COCH3), 20.7 
(COCH3), 20.7 (COCH3), 14.8 (CH3CH2) 
β-anomer: 
170.5 (COCH3), 170.4 (COCH3), 169.5 (COCH3), 84.3 (C1), 75.3 (C5), 68.4 
(C2), 67.9 (C4), 63.0 (C3), 61.8 (C6), 24.4 (CH3CH2), 20.9 (COCH3), 20.8 
(COCH3), 20.7 (COCH3), 14.9 (CH3CH2) 
Rf 0.6 (2:3 hexane/EtOAc) 
ν (cm-1) 2967, 2930 (CH), 2109 (N3), 1744 (C=O) 
m/z (ES+ TOF) 398.0990 [M+Na]+ (C14H21N3O7SNa), calc. 398.0998 – 100% 
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5.3.1.10 Phenyl 1,2,4,6-tetra-O-acetyl-3-azido-3-deoxy-β-D-thiogalactopyranoside (36)61  
 
1,2,4,6-Tetra-O-acetyl-3-azido-3-deoxy-D-galactopyranose (5, 2.28 g, 6.11 mmol), was dissolved in 
DCM (20 mL) at 0 °C. PhSH (1.00 mL, 9.74 mmol) and BF3·Et2O (2.5 mL, 20 mmol) were added and 
stirred overnight at room temperature followed by 3 h heated at reflux. The mixture was quenched 
with sat. Na2CO3, extracted into DCM, dried with MgSO4 and the solvent removed by evaporation, 
producing a pale pink syrup which was solidified by the addition of a few drops of EtOAc. Purification 
by trituration under hexane gave the product as an off-white solid (1.22 g, 47%, β only). 
δH(400 MHz, CDCl3) 7.57 – 7.46 (m, 2H, ArH), 7.37 – 7.29 (m, 3H, ArH), 5.44 (dd, J=3.3, 0.8, 1H, 
H4), 5.21 (ps t, J=10.0, 1H, H2), 4.70 (d, J=10.0, 1H, H1), 4.12 (d, J=6.5, 2H, 
H6 & H6’), 3.89 (d ps t, J=6.5, 0.8, 1H, H5), 3.63 (dd, J=10.0, 3.3, 1H, H3), 
2.18 (s, 3H, COCH3), 2.15 (s, 3H, COCH3), 2.05 (s, 3H, COCH3). Data match 
literature values.61 
δC(101 MHz, CDCl3) 173.1 (COCH3), 171.4 (COCH3), 169.5 (COCH3), 132.6 (Ar), 130.0 (Arq), 
129.0 (Ar), 128.3 (Ar), 87.1 (C1), 75.4 (C5), 68.4 (C2), 67.9 (C4), 63.0 (C3), 
62.0 (C6), 21.0 (COCH3), 20.8 (COCH3), 20.7 (COCH3). No literature values 
found. 
Rf 0.8 (2:3 hexane/EtOAc) 
m.p. 104-106 °C. No literature value found. 
[α]D +14.4° (c=0.5, CHCl3). No literature value found. 
ν (cm-1) 3069, 3033, 2989, 2969, 2948, 2879 (CH), 2094 (N3), 1748, 1737 (C=O) 
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m/z (ES+ TOF) 446.0987 [M+Na]+ (C18H21N3O7SNa), calc. 446.0998 – 100% 
 
5.3.1.11 3-Deoxy-1,2:5,6-di-O-isopropylidene-3-(2-naphthamido)-α-D-galactofuranose (57)  
 
No literature reference found 
1,2:5,6-Di-O-isopropylidene-α-D-gulofuranose (11, 2.00 g, 7.68 mmol) was converted to the galacto-
azide using the method detailed in 5.3.1.6. The azide was dissolved in EtOAc (40 mL), Pd/C (ca. 0.2 g) 
was added and the mixture stirred under hydrogen at atmospheric pressure overnight. The mixture 
was filtered through Celite and the solvent swapped to pyridine (40 mL). 2-Naphthoyl chloride (1.46 
g, 7.68 mmol) was added at 0 °C and the liquor stirred at room temperature for 1.5 h. The reaction 
mixture was poured over ice, extracted into DCM and washed with sat. NaHCO3, water, dried over 
MgSO4 and the solvents removed by evaporation. Precipitation from CHCl3 with hexane, followed by 
filtering and drying resulted in an off-white solid (2.45 g, 76%). 
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δH(400 MHz, CDCl3) 8.28 (d, J=1.3, 1H, ArH), 7.94 – 7.87 (m, 3H, ArH), 7.81 (dd, J=8.6, 1.8, 1H, 
ArH), 7.63 – 7.53 (m, 2H, ArH), 6.50 (d, J=6.5, 1H, NH), 6.05 (d, J=3.8, 1H, 
H1), 4.84 (dd, J=3.8, 1.1, 1H, H2), 4.52 (ps q, J=7.0, 1H, H5), 4.31 (ddd, 
J=6.5, 4.3, 1.1, 1H, H3), 4.20 (dd, J=7.0, 4.3, 1H, H4), 4.15 (dd, J=8.6, 7.0, 
1H, H6), 3.93 (dd, J=8.6, 7.0, 1H, H6’), 1.63 (s, 3H, Me), 1.46 (s, 3H, Me), 
1.39 (s, 3H, Me), 1.36 (s, 3H, Me) 
δC(101 MHz, CDCl3) 167.4 (CONH), 135.1 (Arq), 129.1 (Ar), 128.9 (Ar), 128.1 (Ar), 127.9 (Ar), 
127.8 (Ar), 127.1 (Ar), 123.4 (Ar), 113.7 (C(CH3)2), 110.1 (C(CH3)2), 105.7 
(C1), 85.9 (C2), 85.1 (C4), 75.7 (C5), 66.0 (C6), 57.6 (C3), 27.3 (Me), 26.8 
(Me), 26.6 (Me), 25.4 (Me) 
2 x Arq not seen 
Rf 0.5 (2:3 Hexane/EtOAc) 
m.p. 208-210 °C 
[α]D +13.6° (c = 1, CHCl3) 
ν (cm-1) 3343 (NH), 2989, 2887 (CH), 1639 (C=O) 
m/z (ES+ TOF) 436.1729 [M+Na]+ (C23H27NO6Na), calc. 436.1736 – 100% 
5.3.1.12 1,2,4,6-Tetra-O-acetyl-3-deoxy-3-(2-naphthamido)-α-D-galactopyranose (58)  
 
No literature reference found 
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3-Deoxy-1,2:5,6-di-O-isopropylidene-3-(2-naphthamido)-α-D-galactofuranose (57, 1.00 g, 2.41 mmol) 
was dissolved in 90% aq. TFA (20 mL) and stirred at room temperature for 40 min, when TLC (2:3 
Hexane/EtOAc) revealed only a baseline spot. The solvent was removed by co-evaporation with 
toluene and the crude intermediate was taken up in pyridine (40 mL) and cooled to 0 °C. DMAP (ca. 
0.2 g) and distilled Ac2O (2.3 mL, 24 mmol) were added and the mixture stirred overnight at room 
temperature. The product was extracted into DCM and washed with water then sat. NaHCO3 solution 
and dried over MgSO4. Removal of the solvent by evaporation gave crude product as a pale orange 
solid. Purification by stepped gradient column chromatography (0% → 0.5% → 1% MeOH/DCM) 
yielded the naphthamide as a cream solid (925 mg, 76%, α only). 
δH(400 MHz, CDCl3) 8.20 (d, J=1.4, 1H, ArH), 7.95 – 7.85 (m, 3H, ArH), 7.71 (dd, J=8.6, 1.8, 1H, 
ArH), 7.60 – 7.52 (m, 2H, ArH), 6.55 (d, J=7.9, 1H, NH), 6.38 (d, J=3.6, 1H, 
H1), 5.68 (dd, J=3.1, 1.1, 1H, H4), 5.44 (dd, J=11.5, 3.6, 1H, H2), 4.91 (ddd, 
J=11.5, 7.9, 3.1, 1H, H3), 4.45 (ddd, J=7.1, 6.5, 1.1, 1H, H5), 4.14 (dd, 
J=11.5, 6.5, 1H, H6), 4.05 (dd, J=11.5, 7.1, 1H, H6’), 2.22 (s, 3H, COCH3), 
2.15 (s, 3H, COCH3), 2.06 (s, 3H, COCH3), 2.06 (s, 3H, COCH3) 
δC(101 MHz, CDCl3) 172.1 (COCH3), 170.5 (COCH3), 169.8 (COCH3), 169.1 (COCH3), 167.5 
(COCH3), 135.0 (Arq), 132.7 (Arq), 130.6 (Arq), 129.2 (Ar), 128.8 (Ar), 128.1 
(Ar), 127.8 (Ar), 127.8 (Ar), 127.0 (Ar), 123.2 (Ar), 89.6 (C1), 69.4 (C5), 68.9 
(C4), 67.0 (C2), 61.7 (C6), 49.2 (C3), 21.1 (COCH3), 21.0 (COCH3), 20.8 
(COCH3), 20.7 (COCH3) 
Rf 0.5 (2:3 hexane/EtOAc) 
m.p. 212-214 °C 
[α]D +133.6° (c = 1, CHCl3) 
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ν (cm-1) 3371 (NH), 3058, 2943 (CH), 1738, 1646 (C=O) 
m/z (ES+ TOF) 524.1525 [M+Na]+ (C25H27NO10Na), calc. 524.1533 – 100% 
5.3.1.13 1,4,6-Tri-O-acetyl-3-deoxy-2-O,3-N-(2-naphthimidato)-α-D-talopyranose (60)  
 
No literature reference found 
1,2,4,6-Tetra-O-acetyl-3-Deoxy-3-(2-naphthamido)-α-D-galactopyranose (58, 100 mg, 0.20 mmol) 
was dissolved in HBr (32% in AcOH, 1.0 mL, 4.0 mmol), Ac2O (47 μL, 0.5 mmol) added and the mixture 
stirred overnight in darkness. The liquor was diluted with DCM, poured over ice, washed with water 
and sat. NaHCO3, dried over MgSO4 and the solvents removed by evaporation. The crude glycosyl 
bromide was dissolved in DCM (10 mL), methyl 6-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-
glucopyranoside (110 mg. 0.22 mmol) and 3Å molecular sieves added and the mixture stirred at 
room temperature for 30 min. Ag2CO3 (55 mg, 0.20 mmol) was added and the mixture heated at 
reflux in darkness for 3 days. Cooling, filtering through Celite and purification by flash column 
chromatography gave the oxazoline as a white solid (67 mg, 35%). None of the expected disaccharide 
was obtained. 
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δH(400 MHz, CDCl3) 8.49 (s, 1H, ArH), 8.06 (dd, J=8.7, 1.7, 1H, ArH), 7.95 – 7.90 (m, 1H, ArH), 
7.89 – 7.83 (m, 2H, ArH), 7.59 – 7.48 (m, 2H, ArH), 5.75 (ps t, J=2.2, 1H, 
H1), 5.63 (dd, J=7.3, 4.8, 1H, H4), 5.16 (dd, J=4.8, 2.2, 1H, H2), 4.55 (d ps t, 
J=7.3, 4.8, 1H, H5), 4.34 (d ps t, J=4.8, 2.2, 1H, H3), 4.26 (dd, J=12.0, 4.8, 
1H, H6), 4.18 (dd, J=12.0, 7.3, 1H, H6’), 2.20 (s, 3H, COCH3), 2.16 (s, 3H, 
COCH3), 1.98 (s, 3H, COCH3) 
δC(101 MHz, CDCl3) 170.4 (COCH3), 170.3 (COCH3), 169.8 (COCH3), 156.0 (C7), 135.0 (Arq), 
132.7 (Arq), 129.2 (Ar), 128.7 (Arq), 128.6 (Ar), 128.2 (Ar), 127.8 (Ar), 126.6 
(Ar), 124.4 (Ar), 89.8 (C1), 70.4 (C5), 68.0 (C4), 66.2 (C2), 63.51 (C6), 48.3 
(C3), 21.0 (COCH3), 21.0 (COCH3), 20.8 (COCH3) 
Rf 0.3 (2:3 hexane/EtOAc) 
m.p. 214-216 °C 
[α]D +72.0 (c = 1, CHCl3) 
ν (cm-1) 3059, 2946, 2902, 2852 (CH), 1742, 1714 (C=O), 1641 (C=N) 
m/z (ES+ TOF) 464.1303 [M+Na]+ (C23H23NO8Na) calc. 464.1320 – 100% 
5.3.1.14 Penta-O-acetyl-α-D-galactopyranose (6)62 
 
D-galactose (5.00 g, 27.8 mmol) and DMAP (ca. 0.5 g) were dissolved in pyridine (20 mL) at 0 °C. Ac2O 
(20 mL) was added slowly and the reaction stirred for 4 h. The mixture was poured over ice, allowed 
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to warm to room temperature and the product extracted into DCM. Solvents were removed by 
evaporation and the crude product dissolved in a minimum of ethyl acetate and precipitated with 
hexane, affording an off-white solid (8.07 g, 75%, α only). 
δH(400 MHz, CDCl3) 6.36 (d, J=1.7, 1H, H1), 5.49 – 5.46 (m, 1H, H4), 5.36 – 5.31 (m, 2H, H2 & 
H3), 4.32 (d ps t, J=6.7, 1.0, 1H, H5), 4.08 (dd, J=6.7, 4.9, 2H, H6 & H6’), 2.14 
(s, 6H, 2 x COCH3), 2.02 (s, 3H, COCH3), 2.00 (s, 3H, COCH3), 1.98 (s, 3H, 
COCH3). Data match literature values.
62 
δC(101 MHz, CDCl3) 170.4 (COCH3), 170.2 (COCH3), 169.9 (COCH3), 169.0 (COCH3), 89.8 (C1), 
68.8 (C5), 67.5 (C4), 67.4 (C2/3), 66.5 (C3/2), 61.3 (C6), 20.9 (COCH3), 20.7 
(COCH3), 20.6 (COCH3). Data match literature values.
62 
Rf 0.5 (2:3 hexane/EtOAc) 
ν (cm-1) 2960 (CH), 1760, 1738 (C=O) 
m/z (ES+ TOF) 413.1065 [M+Na]+ (C16H22O11Na), calc. 413.1060 – 100% 
5.3.1.15 Phenyl 2,3,4,6-tetra-O-acetyl-β-D-thiogalactopyranoside (18)30, 63, 64 
 
Penta-O-acetyl-β-D-galactopyranose (10.0 g, 25.7 mmol), was dissolved in DCM (150 mL) at 0 °C. 
PhSH (3.5 mL, 34 mmol) and BF3·Et2O (9.8 mL, 79 mmol) were added and stirred overnight at room 
temperature. The mixture was quenched with sat. Na2CO3, extracted into DCM, dried with MgSO4 
and the solvent removed by evaporation producing a soft white foam which was solidified by 
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freezing (9.11 g, 81%, β only). 
δH(400 MHz, CDCl3) 7.49 – 7.43 (m, 2H, ArH), 7.27 – 7.23 (m, 3H, ArH), 5.34 (dd, J=3.4, 0.8, 1H, 
H4), 5.18 (ps t, J=10.0, 1H, H2), 5.01 (dd, J=10.0, 3.4, 1H, H3), 4.68 (d, 
J=10.0, 1H, H1), 4.11 (dd, J=11.3, 6.7, 1H, H6), 4.04 (dd, J=11.3, 6.7, 1H, 
H6’), 3.88 (d ps t, J= 6.7, 0.8, 1H, H5), 2.05 (s, 3H, COCH3), 2.03 (s, 3H, 
COCH3), 1.97 (s, 3H, COCH3), 1.91 (s, 3H, COCH3). Data match literature 
values.30 
δC(101 MHz, CDCl3) 170.2 (COCH3), 170.0 (COCH3), 169.8 (COCH3), 169.2 (COCH3), 132.4 (2 x 
Ar), 128.8 (Ar), 128.0 (Ar), 86.3 (C1), 74.3 (C5), 71.8 (C3), 67.1 (C2 & C4), 
61.5 (C6), 20.7 (COCH3), 20.5 (COCH3), 20.5 (COCH3), 20.4 (COCH3). Data 
match literature values.63 
Rf 0.7 (2:3 hexane/EtOAc) 
m.p. 74-76 °C not recrystallised (Lit.64 80-81 °C, recrystallised from Et2O/hexane) 
ν (cm-1) 3064, 2981 (CH), 1743 (C=O) 
m/z (ES+ TOF) 463.1040 [M+Na]+ (C20H24O9SNa), calc. 463.1039 – 100% 
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5.3.1.16 Phenyl β-D-thiogalactopyranoside (19) 31, 65 
 
Phenyl 2,3,4,6-tetra-O-acetyl-β-D-thiogalactopyranoside (18, 7.28 g, 16.5 mmol) was dissolved in 73 
mL of MeOH and stood for 1 week at room temperature. The liquor was concentrated by removing 
roughly 65 mL of MeOH by evaporation and the product precipitated with CHCl3, to afford a white 
solid (4.19 g, 93%). 
δH(400 MHz, DMSO-d
6) 7.48 – 7.42 (m, 2H, ArH), 7.33 – 7.26 (m, 2H, ArH), 7.23 – 7.17 (m, 1H, ArH), 
5.13 (d, J=5.1, 1H, OH2), 4.88 (d, J=4.2, 1H, OH4), 4.63 (t, J=4.7, 1H, OH6), 
4.58 (d, J=9.5, 1H, H1), 4.48 (d, J=4.2, 1H, OH3), 3.71 (ps t, J=4.2, 1H, H3), 
3.56 – 3.39 (m, 4H, H2, H5, H6 & H6’), 3.37 (ps t, J=4.2, 1H, H4). Literature 
values not found for DMSO-d6.31 
δC(101 MHz, DMSO-d
6) 135.5 (Ar), 129.2 (Arq), 128.7 (Ar), 126.0 (Ar), 87.7 (C1), 79.1 (C2/5), 74.69 
(C4), 69.2 (C5/2), 68.3 (C3), 60.5 (C6). Literature values not found for 
DMSO-d6.31 
m.p. 98-100 °C (Lit.65 98-100 °C) 
ν (cm-1) 3276 (br, OH), 2896 (CH) 
m/z  295.0629 [M+Na]+ (C12H16O5SNa), calc. 295.0616 – 100% 
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5.3.1.17 Phenyl 4,6-O-benzylidene-β-D-thiogalactopyranoside (20)32 
 
Phenyl β-D-thiogalactopyranoside (19, 4.00 g, 14.4 mmol) was dissolved in MeCN (40 mL) and DCM 
(5 mL), with 4 Å sieves and DOWEX and stirred at room temperature overnight. The solvent was 
removed by evaporation after filtering, and recrystallisation from EtOH afforded the product as a 
white solid (4.05 g, 76%). 
δH(400 MHz, CDCl3) 7.73 – 7.66 (m, 2H, ArH), 7.44 – 7.27 (m, 8H, ArH), 5.52 (s, 1H, H7), 4.54 
(d, J=9.2, 1H, H1), 4.39 (dd, J=12.5, 1.5, 1H, H6), 4.23 (dd, J=2.1, 1.5, 1H, 
H4), 4.05 (dd, J=12.5, 1.5, 1H, H6’), 3.76 – 3.65 (m, 2H, H2 & H3), 3.57 (ps 
q, J=1.5, 1H, H5), 2.52 (d, J=1.3, 1H, OH3), 2.51 – 2.47 (m, 1H, OH2). Data 
match literature values.32 
δC(101 MHz, CDCl3) 137.7 (Arq), 133.9 (Ar), 130.8 (Arq), 129.5 (Ar), 129.1 (Ar), 128.3 (2 x Ar), 
126.6 (Ar), 101.5 (C7), 87.1 (C1), 75.4 (C4), 73.9 (C2), 70.2 (C5), 69.4 (C6), 
68.9 (C3). Data match literature values.32 
m.p. 151-153 °C (Lit.32 164-165 °C, recrystallisation details not specified)  
ν (cm-1) 3534 (OH) ,3393 (br, OH), 3061, 2977, 2910, 2869 (CH) 
m/z 383.0934 [M+Na]+ (C19H20O5SNa), calc. 383.0929 – 100% 
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5.3.1.18 Phenyl 4,6-O-benzylidene-β-D-thiogulopyranoside (21)21 
 
Phenyl 4,6-O-benzylidene-β-D-thiogalactopyranoside (20, 500 mg, 1.39 mmol) and pyridine (0.3 mL) 
were dissolved in DCM (5 mL)  at -20 °C. Triflic anhydride (270 μL, 1.60 mmol) was added dropwise 
over 5 mins and the reaction stirred for 1.5 h. AcCl (151 μL, 1.60 mmol) was added and the reaction 
allowed to warm to room temperature over 1 h. Further AcCl (132 μL, 1.40 mmol) and pyridine (0.1 
mL) were added and the reaction stirred at room temperature for 1 h. The mixture was diluted with 
DCM, washed with 0.5 M HCl, sat. NaHCO3 and brine, dried over MgSO4 and the solvents removed by 
evaporation. The residue was taken up in MeCN (5 mL), nBu4NNO2 (1.21 g, 4.16 mmol) added and the 
reaction stirred at 50 °C for 14 h. The mixture was cooled, diluted with DCM and washed with 0.5 M 
HCl, sat. NaHCO3 and brine. Drying over MgSO4 and removal of the solvent by evaporation produced 
a dark brown syrup (1.15 g, 206%). Analysis showed that no product had been formed, and the by-
products could not be identified. 
5.3.1.19 Ethyl 2,3,4,6-tetra-O-acetyl-D-thiogalactopyranoside (34)66, 67 
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Penta-O-acetyl-D-galactopyranose (10.0 g, 25.7 mmol), was dissolved in DCM (150 mL) at 0 °C. EtSH 
(2.5 mL, 34 mmol) and BF3·Et2O (9.8 mL, 79 mmol) were added and stirred overnight at room 
temperature. The mixture was quenched with sat. NaHCO3, extracted into DCM, dried with MgSO4 
and the solvent removed by evaporation, producing a pale yellow syrup. Purification by trituration 
with 5% Et2O in hexane followed by filtering and drying gave the product as an off-white solid (8.68 g, 
86%, α:β 3:2). 
δH(400 MHz, CDCl3) 5.29 – 5.17 (m, 3H, H2α, H2β & H3α) 
α-anomer: 
5.74 (d, J=5.4, 1H, H1), 5.44 (dd, J=3.1, 1.0, 1H, H4), 4.58 (d ps t, J=6.6, 1.0, 
1H, H5), 4.10 (d, J=6.6, 2H, H6 & H6’), 2.64 – 2.46 (m, 2H, CH2CH3), 2.13 (s, 
3H, COCH3), 2.06(s, 3H, COCH3), 2.03(s, 3H, COCH3), 1.98(s, 3H, COCH3), 
1.26 (t, J=7.4, 3H, CH2CH3). No literature values found. 
β-anomer: 
5.42 (dd, J=3.4, 0.9, 1H, H4), 5.04 (dd, J=10.0, 3.4, 1H, H3), 4.48 (d, J=9.9, 
1H, H1), 4.16 (dd, J=11.4, 6.6, 1H, H6), 4.09 (dd, J=11.4, 6.6, 3H, H6’), 3.92 
(d ps t, J=6.6, 0.9, 1H, H5), 2.80 – 2.64 (m, 2H, CH2CH3), 2.14(s, 3H, COCH3), 
2.06(s, 3H, COCH3), 2.03(s, 3H, COCH3), 1.97(s, 3H, COCH3), 1.27 (t, J=7.4, 
3H, CH2CH3). Data match literature values.
66 
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δC(101 MHz, CDCl3) 170.5 (COCH3), 170.3 (COCH3), 170.2 (COCH3), 170.2 (COCH3), 169.9 
(COCH3), 169.7 (COCH3), 84.2 (C1β), 82.0 (C1α), 74.5 (C5β), 72.0 (C3β), 68.3 
& 68.0 (C2α, C2β & C3α), 67.3 (C4α/β), 67.3 (C4β/α), 66.5 (C5α), 61.9 (C6α), 
61.6 (C6β), 24.5 (CH2CH3), 24.1 (CH2CH3), 20.9, 20.7 & 20.7 ( 5 x COCH3), 
14.9 (CH2CH3), 14.8 (CH2CH3). Data match literature values for β-anomer
66. 
Only partial data available for α-anomer67, data match although 
assignments differ. 
Rf 0.7 (2:3 hexane/EtOAc) 
ν (cm-1) 2985, 2966, 2943, 2916, 2872 (CH), 1750, 1738, 1729 (C=O) 
m/z (ES+ TOF) 415.1043 [M+Na]+ (C16H24O9SNa), calc. 415.1039 – 100% 
5.3.1.20 Phenyl 1,3,4,6-tetra-O-acetyl-2-tetrachlorophthalimido-2-deoxy-β-D-thioglucopyranoside 
(30)68, 69 
 
1,3,4,6-Tetra-O-acetyl-2-tetrachlorophthalimido-2-deoxy-β-D-glucopyranoside (27, 1.00 g, 1.65 
mmol), was dissolved in DCM (25 mL) at 0 °C. PhSH (0.23 mL, 2.2 mmol) and BF3·Et2O (0.60 mL, 4.9 
mmol) were added and the mixture stirred overnight at room temperature. The mixture was 
quenched with sat. Na2CO3, extracted into DCM, dried with MgSO4 and the solvent removed. The 
crude was dissolved in a minimum of CHCl3 and precipitated with hexane affording the product as a 
white solid (0.83 g, 77%, β only). 
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δH(400 MHz, CDCl3) 7.44 – 7.38 (m, 2H, ArH), 7.32 – 7.27 (m, 3H, ArH), 5.72 (dd, J=10.4, 9.2, 1H, 
H3), 5.67 (d, J=10.4, 1H, H1), 5.14 (dd, J=10.2, 9.2, 1H, H4), 4.33 (ps t, J=10.4, 
1H, H2), 4.28 (dd, J=12.3, 5.2, 1H, H6), 4.20 (dd, J=12.3, 2.4, 1H, H6’), 3.86 
(ddd, J=10.2, 5.2, 2.4, 1H, H5), 2.10 (s, 3H, COCH3), 2.03 (s, 3H, COCH3), 1.87 
(s, 3H, COCH3). Data match literature values.
68, 69 
δC(101 MHz, CDCl3) 170.7 (COCH3), 169.4 (COCH3), 163.4 (COCH3), 145.6 (CONCO), 133.4 (Ar), 
130.6 (Ar), 130.2 (Ar), 129.1 (Ar), 128.7 (Ar), 127.2 (Ar), 126.9 (Ar), 82.5 (C1), 
76.1 (C5), 71.8 (C3), 68.5 (C4), 62.2 (C6), 54.5 (C2), 20.8 (COCH3), 20.7 
(COCH3), 20.6 (COCH3). Peaks at δ < 135 match literature values;
68 too many 
peaks at δ > 135 are reported in the literature to be consisted with 30. 
m.p. 180-182 °C (Lit.69 181-183 °C) 
[α]D +70.8° (c=1, CHCl3) (Lit.
69 +55.6°, c=1, CHCl3) 
ν (cm-1) 2970, 2876 (CH), 1744, 1725 (C=O) 
m/z (ES+ TOF) 685.9594 [M+Na]+ (C26H21
35Cl4NO9SNa), calc. 685.9589 – 70% 
688.0 [M+Na]+ (C26H21
35Cl3
37Cl1NO9SNa) – 100% 
690.0 [M+Na]+ (C26H21
35Cl2
37Cl2NO9SNa) – 10% 
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5.3.2 Second Generation 
5.3.2.1 3-Deoxy-1,2:5,6-di-O-ispropylidene-3-phthalimido-α-D-galactofuranose (65)  
 
No literature reference found 
1,2:5,6-Di-O-isopropylidene-α-D-gulofuranose (11, 2.00 g, 7.68 mmol) was converted to the triflate 
using the procedure described in 5.3.1.6. The crude triflate was taken up in DMF (60 mL) and cooled 
to -20 °C, potassium phthalimide (7.10 g, 38.3 mmol) added and the mixture stirred for 18 h whilst 
warming to room temperature. The mixture was diluted with DCM and washed 6 times with water, 
twice with brine and dried over MgSO4. Removal of the solvent and purification by flash column 
chromatography (30% EtOAc in hexane) afforded the phthalimide as a white solid (1.95 g, 66%). 
δH(400 MHz, CDCl3) 7.91 – 7.81 (m, 2H, ArH), 7.81 – 7.71 (m, 2H, ArH), 6.18 (d, J=3.5, 1H, H1), 
4.89 (dd, J=3.5, 1.4, 1H, H2), 4.67 (dd, J=6.6, 1.4, 1H, H3), 4.32 (ps q, J=6.6, 
1H, H5), 4.22 (ps t, J=6.6, 1H, H4), 4.07 (dd, J=8.5, 6.6, 1H, H6), 3.76 (dd, 
J=8.5, 6.6, 1H, H6’), 1.63 (s, 3H, Me), 1.42 (s, 3H, Me), 1.35 (s, 6H, 2 x Me) 
δC(101 MHz, CDCl3) 167.4 (CONCO), 134.6 (Ar), 131.6 (Arq), 123.7 (Ar), 114.6 (C(CH3)2), 110.1 
(C(CH3)2), 106.0 (C1), 85.2 (C2), 81.8 (C4), 76.1 (C5), 65.5 (C6), 54.7 (C3), 
28.0 (Me), 27.1 (Me), 26.4 (Me), 25.2 (Me) 
Rf 0.4 (2:3 hexane/EtOAc) 
m.p. 96-98 °C 
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[α]D 56.8° (c=1, CHCl3) 
ν (cm-1) 3063, 2992, 2946, 2893 (CH), 1703 (C=O) 
m/z (ES+ TOF) 412.1373 [M+Na]+ (C20H23NO7Na), calc. 631.9661 – 100% 
5.3.2.2 3-Deoxy-1,2,5,6-tetra-O-acetyl-3-phthalimido-D-galactofuranose (70)  
 
No literature reference found 
From 3-deoxy-1,2:5,6-di-O-ispropylidene-3-phthalimido-α-D-galactofuranose (65): 
3-Deoxy-1,2:5,6-di-O-ispropylidene-3-phthalimido-α-D-galactofuranose (65, 1.26 g, 3.23 mmol) was 
dissolved in 80% aq. TFA (30 mL) and stirred at room temperature for 1 h, when TLC (2:3 
hexane/EtOAc) revealed only a baseline spot. The solvent was removed by co-evaporation with 
toluene and the residue was taken up in MeCN (15 mL), cooled to 0 °C and imidazole (132 mg, 1.94 
mmol) and Ac2O (1.47 mL, 15.5 mmol) were added and the mixture stirred for 2 days at room 
temperature. The mixture was poured into ice-cold sat. NaHCO3 solution (50 mL) and the product 
extracted into DCM, washed with sat. NaHCO3 solution and dried over MgSO4. Removal of the 
solvents by evaporation gave crude product as a cream foam. Purification by stepped gradient 
column chromatography (20% → 30% → 40% EtOAc in hexane) yielded the product as a white solid 
(785 mg, 51%, α:β 2:1). 
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From 1,2,4,6-tetra-O-acetyl-3-azido-3-deoxy-D-galactopyranose (4): 
1,2,4,6-Tetra-O-acetyl-3-azido-3-deoxy-D-galactopyranose (4, 264 mg, 0.71 mmol) was suspended in 
toluene (20 mL), triphenylphosphine (204 mg, 0.78 mmol) was added and the suspension stirred at 
room temperature until a solution formed. Phthalic anhydride (115 mg, 0.78 mmol) and nBu4NCN (20 
mg, 0.10 mmol) were added and the mixture heated at reflux for 1 week. Removal of the solvents 
and purification by stepped gradient column chromatography (20% → 30% → 40% → 50% EtOAc in 
hexane) afforded the product as a white solid (77 mg, 23%, α:β 2:1).  
δH(400 MHz, CDCl3) 7.92 – 7.81 (m, 2H, ArH), 7.81 – 7.69 (m, 2H, ArH), 6.45 (d, J=4.5, 0.7H, 
H1α), 6.35 (dd, J=11.6, 8.1, 0.3H, H2β), 5.97 (dd, J=9.4, 4.5, 0.7H, H2α), 5.75 
(d, J=8.1, 0.3H, H1β), 5.37 (d, J=2.5, 0.3H, H4β), 5.20 (d ps t, J=6.2, 3.3, 
0.7H, H5α), 5.15 (d ps t, J=7.0, 3.7, 0.3H, H5β), 4.96 (dd, J=9.4, 8.7, 0.7H, 
H3α), 4.82 (dd, J=8.7, 6.2, 0.7H, H4α), 4.65 (dd, J=11.6, 2.5, 0.3H, H3β), 4.38 
(dd, J=12.1, 3.7, 0.3H, H6β), 4.34 (dd, J=12.4, 3.3, 0.7H, H6α), 4.20 – 4.04 
(m, 1H, H6β’ & H6α’), 2.22 – 1.78 (stack, 12H, 4 x COCH3) 
δC(101 MHz, CDCl3) 170.0 (COCH3), 169.4 (COCH3), 168.7 (COCH3), 167.6 (COCH3), 166.6 
(COCH3), 134.7 (Ar), 131.5 (Arq), 123.9 (Ar), 94.0 (C1β), 93.0 (C1α), 75.1 
(C4α), 71.8 (C2α), 71.0 (C5α), 68.5 (C4β), 67.9 (C5β), 65.5 (C2β), 62.3 (C6α/β), 
61.3 (C6β/α), 53.6 (C3β), 52.1 (C3α), 21.2 (COCH3), 21.0 (COCH3), 20.9 
(COCH3), 20.8 (COCH3), 20.7 (COCH3), 20.5 (COCH3), 20.4 (COCH3) 
CONCO not visible. 
Rf 0.4 (2:3 hexane/EtOAc) 
ν (cm-1) 2960, 2939 (CH), 1742, 1713 (C=O) 
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m/z (ES+ TOF) 500.1192 [M+Na]+ (C22H23NO11Na), calc. 500.1169 – 100% 
977.2 [2M+Na]+ (C44H46N2O22Na) – 75% 
5.4 Glycosyl Acceptors 
5.4.1 First Generation 
5.4.1.1 2-Deoxy-2-(4-methoxybenzimino)-D-glucopyranose (24)22, 70, 71 
 
D-glucosamine hydrochloride (20.0 g, 92.8 mmol) was dissolved in 1M NaOH (100 mL) at room 
temperature. p-Anisaldehyde (12.7 mL, 104 mmol) was added and the mixture stirred until cloudy, 
then stirred at 0 °C for a further 5 h. The precipitated product was filtered and washed with water (2 
x 100 mL) and 1:1 MeOH/Et2O (2 x 100 mL) and dried to afford a white solid (20.1 g, 73%). 
δH(400 MHz, DMSO) 8.11 (s, 1H, H7), 7.72 – 7.63 (m, 2H, Ar), 7.03 – 6.96 (m, 2H, Ar), 6.52 (d, 
J=6.8, 1H, OH1), 4.91 (d, J=5.3, 1H, OH4), 4.80 (d, J=5.7, 1H, OH3), 4.70 (dd, 
J=7.9, 6.8 1H, H1), 4.54 (ps t, J=5.9, 1H, OH6), 3.80 (s, 3H, OMe), 3.72 (ddd, 
J=11.9, 5.9, 1.9, 1H, H6), 3.48 (d ps t, J=11.9, 5.9, 1H, H6’), 3.42 (d ps t, 
J=9.1, 5.7, 1H, H3), 3.24 (ddd, J=9.1, 5.9, 1.9, 1H, H5), 3.15 (d ps t, J=9.1, 
5.7, 1H, H4), 2.79 (dd, J=9.1, 7.9, 1H, H2). Data match literature values, 
except for the multiplicity of H3 – reported as dd, found to be d ps t.70 
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δC(101 MHz, DMSO) 161.1 (C7), 161.0 (Ar), 129.6 (Ar), 129.1 (Ar), 113.8 (Ar), 95.6 (C1), 78.1 
(C2), 76.8 (C5), 74.5 (C3), 70.3 (C4), 61.2 (C6), 55.2 (OMe). Data match 
literature values.70 
m.p. 153-154 °C (d) (Lit.71 154-155 °C (d)) 
ν (cm-1) 3487 (OH), 3319, 3205 (br, OH), 3027, 2970, 2932, 2895,2843 (CH), 1637 
(C=N) 
m/z (ES+ TOF) 320.1095 [M+Na]+ (C14H19NO6Na), calc. 320.1110 – 100% 
5.4.1.2 1,3,4,6-Tetra-O-acetyl-2-deoxy-2-(4-methoxybenzimino)- β-D-glucopyranose (25)22, 72 
 
2-Deoxy-2-(4-methoxybenzimino)-D-glucopyranose (24, 12.5 g, 42.1 mmol) and DMAP (ca. 1 g) were 
dissolved in pyridine (70 mL) at room temperature. Ac2O (40 mL) was added slowly and the mixture 
stirred for 4 h, then poured over ice (200 mL) and allowed to warm to room temperature. The 
precipitated product was filtered and washed with H2O (2 x 100 mL) and Et2O (2 x 100 mL) then dried 
to afford the product as a white solid (16.1 g, 82%).  
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δH(400 MHz, DMSO-d
6) 8.28 (s, 1H, H7), 7.68 – 7.63 (m, 2H, Ar), 7.02 – 6.96 (m, 2H, Ar), 6.07 (d, 
J=8.3, 1H, H1), 5.44 (ps t, J=9.7, 1H, H3), 4.97 (ps t, J=9.7, 1H, H4), 4.26 
(ddd, J=9.7, 4.6, 1.8, 1H, H5), 4.22 (dd, J=12.1, 4.6, 1H, H6), 4.01 (dd, 
J=12.1, 1.8, 1H, H6’), 3.79 (s, 3H, OMe), 3.44 (dd, J=9.7, 8.3, 1H, H2), 2.02 
(s, 3H, COCH3), 1.98 (s, 3H, COCH3), 1.98 (s, 3H, COCH3), 1.82 (s, 3H, 
COCH3). No literature reference found for spectrum in DMSO-d
6, data is 
consistent with spectrum reported in CDCl3 except for a downfield shift in 
the signal for H5 (∆δ = 0.3). 
δC(101 MHz, DMSO-d
6) 170.0 (COCH3), 169.4 (COCH3), 168.9 (COCH3), 168.5 (COCH3), 164.4 (C7), 
161.8 (Ar), 129.9 (Ar), 128.2 (Ar), 114.1 (Ar), 92.5 (C1), 72.3 (C2/3), 72.2 
(C2/3), 71.5 (C5), 67.8 (C4), 61.6 (C6), 55.3 (OMe), 20.5 (COCH3), 20.4 
(COCH3), 20.1 (COCH3). No literature reference found for spectrum in 
DMSO-d6, data is consistent with spectrum reported in CDCl3.
72 
m.p. 181-183 °C, not recrystallised (Lit. 175-176 °C, recrystallisation details not 
specified) 
ν (cm-1) 2970 , 2921 (CH), 1748, 1737 (C=O), 1647 (C=N) 
m/z (ES+ TOF) 488.1529 [M+Na]+ (C22H27NO10Na), calc. 488.1533 – 100% 
5.4.1.3 1,3,4,6-Tetra-O-acetyl-β-D-glucosamine hydrochloride (26)22, 72  
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1,3,4,6-Tetra-O-acetyl-2-deoxy-2-(4-methoxybenzimino)-β-D-glucopyranose (25, 16.1 g, 34.7 mmol) 
was dissolved in Me2CO (180 mL) and 5M HCl (6 mL) added dropwise over 10 min with stirring. The 
precipitated product was filtered, washed with Me2CO (2 x 100 mL), Et2O (2 x 100 mL) and dried to 
afford the product as a white solid (9.62 g, 72%). 
δH(400 MHz, DMSO) 8.79 (s, 3H, NH3), 5.91 (d, J=8.7, 1H, H1), 5.35 (dd, J=10.3, 9.3, 1H, H3), 
4.93 (dd, J=10.0, 9.3 1H, H4), 4.19 (dd, J=12.5, 4.4, 1H, H6), 4.05 (ddd, 
J=10.0, 4.4, 2.2, 1H, H5), 3.99 (dd, J=12.5, 2.2, 1H, H6’), 3.56 (dd, J=10.3, 
8.7, 1H, H2), 2.17 (s, 3H, COCH3), 2.03 (s, 3H, COCH3), 1.99 (s, 3H, COCH3), 
1.97 (s, 3H, COCH3). Data are consistent with literature values, 
72 greater 
resolution of H5 and H6’ has been achieved.  
δC(101 MHz, DMSO) 169.9 (COCH3), 169.7 (COCH3), 169.2 (COCH3), 168.6 (COCH3), 90.0 (C1), 
71.5 (C5), 70.3 (C3), 67.7 (C4), 61.2 (C6), 52.1 (C2), 20.9 (COCH3), 20.8 
(COCH3), 20.4 (COCH3), 20.3 (COCH3). Data match literature values.
72 
m.p. 219-222 °C (d) (Lit.72 220-222 °C) 
ν (cm-1) 2948, 2842, 2829 (br, NH), 2750, 2687 (CH), 1766, 1744 (C=O) 
m/z (ES+ TOF) 370.1110 [M-HCl+Na]+ (C14H21NO9Na), calc. 370.1114 – 100% 
5.4.1.4 1,3,4,6-Tetra-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-glucopyranose (27)22, 32  
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1,3,4,6-Tetra-O-acetyl-β-D-glucosamine hydrochloride (26, 5.00 g, 13.0 mmol) was dissolved in 
pyridine (50 mL) and TCPA (4.43 g, 15.5 mmol) partially dissolved in DCM (5 mL) was added and the 
mixture stirred overnight at room temperature. The mixture was cooled to 0 °C and Ac2O (15 mL) 
added and then allowed to warm to room temperature and stirred for a further 1 h. The solvents 
were removed by co-evaporation with toluene. Purification by flash column chromatography (1:1 
hexane/EtOAc) afforded the product as a white solid (7.71 g, 96%). 
δH(400 MHz, CDCl3) 6.47 (d, J=8.8, 1H, H1), 5.79 (dd, J=10.4, 9.1, 1H, H3), 5.23 (dd, J=10.2, 9.1, 
1H, H4), 4.45 (dd, J=10.4, 8.8, 1H, H2), 4.36 (dd, J=12.5, 4.5, 1H, H6), 4.14 
(dd, J=12.5, 2.2, 1H, H6’), 3.98 (ddd, J=10.2, 4.5, 2.2, 1H, H5), 2.11 (s, 3H, 
COCH3), 2.04 (s, 3H, COCH3), 2.03 (s, 3H, COCH3), 1.90 (s, 3H, COCH3). Data 
match literature values.32 
δC(101 MHz, CDCl3) 170.7 (COCH3), 170.6 (COCH3), 169.4 (COCH3), 168.7 (COCH3), 149.3 
(CONCO), 140.9 (Ar), 130.3 (Ar), 126.9 (Ar), 89.7 (C1), 72.7 (C5), 70.8 (C3), 
68.0 (C4), 61.5 (C6), 54.4 (C2), 20.9 (COCH3), 20.8 (COCH3), 20.7 (COCH3), 
20.5 (COCH3). Data match literature values.
32 
Rf 0.7 (hexane/EtOAc 2:3) 
m.p. 163-165 °C, not recrystallised (Lit.32 169-171 °C, recrystallisation details not 
specified) 
ν (cm-1) 2967 (CH), 1749, 1721 (C=O) 
m/z (ES+ TOF) 635.9595 [M+Na]+ (C22H19
35Cl4NO11Na), calc. 635.9610 – 70% 
638.0 [M+Na]+ (C22H19
35Cl3
37Cl1NO11Na) – 100% 
640.0 [M+Na]+ (C22H19 
35Cl2
37Cl2NO11Na) – 10% 
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5.4.1.5 Methyl 3,4,6-tri-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-glucopyranoside (28)32 
 
1,3,4,6-Tetra-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-glucopyranose (27, 8.00 g, 13.0 mmol) 
was dissolved in 32% HBr in AcOH (22 mL, 86 mmol) with Ac2O (4 mL) and stirred, in darkness, 
overnight at room temperature. 200 mL of DCM was added and the mixture poured over ice (200 
mL). Washing with water then sat. NaHCO3, drying over MgSO4 and removal of the solvent afforded 
the crude bromide as a cream solid, which was immediately dissolved in DCM (200 mL), MeOH (8.0 
mL, 200 mmol) and Ag2CO3 (3.60 g, 13.1 mmol) were added and the mixture refluxed in darkness for 
3 d. Filtering through Celite and removal of the solvent afforded the product as a cream solid (7.14 g, 
86%). Analysis showed that the crude was sufficiently pure to be taken through without further 
purification.   
δH(400 MHz, CDCl3) 5.68 (dd, J=10.6, 9.1, 1H, H3), 5.25 (d, J=8.5, 1H, H1), 5.18 (dd, J=10.1, 9.1, 
1H, H4), 4.33 (dd, J=12.3, 4.6, 1H, H6), 4.27 (dd, J=10.6, 8.5, 1H, H2), 4.17 
(dd, J=12.3, 2.3, 1H, H6’), 3.82 (ddd, J=10.1, 4.6, 2.3, 1H, H5), 3.44 (s, 3H, 
OMe), 2.10 (s, 3H, COCH3), 2.02 (s, 3H, COCH3), 1.88 (s, 3H, COCH3). Data 
match literature values.32 
δC(101 MHz, CDCl3) 170.7 (COCH3), 170.6 (COCH3), 169.4 (COCH3), 140.6 (CONCO), 130.1 (Ar), 
127.1 (Ar), 98.7 (C1), 72.0 (C5), 71.0 (C3), 68.7 (C4), 61.9 (C6), 57.1 (OMe), 
55.4 (C2), 20.8 (COCH3), 20.7 (COCH3), 20.6 (COCH3). No literature 
reference found, data match values previously found in the group. 
Rf 0.7 (2:3 hexane/EtOAc) 
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m.p. 90-92 °C. No literature reference found. 
ν (cm-1) 2958 (CH), 1745, 1722 (C=O) 
m/z (ES+ TOF) 607.9668 [M+Na]+ (C21H19
35Cl4NO10Na), calc. 607.9661 – 80% 
609.8 [M+Na]+ (C21H19
35Cl3
37Cl1NO10Na) – 100% 
611.8 [M+Na]+ (C21H19 
35Cl2
37Cl2NO10Na) – 40% 
5.4.1.6 Methyl 6-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-glucopyranoside (4)19 
 
Methyl 3,4,6-tri-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-glucopyranoside (28, 6.18 g, 10.5 
mmol) was dissolved in MeOH (200 mL) and cooled to 0 °C. AcCl (5.0 mL) was added and the mixture 
stirred overnight at room temperature. The solvents were removed by evaporation and the 
intermediate triol suspended in DCM (100 mL) at -20 °C. AcCl (2.0 mL, 28 mmol) and sym-collidine 
(7.0 mL, 53 mmol) were added and the mixture stirred at -20 °C until the suspension cleared, when 
the reaction was quenched with MeOH (10 mL) warmed to room temperature and washed with 0.5 
M HCl, sat. NaHCO3 and water, dried over MgSO4 and the solvents removed by evaporation. 
Purification by stepped gradient column chromatography (2:1 → 3:2 hexane/EtOAc) gave the glycosyl 
acceptor as an off-white solid (3.82 g, 72%). 
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δH(400 MHz, MeOD) 5.10 (d, J=8.5, 1H, H1), 4.50 (dd, J=12.0, 2.2, 1H, H6), 4.33 (dd, J=12.0, 
5.6, 1H, H6’), 4.24 (dd, J=10.7, 8.7, 1H, H3), 3.99 (dd, J=10.7, 8.5, 1H, H2), 
3.67 (ddd, J=9.8, 5.6, 2.2, 1H, H5), 3.50 – 3.43 (m, 4H, H4 & OMe), 2.14 
(s, 3H, COCH3). No literature reference found for spectrum in MeOD, 
data is consistent with spectrum reported in CDCl3.
19 
δC(101 MHz, MeOD) 172.7 (COCH3), 100.2 (C1), 75.5 (C5), 72.3 (C4), 72.1 (C3), 64.5 (C6), 58.9 
(C2), 56.9 (OMe), 20.7 (COCH3). Arqs not seen. No literature reference 
found for spectrum in MeOD, data is consistent with spectrum reported 
in CDCl3.
19 
Rf 0.3 (2:3 hexane/EtOAc) 
m.p. 129-131 °C. No literature reference found. 
[α]D +4.8° (c = 0.5, MeOH) (Lit. -18°, c=1, CHCl3) 
ν (cm-1) 3385 (br, OH), 2974, 2895 (CH), 1719 (C=O) 
m/z (ES+ TOF) 523.9446 [M+Na]+ (C17H17
35Cl4NO8Na), calc. 532.9449 – 60% 
525.8 [M+Na]+ (C17H17
35Cl3
37ClNO8Na) – 100% 
527.8 [M+Na]+ (C17H17
35Cl2
37Cl2NO8Na) – 30% 
5.4.2 Second Generation 
5.4.2.1 2-Deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-D-glucopyranose (73)73, 74 
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D-glucosamine hydrochloride (6.00 g, 27.8 mmol) was dissolved in water (60 mL), TrocCl (5.1 mL, 37 
mmol) was added at 0 °C and the mixture stirred at room temperature overnight. Filtering, washing 
with Et2O and drying gave the product as a fine white solid (9.80 g, 99%). Analysis showed that the 
crude was sufficiently pure to be taken through without further purification. 
δH(400 MHz, DMSO) 7.41 (d, J=8.1, 1H, NH), 6.45 (d, J=4.5, 1H, OH1), 4.98 (ps t, J=4.0, 1H, H1), 
4.91 (d, J=5.5, 1H, OH4), 4.81 (d, J=12.3, 1H, CHHCl3), 4.75 (d, J=12.3, 1H, 
CHHCl3), 4.69 (d, J=5.7, 1H, OH3), 4.42 (ps t, J=5.8, 1H, OH6), 3.61 – 3.44 
(m, 4H, H3, H4, H6 & H6’), 3.30 (d, J=1.2, 1H, H2), 3.12 (d ps t, J=9.3, 5.5, 
1H, H5). No literature reference found. 
δC(101 MHz, DMSO) 154.4 (NCOOCH2), 96.2 (CCl3), 90.4 (C1), 73.5 (CH2CCl3), 72.0 (C4), 71.0 
(C5), 70.0 (C3), 61.0 (C6), 56.7 (C2). No literature reference found. 
m.p. 184-186 °C (d) (Lit.74 183-184 °C (d)) 
ν (cm-1) 3320 (br, OH), 2941, 2919, 2878 (CH), 1698 (C=O), 1539 (NH bend) 
m/z (ES+ TOF) 375.9739 [M+Na]+ (C9H14
35Cl3NO7Na) ,calc. 375.9734 – 100% 
378.0 [M+Na]+ (C9H14
35Cl2
37ClNO7Na) – 90% 
380.0 [M+Na]+ (C9H14
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2-Deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-D-glucopyranose (73, 3.55 g, 10.0 mmol) was 
dissolved in propargyl alcohol (30 mL), TMSCl (15 mL, 120 mmol) was added and the reaction stirred 
at room temperature for 3 days. The solvent was removed by co-evaporation with toluene and the 
brown residue taken up in MeCN (25 mL). 4 Å molecular sieves, DOWEX and benzaldehyde dimethyl 
acetal (2.3 mL, 15 mmol) were added and the mixture stirred at room temperature overnight. The 
mixture was filtered and the product precipitated as a beige solid by addition to a large excess of sat. 
NaHCO3 solution followed by filtering and drying (3.28 g, 68%). Analysis showed that the crude was 
sufficiently pure to be taken through without further purification. 
δH(400 MHz, CDCl3) 7.53 – 7.45 (m, 2H, ArH), 7.42 – 7.34 (m, 3H, ArH), 5.55 (s, 1H, H7), 5.34 (d, 
J=9.6, 1H, TrocNH), 5.08 (d, J=3.7, 1H, H1), 4.82 (d, J=12.0, 1H, CHHCCl3), 
4.69 (d, J=12.0, 1H, CHHCCl3), 4.31 – 4.26 (m, 3H, H6 & 2 x H8), 4.00 (d ps 
t, J=9.6, 3.7, 1H, H2), 3.92 (d ps t, J=9.6, 3.0, 1H, H3), 3.87 (d ps t, J=9.6, 
4.6, 1H, H5), 3.76 (t, J=9.6, 1H, H6’), 3.59 (ps t, J=9.6, 1H, H4), 2.69 (d, 
J=3.0, 1H, OH, exchangeable), 2.48 (t, J=2.3, 1H, H10). Data consistent 
with literature values, except that the literature reports an OCH2CH=CH2 
peak, when no such functionality is present.75 
δC(101 MHz, CDCl3) 155.0 (OCOCH2), 137.0 (Arq), 129.5 (Ar), 128.5 (Ar), 126.4 (Ar), 102.1 (C7), 
96.9 (C1), 95.5 (CCl3), 81.8 (C4), 78.3 (C9), 75.6 (C10), 74.9 (CH2CCl3), 70.1 
(C3), 68.7 (C6), 63.1 (C5), 55.6 (C2), 55.3 (C8). No literature reference 
found. 
Rf 0.6 (2:3 hexane/EtOAc) 
m.p. 163-166 °C. No literature reference found. 
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ν (cm-1) 3425 (br, OH), 3331 (NH), 3302, 3066, 2956, 2917, 2870 (CH), 1709 (C=O), 
1531 (NH bend) 
m/z (ES+ TOF) 375.9739 [M+Na]+ (C19H20
35Cl3NO7Na), calc. 375.9734 – 80% 
378.0 [M+Na]+ (C19H20
35Cl2
37ClNO7Na )– 100% 
380.0 [M+Na]+ (C19H20
35Cl37Cl2NO7Na ) – 35% 
5.4.2.3 Propargyl 3-O-acetyl-4,6-O-benzylidene-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-α-
D-glucopyranoside (67)  
 
No literature reference found 
Propargyl 4,6-O-benzylidene-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-glucopyranoside 
(66, 3.16 g, 6.57 mmol) and DMAP (ca. 0.2 g) were dissolved in pyridine (40 mL). The mixture was 
cooled to 0 °C and Ac2O (1.2 mL, 13 mmol) was added and the mixture stirred overnight at room 
temperature. The mixture was poured over ice and extracted with DCM, washed with sat. NaHCO3, 
dried over MgSO4. Removal of the solvents by evaporation afforded the product as a light brown 
solid (3.31 g, 96%) which analysis showed to be sufficiently pure to be taken through without further 
purification. 
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δH(400 MHz, CDCl3) 7.50 – 7.43 (m, 2H, ArH), 7.42 – 7.34 (m, 3H, ArH), 5.55 (s, 1H, H7), 5.43 – 
5.35 (m, 2H, H3 & AcNH), 5.12 (d, J=3.7, 1H, H1), 4.81 (d, J=12.0, 1H, 
CHHCCl3), 4.71 (d, J=12.0, 1H, CHHCCl3), 4.35 – 4.30 (m, 3H, H6 & 2 x H8), 
4.13 (d ps t, J=10.3, 3.7, 1H, H2), 3.98 (d ps t, J=9.6, 4.8, 1H, H5), 3.81 (ps t, 
J=9.6, 1H, H6’), 3.75 (ps t, J=9.6, 1H, H4), 2.50 (ps t, J=2.4, 1H, H10), 2.07 
(s, 3H, COCH3) 
δC(101 MHz, CDCl3) 170.9 (COCH3), 154.5 (NCOOCH2), 137.0 (Arq), 129.2 (Ar), 128.3 (Ar), 126.3 
(Ar), 101.7 (C7), 96.8 (C1), 95.5 (CCl3), 79.1 (C4), 78.1 (C9), 75.7 (C10), 74.7 
(CH2CCl3), 69.9 (C3), 68.7 (C6), 63.5 (C5), 55.3 (C8), 54.6 (C2), 20.9 (COCH3) 
Rf 0.7 (2:3 hexane/EtOAc) 
m.p. 70-72 °C 
[α]D +4.0 (c=1.5, CHCl3) 
ν (cm-1) 3308 (br, NH), 3075, 2920, 2868 (CH), 2106 (C≡C), 1744, 1714 (C=O), 1539 
(NH bend) 
5.4.2.4 Propargyl 3-O-acetyl-6-O-benzyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-
glucopyranoside (68)  
 
No literature reference found 
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Propargyl 3-O-acetyl-4,6-O-benzylidene-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-
glucopyranoside (67, 6.05 g, 11.6 mmol) and TES (9.2 mL, 58 mmol) were dissolved in DCM at 0 °C 
and TFA (4.3 mL, 58 mmol) added. The mixture was stirred for 20 h at room temperature before the 
solvents were removed by co-evaporation with toluene. Purification by stepped gradient column 
chromatography (20% → 30% →40% EtOAc in hexane) afforded the product as a pale yellow foam 
which collapsed to an extremely viscous syrup (4.38 g, 72%). 
δH(400 MHz, CDCl3) 7.40 – 7.24 (m, 5H, ArH), 5.41 (d, J=10.3, 1H, TrocNH), 5.12 (dd, J=10.3, 
8.8, 1H, H3), 5.06 (d, J=3.7, 1H, H1), 4.79 (d, J=12.0, 1H, CHHCCl3), 4.63 (d, 
J=12.0, 1H, CHHCCl3), 4.62 (d, J=12.0, 1H, PhCHH), 4.56 (d, J=12.0, 1H, 
PhCHH), 4.30 (dd, J=15.9, 2.4, 1H, H7), 4.24 (dd, J=15.8, 2.4, 1H, H7’), 4.01 
(td, J=10.3, 3.7, 1H, H2), 3.88 – 3.70 (m, 4H, H4, H5, H6 &H6’), 2.90 (d, 
J=4.0, 1H, OH, exchangeable), 2.43 (t, J=2.4, 1H, H9), 2.07 (s, 3H, COCH3) 
δC(101 MHz, CDCl3) 172.1 (COCH3), 154.4 (NCOOCH2), 137.7 (Arq), 128.5 (Ar), 127.9 (Ar), 127.7 
(Ar), 96.1 (C1), 95.5 (CCl3), 78.4 (C8), 75.5 (C9), 74.6 (CH2CCl3), 73.8 
(PhCH2), 73.8 (C3), 70.9 (C4/5), 70.1 (C5/4), 69.5 (C6), 55.0 (C7), 53.6 (C2), 
21.0 (COCH3) 
Rf 0.5 (2:3 hexane/EtOAc) 
[α]D +64.5° (c=0.75, CHCl3) 
ν (cm-1) 3428 (br, OH), 3301 (br, NH), 3069, 3032, 2959, 2922, 2871 (CH), 2124 
(C≡C), 1722 (C=O), 1518 (NH bend) 
m/z (ES+ TOF) 546.0452 [M+Na]+ (C21H24
35Cl3NO8Na), calc. 546.0465 – 100% 
548.1 [M+Na]+ (C21H24
35Cl2
37ClNO8Na )– 80% 
550.0 [M+Na]+ (C21H24
35Cl37Cl2NO8Na ) – 20% 
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5.5 Disaccharides 




Phenyl 1,2,4,6-tetra-O-acetyl-3-azido-3-deoxy-β-D-thiogalactopyranoside (36, 400 mg, 0.95 mmol) 
and methyl 6-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-glucopyranoside (4, 317 mg, 0.63 
mmol) were dissolved in DCM (20 ml) and cooled to -20 °C. NIS (319 mg, 1.42 mmol) and TfOH (3 
drops) were added and the mixture stirred for 2 h. The mixture was warmed to room, temperature 
and washed with 5% aq. Na2S2O3, dried over MgSO4 and the solvents removed by evaporation. 
Purification by flash column chromatography (2:1 hexane/EtOAC) yielded product as an off white 
solid (395 mg, 77%). 
δH(400 MHz, CDCl3) 5.36 (d, J=3.3, 1H, H10), 5.15 (dd, J=10.6, 7.9, 1H, H8), 5.11 (d, J=8.4, 1H, 
H1), 4.52 (d, J=7.9, 1H, H7), 4.36 – 4.24 (m, 3H, H3, H6 & OH), 4.16 – 4.03 
(m, 3H, H2, H6’ & H12), 4.01 – 3.85 (m, 2H, H11 &H12’), 3.70 (ddd, J=9.7, 
4.7, 1.7, 1H, H5), 3.59 (dd, J=10.6, 3.3, 1H, H9), 3.52 (dd, J=9.7, 7.8, 1H, 
H4), 3.41 (s, 3H, OMe), 2.15 (s, 3H, COCH3), 2.13 (s, 3H, COCH3), 2.12 (s, 
3H, COCH3), 1.90 (s, 3H, COCH3). Data match literature values.
19 
 
  Experimental 
  136 
δC(101 MHz, CDCl3) 170.8 (COCH3), 170.6 (COCH3), 169.9 (COCH3), 169.5 (COCH3), 140.4 
(CONCO), 127.4 (Arq), 126.8 (Arq), 126.5 (Arq), 102.2 (C7), 98.9 (C1), 83.4 
(C4), 72.6 (C11), 72.1 (C5), 69.6 (C3 & C8), 67.6 (C10), 62.7 (C6), 61.8 
(C12), 61.7 (C9), 57.1 (OMe), 56.3 (C2), 21.0 (COCH3), 20.8 (COCH3), 20.6 
(COCH3), 20.5 (COCH3). No literature reference found 
Rf 0.6 (2:3 hexane/EtOAc) 
m.p. 140-142 °C. No literature reference found. 
[α]D -40.0° (c=1, CHCl3). No literature reference found. 
ν (cm-1) 3473 (OH), 2954, 2899 (CH), 2108 (N3), 1744, 1719 (C=O) 
m/z (ES+ TOF) 837.0380 [M+Na]+ (C29H30
35Cl4N4O15), calc. 837.0359 – 60% 
839.0 [M+Na]+ (C29H30
35Cl3
37ClN4O15) – 100% 
841.1 [M+Na]+ (C29H30
35Cl2




No literature reference found 
Ethyl 1,2,4,6-tetra-O-acetyl-3-azido-3-deoxy-D-thiogalactopyranoside (35, 1.17 g, 2.98 mmol) and 
methyl 6-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-Glucopyranoside (4, 1.00 g, 1.99 mmol) 
were dissolved in DCM (50 ml) and cooled to -20 °C. NIS (671 mg, 2.98 mmol) and TfOH (3 drops) 
  Experimental 
  137 
were added and the mixture stirred overnight whilst warming to room temperature. The mixture was 
washed with 5% aq. Na2S2O3, dried over MgSO4 and the solvents removed by evaporation. 
Purification by dissolution in Et2O, filtration and removal of the solvents gave product as an off white 
solid (1.05 g, 63%). 
δH(400 MHz, CDCl3) 5.37 (d, J=3.4, 1H, H10), 5.23 (dd, J=10.4, 8.0, 1H, H8), 5.13 (d, J=8.5, 1H, 
H1), 5.00 (dd, J=10.4, 3.4, 1H, H9), 4.55 (d, J=8.0, 1H, H7), 4.40 – 4.29 (m, 
3H, H3, H12 & H12’), 4.17 – 4.01 (m, 5H, H2, H6, H6’, H11 & OH), 3.72 (ddd, 
J=9.8, 4.7, 1.8, 1H, H5), 3.58 (dd, J=9.8, 8.1, 1H, H4), 3.44 (s, 3H, OMe), 2.15 
(s, 3H, COCH3), 2.14 (s, 3H, COCH3), 2.09 (s, 3H, COCH3), 1.98 (s, 3H, 
COCH3), 1.94 (s, 3H, COCH3) 
δC(101 MHz, CDCl3) 170.1 (COCH3), 170.0 (COCH3), 169.6 (COCH3), 140.4 (CONCO), 102.1 (C7), 
98.9 (C1), 83.4 (C4), 72.1 (C5), 71.6 (C11), 70.9 (C9), 69.6 (C3), 68.8 (C8), 
66.8 (C10), 62.6 (C12), 61.7 (C6), 57.0 (OMe), 56.4 (C2), 21.0 (COCH3), 20.7 
(COCH3), 20.7 (COCH3), 20.6 (COCH3), 20.5 (COCH3) 
Arqs not visible. 
Rf 0.5 (2:3 hexane/EtOAc) 
m.p. 182-184 °C 
[α]D +9.4° (c=1, CHCl3) 
ν (cm-1) 3570 (OH), 2914, 2849 (CH), 1743, 1712 (C=O) 
m/z (ES+ TOF) 854.0423 [M+Na]+ (C31H33
35Cl4NO17Na), calc. 854.0400 – 60% 
856.0 [M+Na]+ (C31H33
35Cl3
37Cl1NO17Na) – 100% 
856.0 [M+Na]+ (C31H33
35Cl2
37Cl2NO17Na) – 30% 
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5.5.1.3 Methyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-galactopyranosyl-6-O-acetyl-2-amino-2-deoxy-β-D-
glucopyranoside (40)  
 
No literature reference found 
Methyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-galactopyranosyl-6-O-acetyl-2-deoxy-2-tetrachloro-
phthalimido-β-D-glucopyranoside (34, 100 mg, 0.12 mmol) was dissolved in 2:1:1 MeCN/THF/EtOH (8 
mL), ethylene diamine (16 μL, 0.24 mmol) was added and the reaction stirred at 60 °C for 2 h when 
TLC (2:3 Hexane/EtOAc) revealed only a baseline spot. The reaction mixture was cooled, filtered 
through Celite and the solvents removed. The residue was dissolved in DCM, washed with water and 
dried over MgSO4. Removal of the solvents afforded the product as a pale yellow solid (67 mg, 98%). 
δH(400 MHz, CDCl3) 5.39 (dd, J=3.3, 0.6, 1H, H10), 5.23 (dd, J=10.5, 8.0, 1H, H8), 5.00 (dd, 
J=10.5, 3.3, 1H, H9), 4.54 (d, J=8.0, 1H, H7), 4.30 (dd, J=11.8, 1.9, 1H, H6), 
4.19 (dd, J=11.4, 4.6, 1H, H12), 4.14 – 4.00 (m, 4H, H1, H6’, H11 & H12’), 
3.59 – 3.41 (m, 7H, H3, H4, H5, OH & OMe), 2.75 (dd, J=9.2, 8.1, 1H, H2), 
2.16 (s, 3H, COCH3), 2.10 (s, 3H, COCH3), 2.09 (s, 3H, COCH3), 2.07 (s, 3H, 
COCH3), 1.97 (s, 3H, COCH3), 1.28 (br s, 2H, NH2) 
δC(101 MHz, CDCl3) 170.8 (COCH3), 170.5 (COCH3), 170.1 (COCH3), 170.0 (COCH3), 169.6 
(COCH3), 104.8 (C1), 102.2 (C7), 82.9 (C4), 74.9 (C3), 71.9 (C5), 71.5 (C11), 
71.0 (C9), 68.8 (C8), 67.0 (C10), 63.1 (C6), 61.9 (C12), 57.4 (OMe), 56.7 (C2), 
21.0 (COCH3), 20.7 (COCH3), 20.6 (COCH3) 
  Experimental 
  139 
[α]D +8.6° (c=0.5, CHCl3) 
ν (cm-1) 3505 (br, OH, NH), 2999, 2966, 2939, 2917, 2889, 2852 (CH), 1745, 1733 
(C=O) 
m/z (ES+ TOF) 588.1925 [M+Na]+ (C23H35NO15Na), calc. 588.1904 – 100% 
5.5.2 Second Generation 
5.5.2.1 Propargyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-galactopyranosyl-3-O-acetyl-6-O-benzyl-2-deoxy-2-
(2,2,2-trichloroethoxycarbonylamino)-α-D-glucopyranoside (75)  
 
No literature reference found 
Phenyl penta-O-acetyl-β-D-thiogalactopyranoside (18, 672 mg, 1.52 mmol) and propargyl 3-O-acetyl-
6-O-benzyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-glucopyranoside (68, 533 mg, 1.02 
mmol) were dissolved in DCM (20 ml) and cooled to -20 °C. NIS (343 mg, 1.52 mmol) and TfOH (3 
drops) were added and the mixture stirred for 2 h. The mixture was warmed to room, temperature 
and washed with 5% aq. Na2S2O3, dried over MgSO4 and the solvents removed by evaporation. 
Purification by stepped gradient flash column chromatography (3:1 → 2:1 → 1:1 Hexane/EtOAc) 
yielded product as a white solid (577 mg, 66%). 
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δH(400 MHz, CDCl3) 7.41 – 7.28 (m, 5H, ArH), 5.31 (d, J=9.9, 1H, AcNH), 5.24 (d, J=3.5, 1H, 
H10), 5.14 (dd, J=10.7, 9.5, 1H, H3), 5.05 (d, J=3.7, 1H, H1), 4.95 (dd, 
J=10.6, 8.0, 1H, H8), 4.75 (d, J=12.0, 1H, PhCHH), 4.74 (dd, J=10.6, 3.5, 1H, 
H9), 4.73 (d, J=12.0, 1H, CHHCCl3), 4.63 (d, J=12.0, 1H, CHHCCl3), 4.41 (d, 
J=12.0, 1H, PhCHH), 4.31 (d, J=8.0, 1H, H7), 4.24 (dd, J=15.8, 2.4, 1H, H13), 
4.19 (dd, J=15.8, 2.4, 1H, H13’), 4.08 – 3.85 (m, 5H, H2, H4, H12 & H12’), 
3.77 – 3.70 (m, 2H, H5 & H6), 3.65 – 3.56 (m, 2H, H11 & H6’), 2.43 (t, 
J=2.4, 1H, H15), 2.08 (s, 3H, COCH3), 2.03 (s, 3H, COCH3), 2.00 (s, 3H, 
COCH3), 1.92 (s, 3H, COCH3), 1.90 (s, 3H, COCH3) 
δC(101 MHz, CDCl3) 170.6 (COCH3), 170.3 (COCH3), 170.2 (COCH3), 170.0 (COCH3), 168.8 
(COCH3), 154.3 (COCH2), 137.6 (Arq), 128.7 (Ar), 128.2 (Ar), 128.2 (Ar), 
100.3 (C7), 96.1 (C1), 95.4 (CCl3), 78.2 (C14), 75.5 (C15), 74.6 (C4), 74.5 
(CH2CCl3), 73.7 (PhCH2), 71.0 (C9), 70.8 (C5), 70.4 (C3), 69.1 (C11), 67.0 
(C8), 66.8 (C6), 60.9 (C10), 55.1 (C12), 53.9 (C13), 20.8 (COCH3), 20.7 
(COCH3), 20.7 (COCH3), 20.6 (COCH3), 20.5 (COCH3) 
Rf 0.6 (2:3 hexane/EtOAc) 
m.p. 72-74 °C 
[α]D +52.8° (c=0.5, CHCl3) 
ν (cm-1) 3285 (NH), 3068, 3032, 2939, 2914, 2866 (CH), 2122 (C≡C), 1741 (C=O), 
1526 (NH bend) 
m/z (ES+ TOF) 876.1411 [M+Na]+ (C35H42
35Cl3NO17Na), calc. 876.1416 – 60% 
878.2 [M+Na]+ (C35H42
35Cl2
37ClNO17Na) – 100% 
880.2 [M+Na]+ (C35H42
35Cl37Cl2NO17Na) – 30% 
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5.5.2.2 Allyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-galactopyranosyl-3-O-acetyl-6-O-benzyl-2-deoxy-(2,2,2-
trichloroethoxycarbamido)-β-D-glucopyranoside (76)  
 
No literature reference found 
Propargyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-galactopyranosyl-3-O-acetyl-6-O-benzyl-2-deoxy-2-(2,2,2-
trichloroethoxycarbamido)-α-D-glucopyranoside (75, 577 mg, 0.67 mmol) was dissolved in Ac2O (40 
mL) and Zn (activated with 1M HCl followed by filtering and washing with MeOH then Et2O, 2.20 g, 
33.6 mmol) was stirred at room temperature for 24 h. The mixture was filtered and the solvent 
removed by repeated co-evaporation with toluene. The residue was taken up in DCM, washed with 
water, sat. NaHCO3 and dried over MgSO4. Removal of the solvents afforded the product as a white 
solid (468 mg, 96%).  
δH(400 MHz, CDCl3) 7.43 – 7.30 (m, 5H, ArH), 6.19 (d, J=9.5, 1H, AcNH), 5.90 – 5.71 (m, 1H, 
H14), 5.29 – 5.20 (m, 3H, H10 & 2x H15), 5.16 (dd, J=10.8, 9.3, 1H, H3), 
5.00 (dd, J=10.4, 8.0, 1H, H8), 4.88 (d, J=3.8, 1H, H1), 4.79 (dd, J=10.4, 3.5, 
1H, H9), 4.78 (d, J=12.1, 1H, PhCHH), 4.45 (d, J=12.1, 1H, PhCHH), 4.37 (d, 
J=8.0, 1H, H7), 4.26 (ddd, J=10.8, 9.5, 3.8, 1H, H2), 4.16 (dd, J=12.8, 5.3, 
1H, H13), 4.07 (d, J=6.8, 2H, H12 & H12’), 4.01 – 3.92 (m, 2H, H4 & H13’), 
3.80 – 3.70 (m, 2H, H5 & H6), 3.69 – 3.60 (m, 2H, H6’ & H11), 2.12 (s, 3H, 
COCH3), 2.07 (s, 3H, COCH3), 2.04 (s, 3H, COCH3), 1.98 (s, 3H, COCH3), 1.96 
(s, 3H, COCH3), 1.94 (s, 3H, COCH3) 
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δC(101 MHz, CDCl3) 172.2 (COCH3), 171.4 (COCH3), 170.4 (COCH3), 170.2 (COCH3), 170.0 
(COCH3), 169.0 (COCH3), 137.6 (Arq), 133.2 (C14), 128.6 (Ar), 128.1 (Ar), 
118.4 (C15), 100.4 (C7), 96.1 (C1), 74.7 (C4), 73.7 (PhCH2), 71.3 (C3), 70.9 
(C9), 70.4 (C5/11), 70.2 (C11/5), 69.1 (C8), 68.7 (C13), 67.1 (C10), 66.8 
(C6), 60.9 (C12), 52.4 (C2), 23.2 (COCH3), 20.9 (COCH3), 20.7 (COCH3), 20.7 
(COCH3), 20.6 (COCH3), 20.5 (COCH3) 
Rf 0.2 (2:3 hexane/EtOAc) 
m.p. 82-84 °C 
[α]D +28.0° (c=1, CHCl3) 
ν (cm-1) 3330 (NH), 2962, 2931, 2847 (CH), 1745, 1609 (C=O), 1554 (NH bend) 
m/z (ES+ TOF) 746.2603 [M+Na]+ (C34H45NO16Na), calc. 746.2636 – 100% 
5.5.2.3 Propargyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-galactopyranosyl-2-acetamido-3-O-acetyl-6-O-
benzyl-2-deoxy-α-D-glucopyranoside (77)  
 
No literature reference found 
TBAF (1M in THF, 3.0 mL, 3.0 mmol) was added to a solution of propargyl 2,3,4,6-tetra-O-acetyl-β(1-
4)-D-galactopyranosyl-3-O-acetyl-6-O-benzyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-α-D-
glucopyranoside (75, 506 mg, 0.59 mmol) in THF (5 mL) and the mixture stirred at room temperature 
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for 1.5 h. Pyridine (1 mL) and Ac2O (1.0 mL, 11 mmol) were added and the reaction stirred for a 
further 20 h. The mixture was diluted with DCM, washed with sat. NaHCO3 and dried over MgSO4. 
Removal of the solvents afforded the product as a light beige solid (354 mg, 83%).  
δH(400 MHz, CDCl3) 7.42 – 7.29 (m, 5H, ArH), 5.76 (d, J=9.6, 1H, AcNH), 5.25 (dd, J=3.5, 0.8, 
1H, H10), 5.12 (dd, J=10.9, 9.5, 1H, H3), 4.99 (d, J=3.6, 1H, H1), 4.98 (dd, 
J=10.5, 8.1, 2H, H8), 4.77 (dd, J=10.5, 3.5, 1H, H9), 4.75 (d, J=12.1, 1H, 
PhCHH), 4.43 (d, J=12.1, 1H, PhCHH), 4.35 (d, J=8.1, 1H, H7), 4.28 (ddd, 
J=10.9, 9.6, 3.6, 1H, H2), 4.24 (dd, J=15.9, 2.4, 1H, H13), 4.18 (dd, J=15.9, 
2.4, 1H, H13’), 4.05 (d, J=6.8, 2H, H12 & H12’), 3.95 (ps t, J=9.5, 1H, H4), 
3.78 – 3.70 (m, 2H, H5 & H6), 3.67 – 3.58 (m, 2H, H6’ & H11), 2.43 (t, 
J=2.4, 1H, H15), 2.10 (s, 3H, COCH3), 2.05 (s, 3H, COCH3), 2.01 (s, 3H, 
COCH3), 1.94 (s, 3H, COCH3), 1.93 (s, 3H, COCH3), 1.92 (s, 3H, COCH3) 
δC(101 MHz, CDCl3) 171.3 (COCH3), 170.5 (COCH3), 170.3 (COCH3), 170.2 (COCH3), 170.1 
(COCH3), 169.0 (COCH3), 137.8 (Arq), 128.8 (Ar), 128.3 (Ar), 128.2 (Ar), 
100.5 (C1), 96.3 (C7), 78.5 (C14), 75.3 (C15), 74.8 (C4), 73.8 (PhCH2), 71.3 
(C3), 71.1 (C9), 70.9 (C5), 70.5 (C11), 69.3 (C8), 67.2 (C6), 66.9 (C10), 61.1 
(C12), 55.2 (C13), 51.9 (C2), 23.3 (COCH3), 21.0 (COCH3), 20.8 (COCH3), 
20.8 (COCH3), 20.7 (COCH3), 20.6 (COCH3) 
Rf 0.6 (2:1 toluene/Me2CO) 
m.p. 55-57 °C 
[α]D +27.7° (c=1.5, CHCl3) 
ν (cm-1) 3373, 3277 (NH), 2936, 2872 (CH), 2117 (C≡C), 1742, 1674(C=O), 1533 (NH 
bend) 
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m/z (ES+ TOF) 744.2480 [M+Na]+ (C34H43NO16Na), calc. 744.2480 – 100% 
5.6 Linkers 
5.6.1 Short Linkers 
5.6.1.1 N-Boc-2-(2-aminoethoxy)ethanol (45)76 
 
2-(2-Aminoethoxy)ethanol (5.0 mL, 50 mmol) and NaHCO3 (10.5 g, 125 mmol) were dissolved in 1:1 
THF/H2O (100 mL) at room temperature and Boc2O (10.9 g, 49.9 mmol) in THF (50 mL) was added 
dropwise over 2 h and the mixture stirred overnight. The THF was removed by evaporation and the 
product was extracted into EtOAc and washed with 1 M citric acid solution and dried over MgSO4. 
Removal of the solvents by evaporation afforded the product as a colourless syrup (10.2 g, 100%). 
δH(300 MHz, CDCl3) 5.61 (s, 0.25H, BocNH), 5.01 (s, 0.75H, BocNH), 3.83 – 3.68 (m, 2H, 2 x H4), 
3.67 – 3.44 (m, 4H, 4 x H2-3), 3.32 (br ps q, J=4.9, 2H, 2 x H1), 1.44 (s, 9H, 
C(CH3)3). Data match literature values.
76 
δC(101 MHz, CDCl3) 156.3 (COO
tBu), 79.5 (C(CH3)3), 72.2 (C2), 70.3 (C3), 61.7 (C4), 40.4 (C1), 
28.48 (C(CH3)3). Data match literature values.
76 
Rf  0.3 (2:3 hexane/EtOAc) 
ν (cm-1) 3347 (br, OH), 2976, 2932, 2872 (CH), 1687 (C=O), 1532 (NH bend) 
m/z (ES+ TOF) 228.1216 [M+Na]+ (C9H19NO4Na), calc. 228.1212 – 100% 
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5.6.1.2 Ethyl 3,6-dioxa-8-tbutyloxycarbonylaminooctanoate (46)37 
 
N-Boc-2-(2-aminoethoxy)ethanol (45, 959 mg, 4.67 mmol) and KOtBu (524 mg, 5.07 mmol) were 
stirred in THF (20 mL) at 0 °C for 30 min. Ethyl bromoacetate (0.56 mL, 5.1 mmol) was added 
dropwise over 10 min and the reaction stirred  at 4 °C for 4 h and then a further 15 h at room 
temperature. Water (50 mL) was added, the THF removed by evaporation and the product extracted 
into EtOAc. Drying over MgSO4 and removal of the solvents by evaporation gave a colourless syrup 
that was purified by flash column chromatography (1:1 hexane/EtOAc) to afford the product as a 
colourless syrup (346 mg, 27%). 
δH(300 MHz, CDCl3) 5.02 (br s, 1H, BocNH), 4.20 (q, J=7.1, 2H, CH2CH3), 4.12 (s, 2H, 2 x H5), 
3.75 – 3.66 (m, 2H, 2 x H2), 3.66 – 3.59 (m, 2H, 2 x H3), 3.53 (t, J=5.1, 2H, 2 
x H4), 3.30 (br ps q, J=5.2, 2H, 2 x H1), 1.42 (s, 9H, C(CH3)3), 1.27 (t, J=7.1, 
3H, CH2CH3). Data match literature values.
37 
δC(101 MHz, CDCl3) 170.4 (COOEt), 156.1 (COO
tBu), 79.2 (C(CH3)3), 71.0 (C5), 70.5 (C2), 70.1 
(C4), 68.8 (C3), 60.9 (CH2CH3), 40.5 (C1), 28.5 (C(CH3)3), 14.3 (CH2CH3) 
Rf  0.3 (2:3 hexane/EtOAc). Data match literature values.
37 
ν (cm-1) 3347 (br, OH), 2976, 2932, 2872 (CH), 1687 (C=O), 1523 (NH bend) 
5.6.1.3 3,6-Dioxa-8-tbutyloxycarbonylaminooctanoic Acid (47)37 
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Ethyl 3,6-dioxa-8-tbutyloxycarbonylaminooctanoate (46, 355 mg, 1.22 mmol) was dissolved in THF (5 
mL). LiOH (112 mg, 2.68 mmol) was added followed by enough water to form a clear solution. The 
reaction was stirred at room temperature for 2 h. The THF was removed by evaporation and the 
mixture diluted with water, washed with EtOAc, acidified with 1 M citric acid, extracted into EtOAc 
and dried over MgSO4. Removal of the solvents by evaporation afforded the product as a colourless 
syrup (270 mg, 84%). 
δH(300 MHz, CDCl3) 10.67 (s, 1H, COOH), 6.11 (s, 0.25H, BocNH), 5.06 (s, 0.75H, BocNH), 4.16 
(s, 2H, 2 x H5), 3.79 – 3.69 (m, 2H, 2 x H2), 3.69 – 3.59 (m, 2H, 2 x H3), 
3.54 (t, J=4.8, 2H, 2 x H4), 3.31 (br d, J=4.3, 2H, 2 x H1), 1.42 (s, 9H, 
C(CH3)3). Data match literature values.
37 
δC(101 MHz, CDCl3) 173.4 (COOH), 156.2 (COO
tBu), 79.6 (C(CH3)3), 71.1 (C5), 70.5 (C4), 70.2 
(C3), 68.6 (C2) 40.4 (C1), 28.4 (C(CH3)3). Data match literature values.
37 
5.6.1.4 N-Boc-O-methanesulfonyl-2-(2-aminoethoxy)ethanol (80)77 
 
N-Boc-2-(2-aminoethoxy)ethanol (45, 3.00 g, 14.6 mmol) and NEt3 (4.1 mL, 29 mmol) were dissolved 
in DCM (30 mL) at 0 °C. Methanesulfonyl chloride (1.24 mL, 16.1 mmol) was added dropwise over 30 
min and the reaction stirred overnight at room temperature. The solvents were removed by 
evaporation and the residue taken up in EtOAc, washed with water, then brine and dried over 
MgSO4. Removal of the solvents by evaporation afforded the product as a pale yellow syrup (3.51 g, 
85%). 
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δH(300 MHz, CDCl3) 4.90 (br s, 1H, BocNH), 4.38 – 4.32 (m, 2H, 2 x H4), 3.74 – 3.68 (m, 2H, 2 x 
H3), 3.54 (t, J=5.2, 2H, 2 x H2), 3.31 (br ps q, J=5.9, 2H, 2 x H1), 3.05 (s, 3H, 
CH3S), 1.42 (s, 9H, C(CH3)3). Data match literature values.
77 
δC(101 MHz, CDCl3) 156.0 (COO
tBu), 79.5 (C(CH3)3), 70.5 (C4), 68.8 (C3), 68.8 (C2), 40.3 (C1), 
37.8 (CH3S), 28.5 (C(CH3)3). No literature reference found. 
Rf  0.4 (2:3 hexane/EtOAc) 
ν (cm-1) 3397 (br NH), 2977, 2963, 2880 (CH), 1700 (C=O), 1514 (NH bend) 
m/z (ES+ TOF) 306.0981 [M+Na]+ (C10H21NO6SNa), calc. 306.0987 – 100% 
5.6.1.5 N-Boc-2-(2-azidoethoxy)ethylamine (79)78 
 
N-Boc-O-methanesulfonyl-2-(2-aminoethoxy)ethanol (80, 3.51 g, 12.4 mmol) was dissolved in DMF 
(30 mL) and NaN3 (4.03 g, 62.0 mmol) added. The reaction was heated at 60 °C for 2 h, cooled, 
diluted with EtOAc and washed with water and then brine. Drying over MgSO4 and removal of the 
solvents by evaporation afforded the product as a pale yellow syrup (2.37 g, 83%). 
δH(300 MHz, CDCl3) 4.97 (br s, 1H, BocNH), 3.68 – 3.57 (m, 2H, 2 x H2), 3.52 (t, J=5.1, 2H, 2 x 
H3), 3.39 – 3.25 (m, 4H, 2 x H1 & 2 x H4), 1.42 (s, 9H, C(CH3)3). Data match 
literature values.78 
δC(101 MHz, CDCl3) 156.0 (COO
tBu), 79.3 (CCH3)3), 70.4 (C2), 69.9 (C3), 50.7 (C4), 40.4 (C1), 
28.4 (C(CH3)3). Data match literature values.
78 
Rf 0.6 (2:3 hexane/EtOAc) 
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ν (cm-1) 3355 (br, NH), 2977, 2932, 2869 (CH), 2101 (N3), 1694 (C=O), 1511 (NH 
bend) 
m/z (ES+ TOF) 253.1243 [M+Na]+ (C9H18N4O3Na), calc. 253.1277 – 100% 
5.6.2 Long Linkers 
5.6.2.1 Mono-N-Boc-4,7,10-trioxa-trideca-1,13-diamine (42)79, 80 
 
4,7,10-Trioxa-trideca-1,13-diamine (60 mL, 270 mmol) was dissolved in THF (400 mL), Boc2O (10.0 g, 
45.8 mmol) dissolved in THF (100 mL) was added dropwise over 1 h and the mixture stirred overnight 
at room temperature. The solvents were removed by evaporation and the residue taken up in water 
(200 mL) and washed with EtOAc (3 x 100 mL). The organic portions were combined and washed with 
brine (3 x 50 mL). Removal of the solvents by evaporation gave product as a colourless liquid (9.78 g, 
67%) which analysis revealed to be sufficiently pure to proceed without further purification. 
δH(300 MHz, CDCl3) 5.17 (br t, J=5.8 1H, BocNH), 3.63 – 3.44 (m, 12H, 12 x H3-8), 3.15 (dt, 
J=12.3, 5.8, 2H, 2 x H1), 2.73 (t, J=6.7, 2H, 2 x H10), 1.75 – 1.60 (m, 4H, 2 x 
H2 & 2 x H9), 1.37 (s, 9H, C(CH3)3), 1.22 (s, 2H, NH2). Data match literature 
values.79 
δC(101 MHz, CDCl3) 156.0 (COO
tBu), 78.7 (C(CH3)3), 70.6 (CH2O), 70.6 (CH2O), 70.2 (CH2O), 70.2 
(CH2O), 69.5 (CH2O), 69.4 (CH2O), 39.6 (C1), 38.5 (C10), 33.4 (C2), 29.6 
(C9), 28.4 (C(CH3)3). Data match incomplete set of peaks given in 
literature.80 
ν (cm-1) 3357 (br, NH), 2977, 2929, 2866 (CH), 1706 (C=O), 1517 (NH bend)  
  Experimental 
  149 
m/z (ES+ TOF) 321.2391 [M+H]+ (C15H33N2O5), calc. 321.2389 – 100% 
5.6.2.2 N-Boc, N'-succinyl-4,7,10-trioxa-trideca-1,13-diamine (43)79 
 
Succinic anhydride (1.42 g, 14.2 mmol) and pyridine (5 mL) were added to mono-N-Boc-4,7,10-trioxa-
trideca-1,13-diamine (42, 3.80 g, 11.9 mmol) in DCM (20 mL) at 0 °C, and the mixture stirred 
overnight at room temperature. Removal of the solvents by co-evaporation with toluene gave an 
orange syrup. Purification by flash column chromatography (10% MeOH, 1% AcOH in DCM) afforded 
the product as a pale yellow syrup (4.82 g, 97%). 
δH(400 MHz, MeOD) 10.29 (br s, 1H, COOH), 6.98 (s, 0.4H, H11), 6.90 (s, 0.6H, H11), 6.30 (s, 
0.3H, BocNH), 5.07 (s, 0.7H, BocNH), 3.69 – 3.48 (m, 12H, 12 x H3-8), 3.36 
(ps q, J=5.8, 2H, 2 x H10), 3.20 (br ps q, J=6.0 2H, 2 x H1), 2.66 (t, J=5.6, 2H, 
2 x H13), 2.49 (t, J=5.6, 2H, 2 x H14), 1.84 – 1.67 (m, 4H, 2 x H2 & 2 x H9), 
1.42 (s, 9H, C(CH3)3). Data match literature values.
79 
δC(101 MHz, MeOD) 175.1, 172.5 (C12 & C15), 156.2 (COO
tBu), 79.2 (C(CH3)3), 70.5 (CH2O), 
70.3 (CH2O), 70.1 (CH2O), 69.6 (CH2O), 69.4 (CH2O), 68.4 (CH2O), 38.6 
(C1/10), 38.4 (C10/1), 30.9, 30.2, 29.7, 28.7 (C2, C9, C13 & C14), 28.5 
(C(CH3)3). Data match literature values.
79 
Rf 0.6 (10% MeOH, 1% AcOH in DCM) 
ν (cm-1) 3502 (OH), 3348 (NH), 2978, 2927, 2871 (CH), 1694 (C=O), 1525 (NH bend) 
m/z (ES+ TOF) 443.2381 [M+Na]+ (C19H36N2O8Na), calc. 443.2369 – 100% 
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5.6.2.3 N-Boc, N'-succinyl-4,7,10-trioxa-trideca-1,13-diamine NHS Ester (48)81 
 
DCC (413 mg, 2.00 mmol) and NHS (230 mg, 2.00 mmol) were added to N-Boc, N'-succinyl-4,7,10-
trioxa-trideca-1,13-diamine (43, 0.1 M solution in THF, 20 mL, 2.0 mmol) and the mixture left to 
stand overnight at 4 °C. Filtration through Celite and removal of the solvents by evaporation gave the 
product as a thick golden syrup (937 mg, 91%) which analysis revealed to sufficiently pure to proceed 
without further purification. 
δH(400 MHz, CDCl3) 6.53 (br s, 1H, H11), 4.97 (br s, 1H, BocNH), 3.67 – 3.48 (m, 12H, CH2O), 
3.37 (ps q, J=5.9, 2H, 2 x H10), 3.19 (ps q, J=5.9, 2H, 2 x H1), 2.97 (t, J=7.6, 
2H, 2 x H14), 2.82 (br s, 4H, 4 x H17), 2.56 (t, J=7.6, 2H, 2 x H13), 1.80 – 
1.69 (m, 4H, 2 x H2 & 2 x H9), 1.42 (s, 9H, C(CH3)3). Data match literature 
values.81 
5.6.2.4 N-Boc-13-azido-4,7,10-trioxa-tridecylamine (78)82 
 
Mono-N-Boc-4,7,10-trioxa-trideca-1,13-diamine (42, 2.02 g, 6.25 mmol), CuSO4·5H2O (156 mg, 0.63 
mmol) and K2CO3 (1.72 g, 12.5 mmol) were stirred in 3:1 MeOH/H2O (60 mL) for 15 min at room 
temperature. ImSO2N3·HCl
44
 (2.36 g, 11.2 mol) was added and the mixture stirred for 7 h at room 
temperature. The MeOH was removed by evaporation and the residue extracted into EtOAc, washed 
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with 1 M citric acid solution and dried over MgSO4. Removal of the solvent by evaporation afforded 
the product as a pale yellow syrup (2.09 g, 97%).  
δH(300 MHz, CDCl3) 4.98 (s, 1H, BocNH), 3.71 – 3.49 (m, 12H, 12 x H3-8), 3.38 (t, J=6.6, 2H, 2 x 
H10), 3.22 (ps q, J=6.1, 2H, 2 x H1), 1.85 (p, J=6.6, 2H, 2 x H9), 1.75 (p, 
J=6.1, 2H, 2 x H2), 1.43 (s, 9H, C(CH3)3). Data match literature values.
82 
δC(101 MHz, CDCl3) 156.1 (COO
tBu), 79.0 (C(CH3)3), 70.7 (CH2O), 70.5 (CH2O), 70.3 (CH2O), 69.7 
(CH2O), 68.0 (CH2O), 48.6 (C10), 38.7 (C1), 29.7 (C2), 29.2 (C9), 28.5 
(C(CH3)3). Data match literature values.
82 
Rf 0.6 (2:3 hexane/EtOAc) 
ν (cm-1) 3351 (br, NH), 2977, 2930, 2870 (CH),2096 (N3), 1710 (C=O), 1517 (NH 
bend) 
m/z (ES+ TOF) 369.2124 [M+Na]+ (C15H30N4O5Na), calc. 369.2114 – 100% 
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5.7 Linker Attached Disaccharides 
5.7.1 First Generation 
5.7.1.1 Methyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-galactopyranosyl-6-O-acetyl-2-deoxy-2-[N'-(13-
tbutyloxycarbonylamino-4,7,10-trioxa-tridecyl)succinamido]-β-D-glucopyranoside (49)  
 
No literature reference found 
N-Boc, N'-succinyl-4,7,10-trioxa-trideca-1,13-diamine  (43, 0.1 M in THF, 2.7 mL, 0.27 mmol) was 
diluted with MeCN (2.5 mL), DIPEA (0.1 mL, 0.6 mmol) and PyBOP (142 mg, 0.27 mmol)  were added 
and the mixture stirred at room temperature for 30 min. Methyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-
galactopyranosyl-6-O-acetyl-2-amino-2-deoxy-β-D-glucopyranoside (40, 77 mg, 0.14 mmol) in MeCN 
(2.5 mL) was added and the reaction heated at reflux for 20 h. Removal of the solvents by 
evaporation and purification by flash column chromatography (60% Me2CO in toluene) afforded the 
product as a colourless glass (71 mg, 54%). 
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δH(400 MHz, CDCl3) 6.78 (d, J=7.7, 1H, H13), 6.66 (br s, 1H, H18), 5.36 (dd, J=3.4, 0.7, 1H, 
H10), 5.19 (dd, J=10.4, 8.0, 1H, H8), 5.03 (s, J=13.8, 2H, BocNH), 4.98 (dd, 
J=10.4, 3.4, 1H, H9), 4.58 (d, J=8.0, 1H, H7), 4.50 (d, J=8.3, 1H, H1), 4.32 
(dd, J=11.8, 1.7, 1H, H6), 4.28 (s, 1H, OH), 4.16 – 4.05 (m, 2H, H12 & 
H12’), 4.05 – 3.96 (m, 2H, H6’ & H11), 3.89 – 3.81 (m, 1H, H3), 3.65 – 
3.47 (m, 15H, H2, H4, H5 & 12 x H21-26), 3.43 (s, 3H, OMe), 3.32 (ps q, 
J=6.0, 2H, 2 x H19), 3.19 (br ps q, J=6.0, 2H, 2 x H28), 2.54 – 2.44 (m, 4H, 
2 x H15 & 2 x H16), 2.14 (s, 3H, COCH3), 2.08 (s, 3H, COCH3), 2.05 (s, 3H, 
COCH3), 2.03 (s, 3H, COCH3), 1.96 (s, 3H, COCH3), 1.80 – 1.68 (m, 4H, 2 x 
H20 & 2 x H27), 1.41 (s, 9H, C(CH3)3). 
δC(101 MHz, CDCl3) 173.1 (COCH3), 172.3 (COCH3), 170.7 (COCH3), 170.5 (COCH3), 170.1 
(COCH3), 170.0 (CH2CONH), 169.6 (CH2CONH), 156.1 (COO
tBu), 101.8 
(C7), 101.5 (C1), 82.5 (C4), 79.0 (C(CH3)3), 72.5 (C3), 71.8 (C5), 71.3 (C11), 
71.0 (C9), 70.6 (CH2O), 70.2 (CH2O), 70.2 (CH2O), 69.5 (CH2O), 68.9 (C8), 
66.9 (C10), 62.9 (C6), 61.5 (C12), 56.8 (OMe), 56.0 (C2), 38.5 (C28), 38.2 
(C19), 32.2 (C15/16), 31.9 (C16/15), 29.8 (C20/27), 28.8 (C27/20), 28.5 
(C(CH3)3), 20.9 (COCH3), 20.7 (COCH3), 20.6 (COCH3), 20.5 (COCH3). 
Rf 0.4 (10% MeOH in DCM) 
m/z (ES+ TOF) 990.4296 [M+Na]+ (C42H69N3O22Na), calc. 990.4270  – 100% 
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5.7.1.2 Methyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-galactopyranosyl-6-O-acetyl-2-(3,6-dioxa-8-
tbutyloxycarbonylaminooctanamido)-2-deoxy-β-D-glucopyranoside (55)  
 
No literature reference found 
3,6-Dioxa-8-tbutyloxycarbonylaminooctanoic Acid (47, 270 mg, 1.03 mmol), DCC (212 mg, 1.03 mmol) 
and NHS (118 mg, 1.03 mmol) were dissolved in THF (10 mL), stood overnight at 4 °C and filtered. 
The filtrate was added to methyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-galactopyranosyl-6-O-acetyl-2-
amino-2-deoxy-β-D-glucopyranoside (40, 130 mg, 0.23 mmol) in MeCN (10 mL) and the mixture 
stirred at 60 °C for 18 h. Removal of the solvents by evaporation and purification by flash column 
chromatography (100% EtOAc) afforded the product as a off-white foam (77 mg, 41%). 
δH(400 MHz, CDCl3) 7.01 (d, J=6.0, 1H, CH2CONH), 5.36 (d, J=3.4, 1H, H10), 5.19 (dd, J=10.4, 8.3, 
1H, H8), 5.08 (s, 1H, BocNH), 4.98 (dd, J=10.4, 3.4, 1H, H9), 4.70 – 4.61 (m, 
1H, H1), 4.56 (d, J=8.3, 1H, H7), 4.32 (dd, J=11.8, 1.7, 1H, H6), 4.24 (s, 1H, 
OH), 4.16 – 4.07 (m, 2H, H12 & H12’), 4.07 – 3.98 (m, 3H, H3, H6’ & H11), 
3.96 (s, 2H, 2 x H14), 3.69 – 3.63 (m, 2H, 2 x H15), 3.63 – 3.57 (m, 3H, H5 & 
2x H16), 3.56 – 3.47 (m, 4H, H2, H4 & 2 x H17), 3.46 (s, 3H, OMe), 3.34 – 
3.25 (m, 2H, 2 x H18), 2.13 (s, 3H, COCH3), 2.08 (s, 3H, COCH3), 2.05 (s, 3H, 
COCH3), 2.02 (s, 3H, COCH3), 1.95 (s, 3H, COCH3), 1.42 (s, 9H, C(CH3)3) 
  Experimental 
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δC(101 MHz, CDCl3) 170.7 (COCH3), 170.4 (COCH3), 170.4 (COCH3), 170.1 (COCH3), 170.0 
(COCH3), 169.5 (C13), 156.0 (COO
tBu), 101.9 (C7), 101.0 (C1), 83.0 (C4), 
79.5 (C(CH3)3), 72.0 (C11), 71.8 (C5), 71.4 (C3), 71.0 (C9), 70.9 (C15), 70.5 
(C14), 70.5 (C17), 70.1 (C16), 68.9 (C10), 66.9 (C8), 62.8 (C6), 61.6 (C12), 
56.8 (OMe), 56.1 (C2), 40.5 (C18), 28.5 (C(CH3)3), 20.9 (COCH3), 20.6 
(COCH3), 20.6 (COCH3), 20.5 (COCH3), 20.5 (COCH3) 
Rf 0.3 (100% EtOAc) 
5.7.1.3 Methyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-galactopyranosyl-2-acetamido-6-O-acetyl-2-deoxy-β-
D-glucopyranoside (52)  
 
No literature reference found 
Methyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-galactopyranosyl-6-O-acetyl-2-deoxy-2-tetrachloro-
phthalimido-β-D-glucopyranoside (33, 400 mg, 0.48 mmol) was converted to the amine using the 
method in 5.5.1.3. The crude amine was dissolved in DCM (20 mL), pyridine (5 mL) and Ac2O (45 μL, 
1.0 mmol) were added and the mixture stirred at room temperature for 18 h. The mixture was 
washed with water, sat. NaHCO3, dried over MgSO4 and the solvents removed by evaporation. 
Purification by trituration with Et2O afforded the product as a pale yellow solid (231 mg, 79%). 
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δH(400 MHz, CDCl3) 5.59 (d, J=7.7, 1H, NH), 5.38 (d, J=3.4, 1H, H10), 5.22 (dd, J=10.5, 8.0, 1H, 
H8), 5.00 (dd, J=10.5, 3.4, 1H, H9), 4.68 (d, J=8.2, 1H, H1), 4.57 (d, J=8.0, 
1H, H7), 4.34 (dd, J=11.8, 1.9, 1H, H6), 4.30 (s, 1H, OH), 4.19 – 3.97 (m, 5H, 
H3, H6’, H11, H12 & H12’), 3.65 – 3.58 (m, 1H, H5), 3.53 – 3.42 (s, 5H, H2, 
H4 & OMe), 2.16 (s, 3H, COCH3), 2.10 (s, 3H, COCH3), 2.07 (s, 3H, COCH3), 
2.06 (s, 3H, COCH3), 2.01 (s, 3H, COCH3), 1.98 (s, 3H, COCH3) 
δC(101 MHz, CDCl3) 170.8 (COCH3), 170.3 (COCH3), 170.1 (COCH3), 170.0 (COCH3), 169.8 
(COCH3), 169.6 (COCH3), 101.9 (C7), 101.1 (C1), 82.8 (C4), 71.9 (C5 & C11), 
71.5 (C3), 71.0 (C9), 68.9 (C8), 66.9 (C10), 62.9 (C6), 61.7 (C12), 56.9 (OMe), 
56.8 (C2), 21.0 (COCH3), 20.7 (COCH3), 20.6 (COCH3) 
Rf 0.4 (60% Me2CO in toluene) 
m.p. 193-194 °C 
[α]D +21.1° (c=1, CHCl3) 
ν (cm-1) 3482 (br, OH), 3267 (br, NH), 3096, 2939 (CH), 1743, 1652 (C=O), 1555 (NH 
bend)  
m/z (ES+ TOF) 608.2202 [M+H]+ (C25H38NO16), calc. 608.2191 – 100% 
630.2 [M+Na]+ (C25H37NO16Na) – 50% 
 
  Experimental 
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5.7.1.4 Methyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-galactopyranosyl-6-O-acetyl-2-amino-2-deoxy-β-D-
glucopyranoside-N-succinate (53)  
 
No literature reference found 
Methyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-galactopyranosyl-6-O-acetyl-2-amino-2-deoxy-β-D-
glucopyranoside (40, 77 mg, 0.14 mmol), was dissolved in 1:1 DCM/pyridine (4 mL), succinic 
anhydride (15 mg, 1.5 mmol) was added and the reaction stirred at room temperature for 18 h. 
Removal of the solvents  by evaporation and purification by flash column chromatography  (60% 
Me2CO, 1% AcOH in toluene) afforded the product as a colourless glass (56 mg, 61%). 
δH(400 MHz, CDCl3) 6.32 (d, J=8.0, 1H, AcNH), 5.40 (d, J=3.4, 1H, H10), 5.20 (dd, J=10.5, 8.1, 1H, 
H8), 5.02 (dd, J=10.5, 3.4, 1H, H9), 4.63 (d, J=8.3, 1H, H1), 4.61 (d, J=8.1, 
1H, H7), 4.33 (dd, J=11.8, 1.7, 1H, H6), 4.22 (dd, J=11.3, 7.7, 1H, H12), 4.12 
– 4.00 (m, 3H, H6’, H11 & H12’), 3.97 (dd, J=10.0, 8.1, 1H, H3), 3.63 – 3.57 
(m, 1H, H5), 3.54 – 3.44 (m, 6H, H2, H4, OH & OMe), 2.68 (t, J=6.4, 2H, 2 x 
H14), 2.52 (t, J=6.4, 2H, 2 x H13), 2.16 (s, 3H, COCH3), 2.10 (s, 3H, COCH3), 
2.07 (s, 3H, COCH3), 2.06 (s, 3H, COCH3), 1.97 (s, 3H, COCH3) 
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δC(101 MHz, CDCl3) 175.5 (COCH3), 173.1 (COCH3), 171.1 (COCH3), 170.8 (COCH3), 170.2 
(COCH3), 170.1 (COCH3), 169.7 (COCH3), 101.8 (C7), 101.1 (C1), 82.3 (C4), 
71.9 (C3 &C5), 71.4 (C11), 71.0 (C9), 68.9 (C8), 67.0 (C10), 62.9 (C6), 61.6 
(C12), 56.9 (OMe), 56.7 (C2), 31.1 (C14), 29.8 (C13), 20.9 (COCH3), 20.7 
(COCH3), 20.6 (COCH3) 
m/z (ES+ TOF) 688.2085 [M+Na]+ (C27H39NO18Na), calc. 688.2065 – 100% 
5.7.2 Model Reactions 
5.7.2.1 Propargyl 3,4,6-tri-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-glucopyranoside (81)  
 
No literature reference found 
1,3,4,6-Tetra-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-glucopyranose (27, 4.00 g, 6.53 mmol) 
was dissolved in 32% HBr in AcOH (11 mL) with Ac2O (2.0 mL, 21 mmol) and stirred, in darkness, 
overnight at room temperature. 100 mL of DCM was added and the mixture poured over ice. 
Washing with water then sat. NaHCO3, drying over MgSO4 and removal of the solvent afforded the 
crude bromide as a cream solid, which was immediately dissolved in DCM (50 mL), propargyl alcohol 
(6.0 mL, 100 mmol) and Ag2CO3 (1.82 g, 6.53 mmol) were added and the mixture refluxed in darkness 
for 3 days. Filtering through Celite and removal of the solvent produced an orange solid which was 
purified by stepped gradient column chromatography (15% → 20% → 25% EtOAc in hexane) to give 
the product as an off-white solid (2.43 g, 61%). 
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δH(400 MHz, CDCl3) 5.78 (dd, J=10.5, 9.0, 1H, H3), 5.58 (d, J=8.5, 1H, H1), 5.20 (dd, J=10.1, 9.1, 
1H, H4), 4.38 – 4.28 (m, 4H, H2, H6, H7 & H7’), 4.17 (dd, J=12.4, 2.3, 1H, 
H6’), 3.87 (ddd, J=10.2, 4.5, 2.3, 1H, H5), 2.36 (t, J=2.4, 1H, H9), 2.12 (s, 
3H, COCH3), 2.04 (s, 3H, COCH3), 1.91 (s, 3H, COCH3) 
δC(101 MHz, CDCl3) 170.8 (COCH3), 170.6 (COCH3), 169.5 (COCH3), 140.7 (CONCO), 135.9 (Arq), 
130.1 (Arq), 127.1 (Arq), 95.6 (C1), 78.1 (C9), 75.9 (C8), 72.1 (C5), 70.8 (C3), 
68.6 (C4), 61.8 (C6), 56.3 (C7), 55.2 (C2), 20.9 (COCH3), 20.7 (COCH3), 20.6 
(COCH3) 
Rf 0.7 (2:3 hexane/EtOAc) 
m.p. 88-90 °C 
[α]D +25.3 (c=0.6, CHCl3) 
ν (cm-1) 3261, 2950, 2898 (CH), 2122 (C≡C), 1724 (C=O) 
m/z (ES+ TOF) 631.9673 [M+Na]+ (C23H19
35Cl4NO10Na), calc. 631.9661 – 80% 
634.0 [M+Na]+ (C23H19
35Cl3
37ClNO10Na) – 100% 
636.0 [M+Na]+ (C23H19
35Cl2
37Cl2NO10Na) – 60% 
5.7.2.2 1-(3-Oxa-5-tbutyloxycarbonylaminopent-1-yl)-1,2,3-triazol-4-ylmethyl 3,4,6-tri-O-acetyl-2-
deoxy-2-tetrachlorophthalimido-β-D-glucopyranoside (82)  
 
No literature reference found 
  Experimental 
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Propargyl 3,4,6-tri-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-glucopyranoside (81, 200 mg, 
0.33 mmol) and N-Boc-2-(2-azidoethoxy)ethylamine (79, 113 mg, 0.49 mmol) were dissolved in 
Me2CO (5 mL), sodium ascorbate (26 mg, 0.13 mmol) and CuSO4 (0.1 M in H2O, 163 μL, 16.3 μmol) 
were added and the mixture stirred at 50 °C for 26 h. The mixture was cooled, extracted into DCM, 
washed with brine and dried over MgSO4. Removal of the solvents gave a pale yellow syrup that was 
purified by flash column chromatography (3:1 Hexane/EtOAc) to afford the product triazole as a 
colourless syrup (206 mg, 75%). 
δH(400 MHz, CDCl3) 7.56 (s, J=10.5, 1H, H9), 5.70 (dd, J=10.5, 9.1, 1H, H3), 5.41 (d, J=8.5, 1H, 
H1, H1), 5.19 (dd, J=10.0, 9.2, 1H, H4), 4.90 (d, J=12.6, 1H, H7), 4.78 (br s, 
1H, BocNH), 4.75 (d, J=12.6, 1H, H7’), 4.47 (t, J=6.1, 1H, H10), 4.46 (t, 
J=6.1, 1H, H10’), 4.35 (dd, J=12.1, 4.7, 1H, H6), 4.32 (dd, J=10.4, 8.4, 1H, 
H2), 4.19 (dd, J=12.3, 2.3, 1H, H6’), 3.91 – 3.83 (m, 1H, H5), 3.80 (t, J=6.3, 
1H, H11), 3.79 (t, J=6.3, 1H, H11’), 3.48 (t, J=5.1, 2H, 2 x H12), 3.28 (br ps 
q, J=5.1, 2H, 2 x H13), 2.13 (s, 3H, COCH3), 2.03 (s, 3H, COCH3), 1.89 (s, 3H, 
COCH3), 1.44 (s, 9H, C(CH3)3) 
δC(101 MHz, CDCl3) 170.8 (COCH3), 170.6 (COCH3), 169.5 (COCH3), 161.7 (CONCO), 140.5 
(COOtBu), 130.0 (C8), 129.1 (Arq), 128.3 (Arq), 125.4 (Arq), 124.1 (C9), 96.9 
(C1), 73.9 (C(CH3)3), 72.0 (C5), 70.8 (C3), 70.5 (C12), 69.1 (C11), 68.7 (C4), 
62.8 (C7), 61.9 (C6), 55.4 (C2), 50.4 (C10), 40.3 (C13), 28.5 (C(CH3)3), 20.9 
(COCH3), 20.7 (COCH3), 20.6 (COCH3) 
Rf 0.6 (2:3 hexane/EtOAc) 
[α]D +25.5° (c=1, CHCl3) 
  Experimental 
  161 
ν (cm-1) 3413 (NH), 3152, 2961, 2904, 2853 (CH), 1747, 1723 (C=O), 1512 (NH 
bend) 
m/z (ES+ TOF) 840.1187 [M+H]+ (C32H38
35Cl4N5O13), calc. 840.1220 – 80% 
842.2 [M+H]+ (C32H38
35Cl3





acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-glucopyranoside (83)  
 
No literature reference found 
Propargyl 3,4,6-tri-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-glucopyranoside (81, 200 mg, 
0.33 mmol) and N-Boc-13-azido-4,7,10-trioxa-tridecylamine (78, 170 mg, 0.49 mmol) were dissolved 
in Me2CO (5mL), sodium ascorbate (26 mg, 0.13 mmol) and CuSO4 (0.1 M in H2O, 163 μL, 16.3 μmol) 
were added and the mixture stirred at 50 °C for 26 h. The mixture was cooled, extracted into DCM, 
washed with brine and dried over MgSO4. Removal of the solvents gave a pale yellow syrup that was 
purified by stepped gradient column chromatography (10% → 20% → 30% → 40% → 50% Me2CO in 
toluene) to afford the product triazole as a colourless syrup (208 mg, 67%). 
  Experimental 
  162 
δH(400 MHz, CDCl3) 7.52 (s, 1H, H9), 5.69 (dd, J=10.5, 9.0, 1H, H3), 5.41 (d, J=8.5, 1H, H1), 5.18 
(dd, J=10.1, 9.1, 1H, H4), 4.96 (br s, 1H, BocNH), 4.87 (d, J=12.6, 1H, H7), 
4.73 (d, J=12.6, 1H, H7’), 4.40 (t, J=6.9, 2H, 2 x H10), 4.34 (dd, J=12.2, 4.3, 
1H, H6), 4.29 (dd, J=10.5, 8.4, 1H, H2), 4.17 (dd, J=12.2, 2.3, 1H, H6’), 3.85 
(ddd, J=6.9, 4.3, 2.2, 1H, H5), 3.66 – 3.49 (m, 10H, 10 x H13-17), 3.40 (t, 
J=6.2, 2H, 2 x H12), 3.24 – 3.15 (m, 4H, 2 x H19), 2.14 – 2.08 (m, 5H, 2 x 
H11 & COCH3), 2.02 (s, 3H, COCH3), 1.87 (s, 3H, COCH3), 1.78 – 1.69 (m, 
2H, 2 x H18), 1.42 (s, 9H, C(CH3)3) 
δC(101 MHz, CDCl3) 170.8 (COCH3), 170.6 (COCH3), 169.5 (COCH3), 156.1 (CONCO), 143.2 (C8), 
140.4 (COOtBu), 130.0 (Arq), 127.2 (Arq), 127.0 (Arq), 123.7 (C9), 96.9 (C1), 
79.0 (C(CH3)3), 72.0 (C5), 70.7 (C3), 70.6 (OCH2), 70.6 (OCH2), 70.5 (OCH2), 
70.4 (OCH2), 70.3 (OCH2), 68.7 (C4), 67.1 (C12), 62.7 (C7), 61.9 (C6), 55.3 
(C2), 47.2 (C10), 38.6 (C19), 30.2 (C11), 29.7 (C18), 28.5 (C(CH3)3), 20.9 
(COCH3), 20.7 (COCH3), 20.6 (COCH3) 
Rf 0.1 (2:3 hexane/EtOAc) 
[α]d +23.9° (c=1, CHCl3) 
ν (cm-1) 3880 (NH), 3140, 2980, 2935, 2874 (CH), 1749, 1723 (C=O), 1515 (NH 
bend) 
m/z (ES+ TOF) 956.2030 [M+H]+ (C38H50
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No literature reference found 
Propargyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-galactopyranosyl-2-acetamido-3-O-acetyl-6-O-benzyl-2-
deoxy-α-D-glucopyranoside (77, 344 mg, 0.48 mmol) and N-Boc-2-(2-azidoethoxy)ethylamine (79, 
165 mg, 0.72 mmol) were dissolved in Me2CO (10 mL), sodium ascorbate (38 mg, 0.19 mmol) and 
CuSO4 (0.1 M in H2O, 238 μL, 23.8 μmol) were added and the mixture stirred at 50 °C for 18 h. The 
mixture was cooled, extracted into DCM, washed with brine and dried over MgSO4. Removal of the 
solvents gave a beige solid that was purified by flash column chromatography (50% Me2CO, 2% NEt3 
in toluene) to afford the product triazole as a white solid (305 mg, 67%). 
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δH(400 MHz, CDCl3) 7.65 (s, 1H, H15), 7.44 – 7.29 (m, 5H, ArH), 5.94 (d, J=9.0, 1H, AcNH), 5.25 
(d, J=3.0, 1H, H10), 5.12 (ps t, J=9.8, 1H, H3), 4.96 (dd, J=10.6, 7.9, 1H, H8), 
4.94 (br s, 1H, BocNH), 4.92 (d, J=3.1, 1H, H1), 4.86 – 4.72 (m, 3H, H9, H13 
& PhCHH), 4.60 (d, J=12.3, 1H, H13’), 4.52 (br t, J=4.9, 2H, 2 x H16), 4.44 
(d, J=12.1, 1H, PhCHH), 4.34 (d, J=7.9, 1H, H7), 4.30 – 4.19 (m, 1H, H2), 
4.04 (d, J=6.8, 2H, H12 & H12’), 3.95 (ps t, J=9.8, 1H, H4), 3.83 (t, J=4.9, 
2H, 2 x H17), 3.81 – 3.72 (m, 2H, H5 & H6), 3.68 – 3.60 (m, 2H, H6’ & H11), 
3.50 (t, J=5.2, 2H, 2 x H18), 3.33 – 3.24 (m, 2H, 2 x H19), 2.10 (s, 3H, 
COCH3), 2.05 (s, 3H, COCH3), 2.00 (s, 3H, COCH3), 1.94 (s, 3H, COCH3), 1.93 
(s, 3H, COCH3), 1.90 (s, 3H, COCH3), 1.42 (s, 9H, C(CH3)3) 
δC(101 MHz, CDCl3) 171.3 (COCH3), 170.5 (COCH3), 170.3 (COCH3), 170.1 (COCH3), 169.1 
(COCH3), 156.1 (COCH3), 143.5 (C14), 137.8 (COO
tBu), 128.8 (Ar), 128.3 
(Ar), 128.3 (Ar), 124.0 (C14), 100.5 (C7), 96.8 (C1), 79.6 (C(CH3)3), 74.9 
(C4), 73.8 (PhCH2), 71.5 (C3), 71.1 (C9), 70.7 (C5), 70.5 (C11), 70.4 (C18), 
69.3 (C8), 69.1 (C17), 67.3 (C10), 66.9 (C6), 61.1 (C13), 61.0 (C12), 52.0 
(C2), 50.4 (C16), 40.3 (C19), 28.5 (C(CH3)3), 23.2 (COCH3), 21.0 (COCH3), 
20.9 (COCH3), 20.8 (COCH3), 20.7 (COCH3), 20.7 (COCH3) 
Arq not seen. 
Rf 0.3 (50% Me2CO, 2% NEt3 in toluene) 
m.p. 63-65 °C 
[α]D +27.2° (c=1.5, CHCl3) 
ν (cm-1) 3350 (br, NH), 2942, 2937, 2873 (CH), 1745, 1708, 1673, 1522 (C=O) 
m/z (ES+ TOF) 952.4019 [M+H]+ (C43H62N5O19), calc. 952.4039 – 100% 
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5.7.3.2 1-(3-Oxa-5-tbutyloxycarbonylaminopent-1-yl)-1,2,3-triazol-4-ylmethyl 2,3,4,6-tetra-O-acetyl-
β(1-4)-D-galactopyranosyl-2-acetamido-3-O-acetyl-2-deoxy-α-D-glucopyranoside (87)  
 
No literature reference found 
1-(3-Oxa-5-tbutyloxycarbonylaminopent-1-yl)-1,2,3-triazol-4-ylmethyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-
galactopyranosyl-2-acetamido-3-O-acetyl-6-O-benzyl-2-deoxy-α-D-glucopyranoside (84, 50 mg, 0.05 
mmol) was dissolved in MeOH (10 mL), Pd/C (10%, ca. 10 mg) was added and the mixture stirred 
under hydrogen at 1 bar for 16 h. Filtration through Celite and removal of the solvents afforded the 
product alcohol as a white solid (45 mg, 98%). 
δH(400 MHz, CDCl3) 7.69 (s, 1H, H15), 5.98 (d, J=8.4, 1H, AcNH), 5.32 (d, J=3.3, 1H, H10), 5.20 
(ps t, J=10.0, 1H, H3), 5.09 (dd, J=10.4, 7.9, 1H, H8), 4.98 (dd, J=10.4, 3.3, 
1H, H9), 4.89 (br s, 1H, BocNH), 4.89 (d, J=3.3, 1H, H1), 4.78 (d, J=13.3, 1H, 
H13), 4.65 – 4.60 (m, 2H, H7 & H13’), 4.57 – 4.50 (m, 2H, 2 x H16), 4.29 – 
4.15 (m, 1H, H2), 4.07 (dd, J=6.6, 5.1, 2H, H12 & H12’), 3.95 – 3.87 (m, 2H, 
H4 & H11), 3.83 (t, J=4.8, 2H, 2 x H17), 3.80 – 3.76 (m, 1H, H6) 3.75 – 3.67 
(m, 2H, H5 & H6’), 3.51 (t, J=5.2, 2H, 2 x H18), 3.30 (br s, 2H, 2 x H19), 2.12 
(s, 3H, COCH3), 2.06 (s, 3H, COCH3), 2.03 (s, 6H, 2 x COCH3), 1.95 (s, 3H, 
COCH3), 1.90 (s, 3H, COCH3), 1.42 (s, 9H, C(CH3)3) 
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δC(101 MHz, CDCl3) 171.1 (COCH3), 170.5 (COCH3), 170.3 (COCH3), 170.2 (COCH3), 169.5 
(COCH3), 156.1 (COCH3), 143.4 (C14), 124.2 (C15), 101.2 (C1), 96.7 (C7), 
79.6 (C(CH3)3), 75.4 (C4/11), 71.8 (C3), 71.2 (C5), 71.1 (C9), 70.6 (C11/4), 
70.4 (C18), 69.4 (C8), 69.1 (C17), 66.9 (C10), 70.0 (C12), 70.0 (C13), 60.5 
(C6), 52.2 (C2), 50.4 (C16), 40.3 (C19), 28.5 (C(CH3)3), 23.2 (COCH3), 21.0 
(COCH3), 20.9 (COCH3), 20.8 (COCH3), 20.6 (COCH3) 
COOtBu not seen. 
Rf 0.3 (50% Me2CO in toluene) 
m.p. 84-87 °C 
[α]D -4.6° (c=1, CHCl3) 
ν (cm-1) 3361 (br, OH), 2958, 2935, 2901 (CH), 1744, 1642, 1723, 1522 (C=O) 
m/z (ES+ TOF) 862.3561 [M+H]+ (C36H56N5O19), calc. 862.3569 – 100% 
5.7.3.3 1-(3-Oxa-5-tbutyloxycarbonylaminopent-1-yl)-1,2,3-triazol-4-ylmethyl β(1-4)-D-
galactopyranosyl-2-acetamido-2-deoxy-α-D-glucopyranoside (89)  
 
No literature reference found 
1-(3-Oxa-5-tbutyloxycarbonylaminopent-1-yl)-1,2,3-triazol-4-ylmethyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-
galactopyranosyl-2-acetamido-3-O-acetyl-2-deoxy-α-D-glucopyranoside (87, 46 mg, 0.05 mmol) was 
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dissolved in MeOH (4mL), Na (ca. 5mg) was added and the reaction stirred at room temperature for 
4h, when TLC (50% Me2CO in toluene) showed only a baseline spot. The mixture was neutralised by 
addition of DOWEX and filtered. Removal of the solvents by evaporation afforded the product as a 
colourless film (29 mg, 84%). 
δH(500 MHz, MeOD) 8.04 (s, 1H, H15), 4.90 (d, J=3.6, 1H, H1), 4.79 (d, J=12.5, 1H, H13), 4.63 (d, 
J=12.5, 1H, H13’), 4.59 (t, J=5.0, 2H, H16), 4.37 (d, J=7.5, 1H, H7), 3.97 (dd, 
J=10.8, 3.6, 1H, H2), 3.89 – 3.83 (m, 4H, H6, H6’ & 2 X H17), 3.81 (br s, 1H, 
H10), 3.81 (dd, J=10.8, 9.5, 1H, H3), 3.75 (dd, J=11.5, 7.4, 1H, H12), 3.74 
(dd, J=7.1, 3.0, 1H, H5), 3.68 (dd, J=11.5, 4.6, 1H, H12’), 3.63 (dd, J=9.5, 
8.6, 1H, H4), 3.58 (dd, J=7.4, 4.6, 1H, H11), 3.53 (dd, J=9.7, 7.5, 1H, H8), 
3.49 (dd, J=9.7, 3.3, 1H, H9), 3.48 (t, J=5.7, 2H, H18), 3.19 (t, J=5.7, 2H, 
H19), 1.95 (s, 3H, COCH3), 1.43 (s, 9H, C(CH3)3) 
δC(126 MHz, MeOD) 173.5 (COCH3), 158.4 (COO
tBu), 145.0 (C14), 126.0 (C15), 105.1 (C7), 97.9 
(C1), 81.2 (C4), 80.1 (C(CH3)3), 77.1 (C11), 74.8 (C9), 72.6 (C8), 72.5 (C5), 
71.0 (C18), 71.0 (C3), 70.3 (C10), 70.0 (C19), 62.4 (C12), 61.8 (C6), 61.4 
(C13), 54.8 (C2), 51.5 (C16), 41.1 (C19), 28.7 (C(CH3)3), 22.5 (COCH3) 
tR 24.1 min 
m.p. 111-114 °C 
[α]D +42.5° (c=0.7, MeOH) 
ν (cm-1) 3345 (br, OH), 2922 (CH), 1636, 1540 (C=O) 
m/z (ES+ TOF) 652.3025 [M+H]+ (C26H46N5O14), calc.652.3041 – 100% 
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5.7.3.4 1-(3-Oxa-5-(fluorescein-5-thioureyl)pent-1-yl)-1,2,3-triazol-4-ylmethyl β(1-4)-D-
galactopyranosyl-2-acetamido-2-deoxy-α-D-glucopyranoside (91)  
 
No literature reference found 
1-(3-Oxa-5-tbutyloxycarbonylaminopent-1-yl)-1,2,3-triazol-4-ylmethyl β(1-4)-D-galactopyranosyl-2-
acetamido-2-deoxy-α-D-glucopyranoside (89, 2 mg, 3 μmol) was dissolved in 1:1 TFA/DCM (2 mL) 
and stirred for 4 h when HPLC showed complete consumption of the starting material (intermediate 
amine tR = 11.1 min). The solvents were removed and the residue dissolved in 1:1:1 
DCM/DMF/pyridine (0.5 mL), FITC (3 mg, 6 μmol) was added and the mixture stirred at room 
temperature for 1 week. Removal of the solvents and purification by HPLC and lyophilisation 
afforded the product as a yellow/orange solid (2 mg, 77%). 
tR 28.1 min 
m/z (ES+ TOF) 552.3 C21H38N5O12 – 100% 
348.1 C20H14NO5 – 85% 
Fluorescence Absorption: 446 nm 
Emission: 518 nm 
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5.7.3.5 1-(4,7,10-Trioxa-13-tbutyloxycarbonylaminotridec-1-yl)-1,2,3-triazol-4-ylmethyl 2,3,4,6-tetra-
O-acetyl-β(1-4)-D-galactopyranosyl-2-acetamido-3-O-acetyl-6-O-benzyl-2-deoxy-α-D-
glucopyranoside (85)  
 
No literature reference found 
Propargyl 2,3,4,6-tetra-O-acetyl-β(1-4)-D-galactopyranosyl-2-acetamido-3-O-acetyl-6-O-benzyl-2-
deoxy-α-D-glucopyranoside (77, 184 mg, 0.26 mmol) and N-Boc-13-azido-4,7,10-trioxa-tridecylamine 
(78, 133 mg, 0.38 mmol) were dissolved in Me2CO (7 mL), sodium ascorbate (20 mg, 0.10 mmol) and 
CuSO4 (0.1 M in H2O, 128 μL, 12.8 μmol) were added and the mixture stirred at 50 °C for 20 h. The 
mixture was cooled, extracted into DCM, washed with brine and dried over MgSO4. Removal of the 
solvents gave a light brown syrup that was purified by stepped gradient column chromatography 
(30% → 40% → 50% Me2CO, 2% NEt3 in toluene) to afford the product triazole as a colourless film 
(130 mg, 48%). 
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δH(400 MHz, CDCl3) 7.56 (s, 1H, H15), 7.40 – 7.25 (m, 5H, ArH), 5.92 (d, J=9.5, 1H, AcNH), 5.20 
(d, J=2.8, 1H, H10), 5.06 (dd, J=10.8, 9.5, 1H, H3), 4.97 (br s, 1H, BocNH), 
4.91 (dd, J=10.4, 8.0, 1H, H8), 4.86 (d, J=3.6, 1H, H1), 4.78 – 4.67 (m, 3H, 
H9, H13 & PhCHH), 4.53 (d, J=12.3, 1H, H13’), 4.46 – 4.35 (m, 3H, 2 x H16 
& PhCHH), 4.28 (d, J=8.0, 1H, H7), 4.21 (ddd, J=10.8, 9.5, 3.6, 1H, H2), 3.99 
(d, J=6.8, 2H, H12), 3.90 (ps t, J=9.5, 1H, H4), 3.77 – 3.71 (m, 1H, H5), 3.62 
– 3.50 (m, 11H, H6, H6’, H11 & 8 x H19-22), 3.46 (t, J=6.0, 2H, 2 x H23), 
3.39 (t, J=5.7, 2H, 2 x H18), 3.14 (br ps q, J=6.0, 2H, H25), 2.17 – 2.08 (m, 
2H, 2 x H17), 2.05 (s, 3H, COCH3), 2.00 (s, 3H, COCH3), 1.95 (s, 3H, COCH3), 
1.89 (s, 3H, COCH3), 1.88 (s, 3H, COCH3), 1.84 (s, 3H, COCH3), 1.67 (p, 
J=6.0, 2H, 2 x H24), 1.36 (s, 9H, C(CH3)3) 
δC(101 MHz, CDCl3) 171.1 (COCH3), 170.3 (COCH3), 170.1 (COCH3), 170.1 (COCH3), 168.9 
(COCH3), 156.0 (COO
tBu), 143.1 (C14), 128.6 (Ar), 128.1 (Ar), 128.1 (Ar), 
123.5 (C15), 100.4 (C7), 96.8 (C1), 78.8 (C(CH3)3), 74.8 (C4), 73.7 (PhCH2), 
71.4 (C3), 71.0 (C9), 70.5 (OCH2), 70.5 (C5), 70.5 (OCH2), 70.3 (C11), 70.3 
(OCH2),70.2 (OCH2), 69.1 (C8), 67.2 (OCH2), 67.0 (OCH2), 66.7 (C10), 61.0 
(C13), 60.9 (C12), 51.8 (C2), 47.2 (C16), 38.5 (C25), 30.2 (C17), 29.6 (C24), 
28.4 (C(CH3)3), 23.1 (COCH3), 20.8 (COCH3), 20.7 (COCH3), 20.6 (COCH3), 
20.6 (COCH3), 20.5 (COCH3) 
Arq not seen. 
Rf 0.3 (50% Me2CO, 2% NEt3 in toluene) 
[α]D -9.4° (c=2, CHCl3) 
ν (cm-1) 3356 (br, NH), 2981, 2938, 2873 (CH), 1745, 1707, 1675, 1522 (C=O) 
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No literature reference found 
1-(4,7,10-Trioxa-13-tbutyloxycarbonylaminotridec-1-yl)-1,2,3-triazol-4-ylmethyl 2,3,4,6-tetra-O-
acetyl-β(1-4)-D-galactopyranosyl-2-acetamido-3-O-acetyl-6-O-benzyl-2-deoxy-α-D-glucopyranoside 
(85, 86 mg, 0.08 mmol) was dissolved in MeOH (10 mL), Pd/C (10%, ca. 10 mg) was added and the 
mixture stirred under hydrogen at 1 bar for 16 h. Filtration through Celite and removal of the 
solvents afforded the product alcohol as a white foam which slowly collapsed to a colourless, viscous 
syrup (73 mg, 93%). 
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δH(400 MHz, CDCl3) 7.67 (s, 1H, H15), 5.97 (d, J=9.1, 1H, AcNH), 5.32 (d, J=2.8, 1H, H10), 5.19 
(dd, J=10.6, 9.3, 1H, H3), 5.09 (dd, J=10.4, 7.9, 1H, H8), 5.00 (br s, 1H, 
BocNH), 4.98 (dd, J=10.4, 3.4, 1H, H9), 4.88 (d, J=3.6, 1H, H1), 4.78 (d, 
J=12.4, 1H, H13), 4.63 (d, J=7.8, 1H, H7), 4.61 (d, J=12.4, 1H, H13’), 4.50 (t, 
J=6.8, 2H, 2 x H16), 4.20 (ddd, J=10.6, 9.6, 3.5, 1H, H2), 4.13 – 4.02 (m, 2H, 
H12 & H12’), 3.95 – 3.86 (m, 2H, H4 & H11), 3.84 – 3.78 (m, 1H, H6), 3.76 
– 3.70 (m, 2H, H5 & H6’), 3.67 – 3.56 (m, 8H, 8 x H19-H22), 3.52 (t, J=6.1, 
2H, 2 x H23), 3.44 (t, J=5.9, 2H, 2 x H18), 3.20 (br ps q, J=6.1, 2H, 2 x H25), 
2.17 (tt, J=6.8, 5.9, 2H, 2 x H17), 2.12 (s, 3H, COCH3), 2.06 (s, 3H, COCH3), 
2.04 (s, 3H, COCH3), 2.03 (s, 3H, COCH3), 1.95 (s, 3H, COCH3), 1.90 (s, 3H, 
COCH3), 1.73 (p, J=6.1, 2H, 2 x H24), 1.41 (s, 9H, C(CH3)3) 
δC(101 MHz, CDCl3) 171.1 (COCH3), 170.5 (COCH3), 170.2 (COCH3), 170.2 (COCH3), 169.5 
(COCH3), 156.1 (COO
tBu), 143.0 (C14), 123.9 (C15), 101.2 (C7), 96.7 (C1), 
79.1 (C(CH3)3), 75.3 (C4), 71.8 (C3), 71.2 (C5), 71.1 (C9), 70.6 (C11 & OCH2), 
70.4 (OCH2), 70.30 (OCH2), 69.6 (C23), 69.4 (C8), 67.0 (C18), 66.8 (C10), 
60.9 (C13), 60.9 (C12), 60.4 (C6), 52.1 (C2), 47.3 (C16), 38.6 (C25), 30.2 
(C17), 29.7 (C24), 28.5 (C(CH3)3), 23.2 (COCH3), 21.0 (COCH3), 20.8 
(COCH3), 20.7 (COCH3), 20.6 (COCH3) 
Rf 0.1 (50% Me2CO in toluene) 
[α]D -2.5° (c=2, CHCl3) 
ν (cm-1) 3362 (br, OH), 2980, 2933, 2871 (CH), 1746, 1706, 1675, 1525 (C=O) 
m/z (ES+ TOF) 1000.4244 [M+Na]+ (C42H67N5O21Na), calc. 1000.4226 – 100% 
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5.7.3.7 1-(4,7,10-Trioxa-13-tbutyloxycarbonylaminotridec-1-yl)-1,2,3-triazol-4-ylmethyl β(1-4)-D-
galactopyranosyl-2-acetamido-2-deoxy-α-D-glucopyranoside (88)  
 
No literature reference found 
1-(4,7,10-Trioxa-13-tbutyloxycarbonylaminotridec-1-yl)-1,2,3-triazol-4-ylmethyl 2,3,4,6-tetra-O-
acetyl-β(1-4)-D-galactopyranosyl-2-acetamido-3-O-acetyl-2-deoxy-α-D-glucopyranoside (86, 50 mg, 
0.05 mmol) was dissolved in MeOH (4mL), Na (ca. 5mg) was added and the reaction stirred at room 
temperature for 3h, when TLC (80% Me2CO in toluene) showed only a baseline spot . The mixture 
was neutralised by addition of DOWEX and filtered. Removal of the solvents by evaporation afforded 
the product as a sticky white film (31 mg, 77%). 
δH(500 MHz, MeOD) 8.11 (s, 1H, H15), 4.92 (d, J=3.7, 1H, H1), 4.81 (d, J=12.5, 1H, H13), 4.66 (d, 
J=12.5, 2H, H13), 4.57 (t, J=6.8, 3H, 2 x H16), 4.39 (d, J=7.5, 1H, H7), 3.99 
(dd, J=10.8, 3.7, 1H, H2), 3.89 – 3.80 (m, 4H, H3, H6, H6’ & H10), 3.80 – 
3.69 (m, 3H, H5, H12 & H12’), 3.69 – 3.58 (m, 10H, H4, H11 & 8 x H19-22), 
3.56 – 3.46 (m, 6H, H8, H9, 2 x H18 & 2 x H23), 3.13 (t, J=6.8, 2H, 2 x H25), 
2.18 (p, J=6.5, 3H, 2 x H17), 1.97 (s, 3H, COCH3), 1.73 (p, J=6.5, 2H, 2 x 
H24), 1.45 (s, 9H, C(CH3)3) 
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δC(126 MHz, MeOD) 173.5 (COCH3), 158.4 (COO
tBu), 145.0 (C14), 125.7 (C15), 105.1 (C7), 97.8 
(C1), 81.2 (C4), 79.9 (C(CH3)3), 77.1 (C11), 74.8 (C9), 72.6 (C8), 72.6 (C5), 
71.5 (OCH2), 71.3 (OCH2), 71.3 (OCH2), 71.0 (C3), 70.3 (C10), 69.9 (C23), 
68.3 (C18), 62.5 (C12), 61.8 (C6), 61.4 (C13), 54.8 (C2), 38.7 (C25), 31.4 
(C17), 30.9 (C24), 28.8 (C(CH3)3), 22.6 (COCH3) 
tR 23.4 min 
[α]D +58.0° (c=0.6, MeOH) 
m/z (ES+ TOF) 768.3904 [M+H]+ (C32H58N5O16) calc. 768.3879 – 100% 
  References 
  175 
6 References 
1. Cancer Cases and Deaths in the UK, 
http://publications.cancerresearchuk.org/downloads/Product/CS_DT_CASESDEATHS.xlsx, 
Accessed 07/07/2014. 




3. Mortality - UK, 2007, 
http://publications.cancerresearchuk.org/epages/crukstore.sf/en_GB/?ObjectPath=/Shops/c
rukstore/Products/CSMORT06, Accessed 23/12/2009. 
4. N. Lane, Oxygen: The Molecule That Made The World, 1st edn., OUP, 2002. 
5. H. Rang, M. Dale, J. Ritter and P. Moore, Pharmacology, 5th edn., Churchill Livingstone, 2003. 
6. M. Ridley, Genome, 1st edn., Fourth Estate, 1999. 
7. CT, http://www.med.harvard.edu/JPNM/TF00_01/Oct3/CT.gif, Accessed 19/5/2014. 
8. MRI, http://www.hawaii.edu/medicine/pediatrics/pemxray/v3c09.html, Accessed 
19/5/2014. 
9. 3D-PET/CT, http://www.texascancerclinic.com/equipment/sami_petct.cfm, Accessed 
28/6/2010. 
10. PET/CT, http://www.njironline.org/pet-ct-radiology-imaging-center-carlstadt-new-
jersey.htm, Accessed 28/6/2010. 
11. N. Ramanujam, Enc. Anal. Chem., 2000, 1, 20-56. 
  References 
  176 
12. F. T. Liu and G. A. Rabinovich, Nat. Rev. Cancer, 2005, 5, 29-41. 
13. S. H. Barondes, D. N. W. Cooper, M. A. Gitt and H. Leffler, J. Biol. Chem., 1994, 269, 20807-
20810. 
14. P. Sorme, P. Arnoux, B. Kahl-Knutsson, H. Leffler, J. M. Rini and U. J. Nilsson, J. Am. Chem. 
Soc., 2005, 127, 1737-1743. 
15. C. Diehl, S. Genheden, K. Modig, U. Ryde and M. Akke, J. Biomol. NMR, 2009, 45, 157-169. 
16. C. Diehl, O. Engstr m, T. Delaine, M. H kansson, S. Genheden, K. Modig, H. Leffler,  . Ryde, 
U. J. Nilsson and M. Akke, J. Am. Chem. Soc., 2010, 132, 14577-14589. 
17. C. G. Hadjipanayis, M. J. Bonder, S. Balakrishnan, X. Wang, H. Mao and G. C. Hadjipanayis, 
Small, 2008, 4, 1925-1929. 
18. T. L. Lowary and O. Hindsgaul, Carbohydr. Res., 1994, 251, 33-67. 
19. P. Sorme, Y. N. Qian, P. G. Nyholm, H. Leffler and U. J. Nilsson, ChemBioChem, 2002, 3, 183-
189. 
20. W. zu Reckendorf, Angew. Chem., Int. Ed., 1967, 6, 177. 
21. C. Oberg, A. L. Noresson, T. Delaine, A. Larumbe, J. Tejler, H. von Wachenfeldt and U. J. 
Nilsson, Carbohydr. Res., 2009, 344, 1282-1284. 
22. M. Main, PhD Thesis, University of Birmingham, 2010. 
23. D. J. Bell, J. Chem. Soc., 1935, 1874-1875. 
24. F. Andersson and B. Samuelsson, Carbohydr. Res., 1984, 129, C1-C3. 
25. J. Elhalabi and K. G. Rice, Nucleosides Nucleotides Nucleic Acids, 2004, 23, 195-205. 
26. K. N. Slessor and A. S. Tracey, Can. J. Chem., 1969, 47, 3989-3995. 
27. M. P. Watterson, L. Pickering, M. D. Smith, S. J. Hudson, P. R. Marsh, J. E. Mordaunt, D. J. 
Watkin, C. J. Newman and G. W. J. Fleet, Tetrahedron: Asymmetry, 1999, 10, 1855-1859. 
28. P. Phukan, Tetrahedron Lett., 2004, 45, 4785-4787. 
  References 
  177 
29. Z. Wang, M. Matin and S. Sheikh, Molecules, 2005, 10, 1325-1334. 
30. S. Deng, U. Gangadharmath and C.-W. T. Chang, J. Org. Chem., 2006, 71, 5179-5185. 
31. A. J. Janczuk, W. Zhang, P. R. Andreana, J. Warrick and P. G. Wang, Carbohydr. Res., 2002, 
337, 1247-1259. 
32. U. Ellervik and G. Magnusson, J. Org. Chem., 1998, 63, 9314-9322. 
33. J. S. Debenham, S. D. Debenham and B. Fraser-Reid, Bioorg. Med. Chem., 1996, 4, 1909-1918. 
34. K. Aplander, J. Tejler, J. Toftered, S. Carlsson, B. Kahl-Knutsson, A. Sundin, H. Leffler and U. J. 
Nilsson, Carbohydr. Res., 2006, 341, 1363-1369. 
35. J. Burés, M. Martín, F. Urpí and J. Vilarrasa, J. Org. Chem., 2009, 74, 2203-2206. 
36. I. L. Cartwright, D. W. Hutchinson and V. W. Armstrong, Nucleic Acids Res., 1976, 3, 2331-
2340. 
37. M. Adamczyk, J. R. Fishpaugh and M. Thiruvazhi, Org. Prep. Proced. Int., 2002, 34, 326-331. 
38. D. O. Jang, D. J. Park and K. Joonggon, Tetrahedron Lett., 1999, 40, 5323-5326. 
39. H. Paulsen and C.-p. Herold, Chem. Ber., 1971, 104, 1311-1321. 
40. M. Izumi, K. Fukase and S. Kusumoto, Biosci. Biotechnol. Biochem., 2002, 66, 211-214. 
41. J. Garcia, J. Vilarrasa, X. Bordas and A. Banaszek, Tetrahedron Lett., 1986, 27, 639-640. 
42. M. P. DeNinno, J. B. Etienne and K. C. Duplantier, Tetrahedron Lett., 1995, 36, 669-672. 
43. C. Huang, N. Wang, K. Fujiki, Y. Otsuka, M. Akamatsu, Y. Fujimoto and K. Fukase, J. 
Carbohydr. Chem., 2010, 29, 289-298. 
44. E. D. Goddard-Borger and R. V. Stick, Org. Lett., 2007, 9, 3797-3800. 
45. F. Himo, T. Lovell, R. Hilgraf, V. V. Rostovtsev, L. Noodleman, K. B. Sharpless and V. V. Fokin, J. 
Am. Chem. Soc., 2004, 127, 210-216. 
46. V. V. Rostovtsev, L. G. Green, V. V. Fokin and K. B. Sharpless, Angew. Chem., Int. Ed., 2002, 
41, 2596-2599. 
  References 
  178 
47. H. J. Cristau, A. Hervé, F. Loiseau and D. Virieux, Synthesis, 2003, 2003, 2216-2220. 
48. P. K. Mandal and J. S. McMurray, J. Org. Chem., 2007, 72, 6599-6601. 
49. S. K. Boovanahalli, D. W. Kim and D. Y. Chi, J. Org. Chem., 2004, 69, 3340-3344. 
50. P. Angibeaud, J. Defaye, A. Gadelle and J.-P. Utille, Synthesis, 1985, 1985, 1123-1125. 
51. M. A. Rahim, S. Matsumura and K. Toshima, Tetrahedron Lett., 2005, 46, 7307-7309. 
52. E. Alonso, D. J. Ramón and M. Yus, Tetrahedron, 1997, 53, 14355-14368. 
53. B. L. Wilkinson, L. F. Bornaghi, S.-A. Poulsen and T. A. Houston, Tetrahedron, 2006, 62, 8115-
8125. 
54. N. Hada, T. Takeda and Y. Ogihara, Carbohydr. Res., 1994, 258, 93-104. 
55. W. L. F. Armarego, Perrin, D. D., Purification of laboratory chemicals, Butterworth 
Heinemann, Oxford ; Boston :, 1996. 
56. L. Hall, S. Black, K. Slessor and A. Tracey, Can. J. Chem., 1972, 50, 1912-1924. 
57. M. R. Maddani and K. R. Prabhu, Synlett, 2011, 2011, 821-825. 
58. M. Ellermann, R. Paulini, R. Jakob-Roetne, C. Lerner, E. Borroni, D. Roth, A. Ehler, W. B. 
Schweizer, D. Schlatter, M. G. Rudolph and F. Diederich, Chem. Eur. J., 2011, 17, 6369-6381. 
59. M. Hainrichson, V. Pokrovskaya, D. Shallom-Shezifi, M. Fridman, V. Belakhov, D. Shachar, S. 
Yaron and T. Baasov, Bioorg. Med. Chem., 2005, 13, 5797-5807. 
60. S. M. Christensen, H. F. Hansen and T. Koch, Org. Process Res. Dev., 2004, 8, 777-780. 
61. US Pat., US20110130553A1, 2011. 
62. P. Tiwari and A. K. Misra, J. Org. Chem., 2006, 71, 2911-2913. 
63. J. M. Jacobson, P. I. Kitov and D. R. Bundle, Carbohydr. Res., 2013, 378, 4-14. 
64. G. Agnihotri, P. Tiwari and A. K. Misra, Carbohydr. Res., 2005, 340, 1393-1396. 
65. A. K. Sarkar and K. L. Matta, Carbohydr. Res., 1992, 233, 245-250. 
66. S. Valerio, A. Iadonisi, M. Adinolfi and A. Ravidà, J. Org. Chem., 2007, 72, 6097-6106. 
  References 
  179 
67. M. Contour, J. Defaye, M. Little and E. Wong, Carbohydr. Res., 1989, 193, 283-287. 
68. C. Xu, H. Liu and X. Li, Carbohydr. Res., 2011, 346, 1149-1153. 
69. L. Lay, L. Manzoni and R. R. Schmidt, Carbohydr. Res., 1998, 310, 157-171. 
70. A. Kyas and M. Feigel, Helv. Chim. Acta, 2005, 88, 2375-2396. 
71. G. Sosnovsky and C. T. Gnewuch, J. Pharm. Sci., 1994, 83, 989-998. 
72. C. Dang, C. Nguyen, T. Nguyen and C. Im, RSC Advances, 2014, 4, 6239-6245. 
73. H. Liu and C. Wong, Bioorg. Med. Chem., 2006, 14, 7187-7195. 
74. M. Imoto, H. Yoshimura, T. Shimamoto, N. Sakaguchi, S. Kusumoto and T. Shiba, Bull. Chem. 
Soc. Jpn., 1987, 60, 2205-2214. 
75. M. Izumi, K. Fukase and S. Kusumoto, Biosci. Biotechnol. Biochem., 2002, 66, 211-214. 
76. F. Javier Munoz, S. Andre, H.-J. Gabius, J. V. Sinisterra, M. J. Hernaiz and R. J. Linhardt, Green 
Chem., 2009, 11, 373-379. 
77. US Pat., US2010052385, 2011. 
78. M. A. Azagarsamy, V. Yesilyurt and S. Thayumanavan, J. Am. Chem. Soc., 2010, 132, 4550-
4551. 
79. M. Trester-Zedlitz, K. Kamada, S. K. Burley, D. Fenyö, B. T. Chait and T. W. Muir, J. Am. Chem. 
Soc., 2003, 125, 2416-2425. 
80. S. Dhar, Z. Liu, J. Thomale, H. Dai and S. J. Lippard, J. Am. Chem. Soc., 2008, 130, 11467-
11476. 
81. M. Kita, Y. Hirayama, K. Yoneda, K. Yamagishi, T. Chinen, T. Usui, E. Sumiya, M. Uesugi and H. 
Kigoshi, J. Am. Chem. Soc., 2013, 135, 18089-18095. 
82. T. Wang, D. Y. W. Ng, Y. Wu, J. Thomas, T. TamTran and T. Weil, Chem. Commun., 2014, 50, 
1116-1118. 
 
  References 
  180 
 
